appendix a - home - springer978-0-230-29… · · 2017-08-25cardiovascular tab 14 11.50 8.50...
TRANSCRIPT
Appendix A
225
226
Ex
amin
atio
no
fd
rug
pri
ces
the
do
mes
tic
firm
sag
reed
tore
du
ce
Tabl
eA
.1V
olu
nta
ryp
rice
red
uct
ion
–m
arke
tp
rice
sve
rsu
scl
aim
edp
rice
s
CIM
SD
TID
RO
rigi
nal
Nam
eo
fth
efo
rmu
lati
on
and
stre
ngt
h
Th
erap
euti
cca
tego
ry/
Co
mp
osi
tio
n
Cla
imed
pri
ces
Mar
ket
pri
ces
Pag
e/re
fere
nce
S.N
o.
Pac
kSi
zeO
ldp
rice
(Rs.
)
New
pri
ce(R
s.)
Red
uct
ion
%ag
eO
ldp
rice
per
un
it
New
pri
cep
eru
nit
CIM
SD
TID
RSt
atu
s
305
187
13B
acip
en25
0A
nti
bact
eria
lC
ap10
30.8
028
.50
7.47
%3.
082.
852.
882.
88H
305
187
14B
acip
en50
0A
nti
bact
eria
lC
ap10
57.6
053
.00
7.99
%5.
765.
305.
385.
38H
191
15O
din
ol25
mg
Car
dio
vasc
ula
rTa
b14
11.5
08.
5026
.09%
0.82
0.61
0.71
H
191
16O
din
ol50
mg
Car
dio
vasc
ula
rTa
b14
19.0
016
.00
15.7
9%1.
361.
141.
25H
204
17A
lcep
hin
250
An
tiba
cter
ial
Cap
1062
.00
51.0
017
.74%
6.20
5.10
6.20
H
204
18A
lcep
hin
500
An
tiba
cter
ial
Cap
1011
0.00
95.5
013
.18%
11.0
09.
5511
.00
H
204
19A
lcep
hin
An
tiba
cter
ial
Dry
syru
p30
ml
23.8
521
.00
11.9
5%0.
80/m
l0.
70/m
l0.
70/m
lE
204
20A
lcep
hin
Kid
An
tiba
cter
ial
Tab
1029
.95
21.0
029
.88%
3.00
2.10
3.00
H
295
696
312
50A
lsig
ra50
An
tifu
nga
lsTa
b4
72.0
051
.00
29.1
7%7.
205.
107.
207.
207.
20H
268
273
72Fo
rmin
al10
00A
nti
dia
beti
csTa
b10
16.0
512
.50
22.1
2%1.
611.
251.
501.
50H
270
966
297
75Pi
olem
15A
nti
dia
beti
csd
rug
Tab
1018
.00
16.0
011
.11%
1.80
1.60
1.80
1.80
1.80
H
227
270
966
297
76Pi
olem
30A
nti
dia
beti
csd
rug
Tab
1035
.00
32.0
08.
57%
3.50
3.20
3.50
3.50
3.50
H
1,05
110
1Fo
lin
alp
lus
Iron
&V
itam
ins
sup
ple
men
tsSy
rup
300
ml
72.0
063
.50
11.8
1%0.
24/m
l0.
21/m
l0.
37/m
lH
312
180
111
Am
oxil
Am
oxyc
illi
nD
rysy
rup
30m
l25
.68
22.4
712
.50%
1.00
/m
l0.
86/m
l0.
47/m
l0.
49/m
lL
312
180
114
Am
oxil
250
mg
Am
oxil
cill
in25
0m
gC
ap20
×10
802.
5074
8.32
6.75
%4.
013.
743.
103.
58L
312
180
115
Am
oxil
500
mg
Am
oxil
cill
inC
ap20
×10
1510
.84
1337
.41
11.4
8%7.
556.
695.
905.
50L
528
164
Cad
flo
20m
gFl
uox
etin
eC
ap30
×10
C89
8.80
791.
8011
.90%
3.00
2.64
2.35
L
418
173
Cad
ith
ro50
mg
Rox
yth
rom
ycin
Tab
20×
10T
1005
.80
963.
004.
26%
5.03
4.82
4.70
L
418
174
Cad
ith
ro15
0m
gR
oxyt
hro
myc
inTa
b20
×10
T16
47.8
014
98.0
09.
09%
8.24
7.49
11.1
3H
476
825
212
176
Cet
icad
10m
gC
etri
zin
eH
Cl
Tab
50×
10T
1281
.86
805.
7137
.15%
2.56
1.61
2.60
2.60
2.60
H
188
548
236
178
Dom
coli
c10
mg
×D
omp
erid
one
Tab
50×
10T
1352
.48
1070
.00
20.8
9%2.
702.
142.
532.
532.
53H
373
479
184
Flu
med
150
mg
Flu
con
azol
eTa
b20
×1
684.
8057
7.80
15.6
3%34
.20
28.8
530
.00
26.0
0M
7362
926
419
0La
nzo
fast
30m
gLa
nso
pra
zole
asen
teri
c-co
ated
gran
ule
s
Cap
20×
10C
1070
.00
856.
0020
.00%
5.35
4.14
4.93
4.90
4.93
H
250
198
Nim
du
s-P
Nim
esu
lid
e10
0m
g+
Para
ceta
mol
500
mg
Tab
20×
10T
620.
6051
3.60
17.2
4%3.
102.
572.
90H
228
Tabl
eA
.1(C
onti
nu
ed)
CIM
SD
TID
RO
rigi
nal
Nam
eo
fth
efo
rmu
lati
on
and
stre
ngt
h
Th
erap
euti
cca
tego
ry/
Co
mp
osi
tio
n
Cla
imed
pri
ces
Mar
ket
pri
ces
Pag
e/re
fere
nce
S.N
o.
Pac
kSi
zeO
ldp
rice
(Rs.
)
New
pri
ce(R
s.)
Red
uct
ion
%ag
eO
ldp
rice
per
un
it
New
pri
cep
eru
nit
CIM
SD
TID
RSt
atu
s
250
199
Nim
du
s-Pl
us
Nim
esu
lid
e10
0m
g+
Para
ceta
mol
500
mg
Tab
50×
1015
51.5
010
86.0
530
.00%
3.10
2.17
2.90
H
354
201
Ori
ph
ex12
5D
TC
eph
alex
inTa
b20
×10
T62
8.95
588.
506.
43%
3.14
2.94
3.25
H
318
204
203
Ori
ph
ex25
0m
gC
eph
alex
inC
ap20
×10
C13
05.4
011
77.0
09.
84%
6.53
5.89
6.50
6.50
H
318
204
204
Ori
ph
ex50
0m
gC
eph
alex
inC
ap10
×10
C11
50.2
510
16.5
011
.63%
11.5
010
.17
12.1
012
.10
H
308
306
187
210
Zyci
llin
250
mg
Am
pic
illi
nTr
ihyd
rate
Cap
20×
10C
642.
0053
5.00
16.6
7%3.
212.
683.
003.
003.
00H
308
306
187
211
Zyci
llin
500
mg
Am
pic
illi
nTr
ihyd
rate
Cap
20×
10C
1241
.20
1070
.00
13.7
9%6.
215.
355.
805.
805.
80H
380
510
173
330
Zelb
end
400
mg,
Alb
end
azol
eI.
P.ex
cip
ien
tq
sTa
b20
×10
2675
.00
2247
.00
16.0
0%13
.38
11.2
310
.00
10.0
010
.00
L
409
404
Cad
imyc
etin
500
mg
Ch
lora
mp
hen
icol
Cap
10×
10C
730.
2864
2.00
12.0
9%7.
306.
426.
83H
409
405
Cad
imyc
etin
250
mg
Ch
lora
mp
hen
icol
Cap
20×
10C
770.
4066
3.40
13.8
9%3.
853.
313.
60H
229
1094
419
Cad
pro
250
gmG
BPr
otei
nG
ran
ule
s25
0gm
149.
7513
6.96
8.54
%0.
60/gm
0.55
/gm
0.50
/gm
L
155
148
239
425
Can
vas
5m
gEn
alap
ril
Tab
30×
1063
5.58
535.
0015
.82%
2.12
1.78
0.07
0.07
0.07
L31
849
5Zo
xLB
250
Am
oxyc
illi
n25
0m
g+
Lact
oB
acil
lus
Cap
10×
10C
406.
6032
1.00
21.0
5%4.
073.
213.
80H
318
496
Zox
LB50
0A
mox
ycil
lin
500
mg
+La
cto
Bac
illu
s
Cap
10×
10C
757.
5669
5.50
8.19
%7.
586.
967.
08H
380
508
173
501
Alz
adSu
spen
sion
Alb
end
azol
e5
ml-
IP-
200
mg
Liq
uid
10m
lB
ot21
.61
17.4
119
.43%
2.16
/m
l1.
74/m
l1.
83/m
l1.
83/m
l1.
83/m
lH
380
508
173
502
Alz
adA
lben
daz
ole
IP−4
00m
gTa
b1
14.8
011
.87
19.8
1%14
.80
11.8
712
.00
2.56
12.0
0H
112
240
532
Enp
ril
10m
gEn
alap
ril
Tab
1054
.86
49.3
710
.00%
5.49
4.94
2.18
2.18
L11
224
053
3En
pri
l5
mg
Enal
apri
lTa
b10
30.6
027
.54
10.0
0%3.
062.
751.
201.
20L
118
154
269
544
Lozi
tan
50m
gLo
sart
enTa
b10
46.4
232
.49
30.0
0%4.
643.
253.
903.
903.
90H
332
209
559
Nos
ocef
250
mg
Cef
tria
xon
eIn
j1
vial
47.4
837
.98
20.0
0%47
.48
37.9
848
.80
48.8
0H
322
344
205
565
O-P
ower
cef
100
mg
Cefi
xim
eD
TTa
b10
137.
1510
9.72
20.0
0%13
.72
10.9
727
.00
27.0
027
.00
H
322
205
566
O-P
ower
cef
200
mg
Cefi
xim
eTa
b4
100.
2380
.18
20.0
0%25
.06
20.0
549
.00
49.0
0H
322
205
567
O-P
ower
cef
DS
Cefi
xim
e50
mg/
5m
lLi
qu
id30
ml
63.3
050
.64
20.0
0%2.
11/m
l1.
69/m
l3.
27/m
l3.
27/m
lH
207
209
292
573
Pyre
xon
650
mg
Para
ceta
mol
-IP
-DT
Tab
69.
598.
6310
.00%
1.60
1.44
1.35
1.35
1.35
L
230
Tabl
eA
.1(C
onti
nu
ed)
CIM
SD
TID
RO
rigi
nal
Nam
eo
fth
efo
rmu
lati
on
and
stre
ngt
h
Th
erap
euti
cca
tego
ry/
Co
mp
osi
tio
n
Cla
imed
pri
ces
Mar
ket
pri
ces
Pag
e/re
fere
nce
S.N
o.
Pac
kSi
zeO
ldp
rice
(Rs.
)
New
pri
ce(R
s.)
Red
uct
ion
%ag
eO
ldp
rice
per
un
it
New
pri
cep
eru
nit
CIM
SD
TID
RSt
atu
s
7462
128
857
4R
ESEC
Om
epra
zole
–IP
Cap
1046
.95
37.5
620
.00%
4.70
3.76
3.98
3.95
3.98
H
195
602
Bec
laso
ne
–C
15gm
Top
ical
Ster
oid
sC
ream
15gm
22.9
014
.80
35.3
7%1.
53/g
m0.
99/g
m1.
53/g
mH
195
603
Bec
laso
ne
–C
5gm
Top
ical
Ster
oid
sC
ream
5gm
11.7
58.
6026
.81%
2.35
/gm
1.72
/gm
2.35
/gm
H
195
604
BEC
LASO
NE
–G
M15
gmTo
pic
alSt
eroi
ds
Cre
am15
gm24
.90
16.9
032
.13%
1.66
/gm
1.13
/gm
1.66
/gm
H
195
605
Bec
laso
ne
–G
M5
gmTo
pic
alSt
eroi
ds
Cre
am5
gm13
.90
9.60
30.9
4%2.
78/g
m1.
92/g
m2.
78/g
mH
219
608
Cip
robi
otic
–25
0A
nti
-B
acte
rial
Tab
1030
.66
11.6
062
.17%
3.07
1.16
2.88
H
219
609
Cip
robi
otic
–50
0A
nti
-B
acte
rial
Tab
1059
.42
20.4
065
.67%
5.94
2.04
5.87
H
220
610
Cip
robi
otic
–T
N–
250
An
ti-
Bac
teri
alTa
b10
34.6
422
.20
35.9
1%3.
462.
222.
99H
220
611
Cip
robi
otic
–T
N–
500
An
ti-
Bac
teri
alTa
b10
67.9
439
.10
42.4
5%6.
793.
915.
99H
297
181
671
Ran
oxyl
Cap
s25
0m
gA
mox
icil
lin
Cap
1042
.00
37.8
010
.00%
4.20
3.78
3.00
3.00
L
231
297
181
672
Ran
oxyl
Cap
s50
0m
gA
mox
icil
lin
Cap
1067
.20
60.4
810
.00%
6.72
6.05
5.30
5.30
L
297
181
675
Ran
oxyl
Syru
p60
ml.
Am
oxic
illi
n12
5m
g/5
ml
Dry
syru
p60
ml
29.4
026
.46
10.0
0%0.
49/m
l0.
44/m
l0.
42/m
l0.
42/m
lL
155
149
240
688
Invo
ril
5mg
Enal
apri
l5
mg
Tab
1023
.73
18.9
820
.02%
2.38
1.90
1.88
1.88
1.88
L38
017
370
2Lu
pib
end
400
An
thel
min
tics
Tab
50×
162
6.76
575.
008.
26%
12.5
411
.50
12.0
012
.00
H38
227
070
3Lu
pim
ebA
nth
elm
inti
csTa
b20
×6
240.
2621
9.20
8.76
%2.
001.
101.
921.
92H
7628
871
0Lu
pom
e-D
An
tip
epti
cU
lcer
ants
Cap
20×
1094
0.14
835.
6011
.12%
4.70
4.18
4.18
4.18
E
134
178
711
Defi
din
5m
gA
nti
hyp
erte
nsi
ves
Tab
5×
6×
1067
8.99
600.
6011
.55%
2.26
2.00
2.17
2.17
H38
017
371
6Lu
pib
end
10m
lA
nth
elm
inti
csSy
rup
10m
l21
.94
18.8
014
.30%
2.19
/m
l1.
88/m
l2.
102.
10/m
lH
354
285
723
Eufo
x20
0A
nti
biot
ics
Tab
10×
1088
7.91
731.
2017
.65%
8.88
7.31
7.31
7.31
E35
628
672
5Eu
fox-
Tz
An
tibi
otic
sTa
b10
×10
1044
.60
835.
6020
.01%
10.4
58.
368.
368.
36E
509
275
742
Lup
igyl
Gel
An
thel
min
tics
Gel
30gm
28.2
020
.35
27.8
5%0.
94/gm
0.68
/gm
1.35
/gm
1.35
/gm
H23
228
174
8Lu
pis
uli
de
Gel
Pain
Man
agem
ent
Gel
30gm
25.0
716
.70
33.3
9%0.
84/gm
0.56
/gm
1.20
/gm
1.20
/gm
H
232
281
753
Lup
isu
lid
ePa
inM
anag
emen
tTa
b5
×5
×10
626.
7639
1.75
37.5
0%2.
501.
562.
402.
40H
7629
176
2Lu
pip
an40
An
tip
epti
cU
lcer
ants
Tab
10×
1062
6.76
313.
4050
.00%
6.27
3.13
6.00
6.00
H
320
354
204
768
Rof
ex50
0m
gC
aps
An
hyd
rou
sC
eph
alax
inC
ap10
×10
118.
1810
5.00
11.1
5%1.
181.
0510
.57
11.8
210
.57
H
320
354
204
771
Cep
hal
axin
Cep
hal
axin
Cap
20×
1062
.66
60.0
04.
25%
0.31
0.30
5.94
6.27
5.94
H28
178
6N
icip
An
alge
sics
/A
nti
pyr
etic
s/A
nti
-in
flam
mat
ory
Tab
10’s
25.0
021
.00
16.0
0%2.
502.
102.
50H
212
787
Cet
cip
An
tial
lerg
icTa
b10
’s33
.65
25.0
025
.71%
3.37
2.50
2.75
H
232
Tabl
eA
.1(C
onti
nu
ed)
CIM
SD
TID
RO
rigi
nal
Nam
eo
fth
efo
rmu
lati
on
and
stre
ngt
h
Th
erap
euti
cca
tego
ry/
Co
mp
osi
tio
n
Cla
imed
pri
ces
Mar
ket
pri
ces
Pag
e/re
fere
nce
S.N
o.
Pac
kSi
zeO
ldp
rice
(Rs.
)
New
pri
ce(R
s.)
Red
uct
ion
%ag
eO
ldp
rice
per
un
it
New
pri
cep
eru
nit
CIM
SD
TID
RSt
atu
s
287
788
Om
ecip
10A
nta
cid
Cap
10’s
24.0
019
.50
18.7
5%2.
401.
952.
40H
287
789
Om
ecip
20A
nta
cid
Cap
15’s
58.5
046
.00
21.3
7%3.
903.
073.
90H
281
790
Nod
ard
An
alge
sics
/A
nti
pyr
etic
s/A
nti
-in
flam
mat
ory
Tab
10’s
25.0
021
.00
16.0
0%2.
502.
102.
50H
232
282
792
Nic
iflex
-TA
nal
gesi
cs/
An
tip
yret
ics/
An
ti-
infl
amm
ator
y
Tab
10’s
55.0
040
.00
27.2
7%5.
504.
005.
505.
50H
189
236
793
Vom
isto
p10
DT
An
tiem
etic
s/A
nti
nau
sean
tsTa
b10
’s24
.00
16.0
033
.33%
2.40
1.60
2.40
2.40
H
408
330
794
Bro
mex
An
tiC
ough
&C
old
Prep
arat
ion
s
Liq
uid
100
ml
27.0
022
.00
18.5
2%0.
27/m
l0.
22/m
l0.
27/m
l0.
27/m
lH
308
187
796
Meg
asyn
250
An
tibi
otic
sC
ap10
’s30
.00
24.0
020
.00%
3.00
2.40
3.00
3.00
H
241
230
798
Ver
ub
Pain
reli
evin
goi
ntm
ent
Gel
30gm
37.0
030
.00
18.9
2%1.
23/g
m1.
00/g
m1.
23/g
m1.
23/g
mH
313
799
Bu
rnh
eal
An
tise
pti
cPo
wd
er10
gm21
.00
16.0
023
.81%
2.10
/gm
1.60
/gm
2.10
/gm
H
233
293
800
Para
cod
An
alge
sics
/A
nti
pyr
etic
s/A
nti
-in
flam
mat
ory
Tab
10’s
31.0
025
.00
19.3
5%3.
102.
503.
10H
382
264
801
Levo
mol
50A
nth
elm
inti
csTa
b1’
s7.
756.
0022
.58%
7.75
6.00
7.75
7.75
H38
226
480
2Le
vom
ol15
0A
nth
elm
inti
csTa
b1’
s15
.70
13.5
014
.01%
15.7
013
.50
15.7
015
.70
H23
880
3V
omin
ate
An
tiem
etic
s/A
nti
nau
sean
tsTa
b10
’s19
.50
15.0
023
.08%
1.95
1.50
1.95
H
344
804
Q-G
at20
0A
nti
biot
ics
&A
nti
bact
eria
lsTa
b5’
s40
.00
33.0
017
.50%
8.00
6.60
8.00
H
242
383
806
Pow
erge
lPa
inre
liev
ing
oin
tmen
tG
el30
gm37
.00
30.0
018
.92%
1.23
/gm
1.00
/gm
1.23
/gm
1.23
/gm
H
196
296
807
Phen
oton
e30
An
tiep
ilep
tic
dru
gsTa
b10
’s7.
406.
0018
.92%
0.74
0.60
0.74
0.74
H
196
296
808
Phen
oton
e60
An
tiep
ilep
tic
dru
gsTa
b10
’s10
.20
9.00
11.7
6%1.
020.
901.
021.
02H
346
809
Feri
cip
Vit
amin
sSu
pp
lem
ents
Cap
10’s
73.3
455
.00
25.0
1%7.
335.
504.
50H
173
810
Alf
aric
h0.
25V
itam
ins
Sup
ple
men
tsC
ap10
’s65
.00
50.0
023
.08%
6.50
5.00
5.00
E
518
195
811
Bec
der
mTo
pic
alp
rep
arat
ion
sC
ream
15gm
18.0
015
.00
16.6
7%1.
20/g
m1.
00/g
m1.
20/g
m1.
20/g
mH
408
330
813
Bro
mex
An
tiC
ough
&C
old
Prep
arat
ion
s
Cre
am10
’s12
.00
9.00
25.0
0%1.
200.
901.
201.
20H
519
814
Clo
der
mA
nti
fun
gal
crea
mC
ream
15gm
28.0
024
.00
14.2
9%1.
871.
602.
13/g
mH
409
331
815
Cof
dex
Fort
eA
nti
Cou
gh&
Col
dPr
epar
atio
ns
Liq
uid
100
ml
35.0
029
.00
17.1
4%0.
35/m
l0.
29/m
l0.
35/m
l0.
35/m
lH
234
Tabl
eA
.1(C
onti
nu
ed)
CIM
SD
TID
RO
rigi
nal
Nam
eo
fth
efo
rmu
lati
on
and
stre
ngt
h
Th
erap
euti
cca
tego
ry/
Co
mp
osi
tio
n
Cla
imed
pri
ces
Mar
ket
pri
ces
Pag
e/re
fere
nce
S.N
o.
Pac
kSi
zeO
ldp
rice
(Rs.
)
New
pri
ce(R
s.)
Red
uct
ion
%ag
eO
ldp
rice
per
un
it
New
pri
cep
eru
nit
CIM
SD
TID
RSt
atu
s
335
816
Rid
cof
An
tiC
ough
&C
old
Prep
arat
ion
s
Liq
uid
60m
l20
.00
17.0
015
.00%
0.33
/ml
0.28
/ml
0.33
/ml
H
409
331
817
Cof
dex
Plu
sA
nti
Cou
gh&
Col
dPr
epar
atio
ns
Liq
uid
60m
l27
.00
23.0
014
.81%
0.27
/ml
0.23
/ml
0.27
/ml
0.27
/ml
H
332
818
Dex
cof
An
tiC
ough
&C
old
Prep
arat
ion
s
Liq
uid
100
ml
30.0
027
.00
10.0
0%0.
30/m
l0.
27/m
l0.
30/m
lH
236
299
819
Dol
ocip
DT
An
alge
sics
/A
nti
pyr
etic
s/A
nti
-in
flam
mat
ory
Tab
10’s
44.5
025
.00
43.8
2%4.
452.
503.
003.
00H
7325
582
3H
elip
acK
itA
nta
cid
Tab
6’s
Kit
25.2
020
.00
20.6
3%4.
203.
334.
204.
20H
228
254
824
Ost
eoci
pA
nal
gesi
cs/
An
tip
yret
ics/
An
ti-
infl
amm
ator
y
Tab
10’s
150.
0010
0.00
33.3
3%15
.00
10.0
015
.00
15.0
0h
411
333
825
Lexc
ofA
nti
Cou
gh&
Col
dPr
epar
atio
ns
Liq
uid
50m
l26
.00
23.0
011
.54%
0.52
/ml
0.46
/ml
0.52
/ml
0.52
/ml
H
235
428
349
827
Max
ifer
onso
ftV
itam
ins/
Nu
trit
ion
alSu
pp
lem
ents
Cap
10’s
27.0
023
.00
14.8
1%2.
702.
302.
702.
70H
7327
882
8M
osap
id5
An
taci
dTa
b10
’s27
.00
20.0
025
.93%
2.70
2.00
2.70
2.70
H31
883
1To
scof
An
tiC
ough
&C
old
Prep
arat
ion
s
Liq
uid
100
ml
30.0
024
.00
20.0
0%0.
30/m
l0.
24/m
l0.
30/m
lH
8237
183
2U
riso
da
Syst
emic
Alk
aliz
erG
ran
ule
s4
gm8.
506.
0029
.41%
2.13
/gm
1.50
/gm
2.13
/gm
2.13
/gm
H
275
833
Vom
inor
mA
nti
emet
ics/
An
tin
ause
ants
Inj
2m
l6.
004.
0033
.33%
3.00
2.00
3.00
H
178
229
834
Zep
ose
An
tid
epre
ssan
tIn
j2
ml
12.0
06.
0050
.00%
6.00
/ml
3.00
/ml
6.00
/ml
6.00
/ml
H30
232
618
483
5C
lava
m37
5m
gA
mox
icil
lin
+C
lavu
lan
ate
Pota
ssiu
m
Tab
10’s
296.
4019
7.08
33.5
1%29
.64
19.9
128
.50
28.5
028
.50
H
302
326
184
836
Cla
vam
625
mg
Am
oxic
illi
n+
Cla
vula
nat
ePo
tass
ium
Tab
10’s
379.
6020
7.48
45.3
4%37
.96
20.7
519
.95
36.5
019
.95
H
302
326
184
837
Cla
vam
Am
oxic
illi
nA
nd
Cla
vula
nat
e
Dry
syru
p30
ml
72.8
048
.78
33.0
0%2.
43/m
l1.
63/m
l2.
50/m
l2.
33/m
l2.
50/m
lH
302
326
184
839
Cla
vam
1000
mg
Am
oxic
illi
n+
Cla
vula
nat
ePo
tass
ium
Tab
10’s
483.
6031
1.48
35.5
9%48
.36
31.1
529
.95
46.5
029
.95
H
302
184
840
Cla
vam
DT
Am
oxic
illi
n+
Cla
vula
nat
ePo
tass
ium
Tab
10’s
132.
6082
.68
37.6
5%13
.26
8.27
12.7
512
.75
H
1127
845
Gem
fos
Ris
edro
nat
eSo
diu
mTa
b4’
s20
8.00
124.
8040
.00%
52.0
031
.20
50.0
0H
330
351
209
847
Tazi
d25
0m
gC
efta
zid
ime
Inj
Via
l86
.32
78.0
09.
64%
86.3
278
.00
85.0
075
.00
85.0
0H
236
Tabl
eA
.1(C
onti
nu
ed)
CIM
SD
TID
RO
rigi
nal
Nam
eo
fth
efo
rmu
lati
on
and
stre
ngt
h
Th
erap
euti
cca
tego
ry/
Co
mp
osi
tio
n
Cla
imed
pri
ces
Mar
ket
pri
ces
Pag
e/re
fere
nce
S.N
o.
Pac
kSi
zeO
ldp
rice
(Rs.
)
New
pri
ce(R
s.)
Red
uct
ion
%ag
eO
ldp
rice
per
un
it
New
pri
cep
eru
nit
CIM
SD
TID
RSt
atu
s
330
351
209
848
Tazi
d50
0m
gC
efta
zid
ime
Inj
Via
l16
1.20
145.
609.
68%
161.
2014
5.60
140.
0016
2.00
140.
00M
330
351
209
849
Tazi
d10
00m
gC
efta
zid
ime
Inj
Via
l28
0.80
192.
4031
.48%
280.
8019
2.40
270.
0018
5.00
270.
00H
382
850
Zoce
f25
0m
gC
efu
roxi
me
Sod
ium
Inj
Via
l58
.76
46.8
020
.35%
58.7
646
.80
56.5
0H
336
382
211
851
Zoce
f75
0m
gC
efu
roxi
me
Sod
ium
Inj
Via
l11
8.56
99.8
415
.79%
118.
5699
.84
99.8
411
4.00
99.8
4M
382
852
Zoce
f1.
5gm
Cef
uro
xim
eSo
diu
mIn
jV
ial
225.
6818
7.20
17.0
5%22
5.68
187.
2021
7.00
H
382
853
Zoce
f12
5m
gC
efu
roxi
me
Axe
til
Tab
10’s
161.
2013
5.20
16.1
3%16
.12
13.5
215
.50
H
382
854
Zoce
f25
0m
gC
efu
roxi
me
Axe
til
Tab
10’s
338.
0020
6.96
38.7
7%33
.80
20.7
032
.50
H
382
855
Zoce
f50
0m
gC
efu
roxi
me
Axe
til
Tab
10’s
676.
0039
5.20
41.5
4%67
.60
39.5
265
.00
H
367
209
859
Cef
xo1
gmC
eftr
iaxo
ne
Inj
Via
l98
.00
82.0
016
.32%
98.0
082
.00
75.0
075
.00
L36
720
986
0C
efxo
250
mg
Cef
tria
xon
eIn
jIn
jV
ial
43.0
035
.80
16.7
4%43
.00
35.8
030
.00
30.0
0L
237
367
209
861
Cef
xo50
0m
gC
eftr
iaxo
ne
Inj
Inj
Via
l58
.00
48.3
016
.72%
58.0
048
.30
50.0
050
.00
H47
621
286
4O
nce
tC
etir
izin
eD
ihyd
roch
lori
de
Tab
10’s
25.0
015
.00
40.0
0%2.
501.
501.
001.
00L
382
507
270
876
Hel
min
tol
100
mg
Meb
end
azol
eTa
b6’
s6.
955.
8016
.55%
1.16
0.97
0.99
1.16
0.99
H24
528
187
8N
imsa
idN
imes
uli
de
Tab
10’s
24.0
020
.00
16.6
7%2.
402.
001.
871.
87L
697
313
882
Vig
reks
100
mg
Sild
enafi
lC
itra
teTa
b4’
s10
8.00
90.0
016
.67%
27.0
022
.50
25.0
025
.00
H
697
313
883
Vig
reks
50m
gSi
lden
afil
Cit
rate
Tab
4’s
72.0
060
.00
16.6
7%18
.00
15.0
014
.90
14.9
0L
Not
e:C
IMS,
DT
(Dru
gTo
day
),an
dID
Rar
eco
nsi
der
edto
refl
ect
the
mar
ket
pri
ces.
Th
ele
tter
inth
ela
stco
lum
nre
pre
sen
tsth
est
atu
sof
the
mar
ket
pri
cere
lati
veto
the
clai
med
pri
cere
du
ctio
n.
H=
the
mar
ket
pri
ceis
hig
her
than
the
clai
med
pri
ce;
L=
the
mar
ket
pri
ceis
low
erth
anth
ecl
aim
edp
rice
;E
=th
em
arke
tp
rice
iseq
ual
toth
ecl
aim
edp
rice
;an
dM
=th
em
arke
tp
rice
ism
ixed
,wh
ich
mea
ns
atle
ast
inon
eof
the
refe
ren
cebo
oks
the
pri
ceis
hig
her
wh
ile
inth
eot
her
book
sth
ep
rice
islo
wer
than
the
clai
med
pri
ce.
Sour
ce:A
uth
orca
lcu
lati
ons
base
don
Gov
ern
men
tof
Ind
ia(2
006h
),C
IMS
(200
7),D
rug
Tod
ay(2
007)
,an
dID
R(2
008)
.
Appendix B
238
239
Ex
amin
atio
no
fch
ange
sto
dru
gp
rice
s
Tabl
eB
.1Pr
ice
chan
ges
tod
rugs
for
card
iova
scu
lar
dis
ease
s
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
Car
bop
rost
Trom
eth
amin
ePr
osto
din
Inj
250
mcg
/ml
1m
lU
teri
ne
stim
ula
nts
Ast
raZe
nec
a−2
.74
24.3
1
Car
bop
rost
Trom
eth
amin
eD
evip
rost
Inj
250
mcg
/ml
1m
lU
teri
ne
stim
ula
nts
DR
L12
.97
Sild
enafi
lC
itra
teA
lsig
raTa
b25
mg
4U
teri
ne
stim
ula
nts
Ale
mbi
c0.
00
Sild
enafi
lC
itra
teA
lsig
raTa
b50
mg
4U
teri
ne
stim
ula
nts
Ale
mbi
c0.
00
Bis
opro
lol
Con
cor
Tab
5m
g10
An
ti-a
ngi
nal
sM
erck
−5.5
59.
34A
ten
olol
+N
ifed
ipin
eye
sC
ard
ule
sPl
us
10m
gTa
b50
mg
+10
mg
10A
nti
-an
gin
als
Nic
hol
asPi
ram
al3.
7440
.00
Ate
nol
ol+
Nif
edip
ine
yes
Car
du
les
Plu
s20
mg
Tab
50m
g+
20m
g10
An
ti-a
ngi
nal
sN
ich
olas
Pira
mal
37.5
9
Nif
edap
ine
yes
Cad
ule
sC
ap10
mg
10A
nti
-an
gin
als
Nic
hol
asPi
ram
al43
.18
Nif
edap
ine
yes
Cad
ule
sC
ap10
mg
(Ret
ard
)10
An
ti-a
ngi
nal
sN
ich
olas
Pira
mal
62.8
0
Nif
edap
ine
yes
Cad
ule
sC
ap20
mg
(Ret
ard
)10
An
ti-a
ngi
nal
sN
ich
olas
Pira
mal
35.4
8
Nif
edip
ine
yes
Dep
inC
ap5
mg
50×
3A
nti
-an
gin
als
Zyd
us
Cad
ila
6.24
0.00
Nif
edip
ine
yes
Dep
inC
ap10
mg
4×
30A
nti
-an
gin
als
Zyd
us
Cad
ila
0.00
Nif
edip
ine
yes
Dep
inC
ap20
mg
(Ret
ard
)30
An
ti-a
ngi
nal
sZy
du
sC
adil
a0.
00
240
Tabl
eB
.1(C
onti
nu
ed)
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
Ind
apam
ide
Lorv
asTa
b2.
5m
g10
An
ti-h
ypot
ensi
ves
Torr
ent
6.78
0.00
Met
opro
lol+
Hyd
roch
loro
thia
zid
eSe
lop
res
Tab
100
mg
+12
.5m
g10
An
ti-H
yper
ten
sive
sA
stra
Zen
eca
0.00
0.00
Ch
lon
idin
e+
Hyd
roch
loro
thia
zid
eye
sA
rkam
in-H
Tab
100
mcg
+20
mg
10A
nti
-Hyp
erte
nsi
ves
Un
isea
rch
2.05
17.8
5
Ch
lon
idin
eye
sA
rkam
inTa
b10
0m
cg10
An
ti-H
yper
ten
sive
sU
nis
earc
h18
.46
Enal
apri
lm
alea
teye
sEn
ace
Tab
2.5
mg
10A
nti
-Hyp
erte
nsi
ves
Nic
hol
asPi
ram
al4.
5218
.80
Enal
apri
lm
alea
teye
sEn
ace
Tab
5m
g10
An
ti-H
yper
ten
sive
sN
ich
olas
Pira
mal
20.2
3
Enal
apri
lm
alea
teye
sEn
ace
Tab
10m
g10
An
ti-H
yper
ten
sive
sN
ich
olas
Pira
mal
6.90
Enal
apri
lm
alea
te+
Hyd
roch
loro
thia
zid
eye
sEn
ace-
DTa
b10
mg
+25
mg
10A
nti
-Hyp
erte
nsi
ves
Nic
hol
asPi
ram
al5.
8715
.64
Res
erp
ine
+D
ihyd
rall
azin
e+
Hyd
roch
loro
thia
zid
e
Ad
elp
han
e-Es
idre
xTa
b0.
1m
g+
10m
g+
10m
g10
An
ti-H
yper
ten
sive
sN
ovar
tis
7.00
10.1
4
Res
erp
ine
+D
ihyd
rall
azin
eA
del
ph
ane
Tab
0.1
mg
+10
mg
10A
nti
-Hyp
erte
nsi
ves
Nov
arti
s10
.14
Ram
ipri
lC
ard
ace
Tab
1.25
mg
10C
ard
iac
Dis
ord
ers
San
ofi-
Ave
nti
s2.
130.
00
Ram
ipri
lC
ard
ace
Tab
2.5
mg
10C
ard
iac
Dis
ord
ers
San
ofi-
Ave
nti
s1.
43
Ram
ipri
lC
ard
ace
Tab
5m
g10
Car
dia
cD
isor
der
sSa
nofi
-A
ven
tis
5.00
Ram
ipri
lC
ard
ace
Tab
10m
g10
Car
dia
cD
isor
der
sSa
nofi
-A
ven
tis
0.00
241
Ram
ipri
l+
Hyd
roch
loro
thia
zid
eC
ard
ace
–H
Tab
2.5
mg
+12
.5m
g10
Car
dia
cD
isor
der
sSa
nofi
-A
ven
tis
4.76
Dig
oxin
yes
Car
dio
xin
Tab
0.25
mg
10C
ard
iac
Dis
ord
ers
Nov
arti
s11
.28
0.00
Dig
oxin
yes
Lan
oxin
Tab
0.25
mg
10C
ard
iac
Dis
ord
ers
GSK
16.6
417
.63
Ate
nol
ol+
Nif
edip
ine
yes
Ten
ofed
Cap
50m
g+
20m
g10
Peri
ph
eral
Vas
odil
ator
sIP
CA
−0.3
56.
89
Ate
nol
olTe
nol
olTa
b25
mg
14Pe
rip
her
alV
asod
ilat
ors
IPC
A7.
517.
84
Ate
nol
olye
sTe
nol
olTa
b50
mg
14Pe
rip
her
alV
asod
ilat
ors
IPC
A8.
73
Ate
nol
olye
sTe
nol
olTa
b10
0m
g14
Peri
ph
eral
Vas
odil
ator
sIP
CA
0.00
Sour
ce:
For
1994
–200
4M
IMS
Ind
ia,
asci
ted
inSa
kth
ivel
2006
,fo
r20
05–0
8,D
rug
Tod
ay,
vari
ous
issu
es,
CIM
SIn
dia
,20
07Ju
ly–O
ctob
er,
and
IDR
Phar
mac
yTr
ipp
leC
omp
end
ium
,200
8,N
ovem
ber
07–J
anu
ary
08.
242
Tabl
eB
.2Pr
ice
chan
ges
tod
rugs
for
cen
tral
ner
vou
ssy
stem
dis
ord
ers
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
Para
ceta
mol
+C
affe
ine
+C
adei
ne
yes
Zim
algi
nC
ap50
0m
g+
15m
g+
5m
g10
Mas
tce
llst
abli
zer
Shre
ya7.
480.
08
Asp
irin
+C
alca
rbor
ae+
An
hyd
rou
sci
tric
acid
yes
Dis
pri
nTa
b35
0m
g+
105
mg
+35
mg
12×
10A
nal
gesi
csan
dA
nti
pyr
etic
s
Rec
kitt
Ben
ckis
er−0
.26
0.00
Car
bam
azep
ine
yes
yes
Maz
etol
Tab
100
mg
10A
nal
gesi
csan
dA
nti
pyr
etic
s
Nic
hol
asPi
ram
al−1
.36
1.93
Car
bam
azep
ine
yes
yes
Maz
etol
Tab
200
mg
10A
nal
gesi
csan
dA
nti
pyr
etic
s
Nic
hol
asPi
ram
al1.
87
Car
bam
azep
ine
yes
Maz
etol
Tab
400
mg
10A
nal
gesi
csan
dA
nti
pyr
etic
s
Nic
hol
asPi
ram
al6.
83
Car
bam
azep
ine
yes
yes
Maz
etol
–SR
Tab
200
mg
10A
nal
gesi
csan
dA
nti
pyr
etic
s
Nic
hol
asPi
ram
al2.
43
Car
bam
azep
ine
yes
Maz
etol
–SR
Tab
400
mg
10A
nal
gesi
csan
dA
nti
pyr
etic
s
Nic
hol
asPi
ram
al2.
25
Met
oclo
pro
mid
eye
sR
egla
nTa
b10
mg
10A
nti
emet
ics
and
An
tin
au-
sean
ts
CFL
Phar
ma
3.57
31.2
3
Met
oclo
pro
mid
eye
sR
egla
nSy
rup
5m
g/5
ml
30m
lA
nti
emet
ics
and
An
tin
au-
sean
ts
CFL
Phar
ma
29.8
2
243
Met
oclo
pro
mid
eR
egla
nIn
j10
mg/
ml
2m
lA
nti
emet
ics
and
An
tin
ause
ants
CFL
Phar
ma
33.3
3
Met
oclo
pro
mid
eR
egla
nIn
j10
mg/
ml
10m
lA
nti
emet
ics
and
An
tin
ause
ants
CFL
Phar
ma
29.6
3
Met
oclo
pro
mid
eye
sR
egla
nTa
b10
mg
10In
test
inal
mot
ilit
y/A
lim
enta
rysy
stem
CFL
Phar
ma
0.00
Met
oclo
pro
mid
eye
sR
egla
nSy
rup
5m
g/5
ml
30m
lIn
test
inal
mot
ilit
y/A
lim
enta
rysy
stem
CFL
Phar
ma
0.00
Met
oclo
pro
mid
eR
egla
nIn
j10
mg/
ml
2m
lIn
test
inal
mot
ilit
y/A
lim
enta
rysy
stem
CFL
Phar
ma
0.00
Met
oclo
pro
mid
eR
egla
nIn
j10
mg/
ml
10m
lIn
test
inal
mot
ilit
y/A
lim
enta
rysy
stem
CFL
Phar
ma
0.00
Imip
ram
ine
yes
An
tid
epTa
b25
mg
10A
nti
dep
ress
ants
Torr
ent
2.12
0.00
Imip
ram
ine
yes
An
tid
epTa
b75
mg
10A
nti
dep
ress
ants
Torr
ent
0.00
Lith
ium
Car
bon
ate
Lica
b/X
LTa
b30
0m
g10
An
tid
epre
ssan
tsTo
rren
t−1
.04
0.00
Lith
ium
Car
bon
ate
Lica
bTa
b40
0m
g10
An
tid
epre
ssan
tsTo
rren
t0.
00Lo
raze
pam
Larp
ose
Tab
1m
g10
Sed
ativ
esan
dTr
anq
uil
iser
sC
ipla
−0.4
213
.33
Lora
zep
amLa
rpos
eTa
b2
mg
10Se
dat
ives
and
Tran
qu
ilis
ers
Cip
la13
.90
Trifl
uop
eraz
ine
+Tr
ihex
yph
enid
ylye
sTr
inic
alm
Plu
sTa
b5
mg
+2
mg
10Se
dat
ives
and
Tran
qu
ilis
ers
Torr
ent
−0.1
30.
00
Trifl
uop
eraz
ine
+Tr
ihex
yph
enid
yl+
Ch
lorp
rom
azin
e
yes
yes
Trin
ical
mFo
rte
Tab
5m
g+
2m
g+
50m
g10
Sed
ativ
esan
dTr
anq
uil
iser
sTo
rren
t0.
00
Trifl
uop
eraz
ine
yes
Trin
ical
mTa
b5
mg
10A
nti
emet
ics
and
An
tin
ause
ants
Torr
ent
0.00
Clo
zap
ine
Sizo
pin
Tab
25m
g10
Sed
ativ
esan
dTr
anq
uil
iser
sSu
nPh
arm
a0.
008.
57
244
Tabl
eB
.2(C
onti
nu
ed)
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
Clo
zap
ine
Sizo
pin
Tab
100
mg
10Se
dat
ives
and
Tran
qu
ilis
ers
Sun
Phar
ma
3.24
Hal
oper
idol
yes
Sere
nac
eTa
b1.
5m
g10
Sed
ativ
esan
dTr
anq
uil
iser
sR
PGPh
arm
a0.
0023
.77
Hal
oper
idol
yes
Sere
nac
eTa
b5
mg
10Se
dat
ives
and
Tran
qu
ilis
ers
RPG
Phar
ma
23.5
3
Hal
oper
idol
yes
Sere
nac
eTa
b10
mg
10Se
dat
ives
and
Tran
qu
ilis
ers
RPG
Phar
ma
23.7
7
Hal
oper
idol
Sere
nac
eTa
b20
mg
10Se
dat
ives
and
Tran
qu
ilis
ers
RPG
Phar
ma
10.2
1
Hal
oper
idol
Sere
nac
eLi
qu
id2
mg/
1m
l15
ml
Sed
ativ
esan
dTr
anq
uil
iser
sR
PGPh
arm
a50
.38
Hal
oper
idol
yes
Sere
nac
eIn
j5
mg/
ml
5×
1m
lSe
dat
ives
and
Tran
qu
ilis
ers
RPG
Phar
ma
42.7
2
Clo
zap
ine
Loza
pin
Tab
25m
g10
An
tiem
etic
san
dA
nti
nau
sean
ts
Torr
ent
1.76
0.00
Clo
zap
ine
Loza
pin
Tab
100
mg
10A
nti
emet
ics
and
An
tin
ause
ants
Torr
ent
0.00
Dia
zep
amye
sPa
xum
Tab
5m
g10
Sed
ativ
esan
dTr
anq
uil
iser
sEa
stIn
dia
2.40
37.4
4
Dia
zep
amye
sPa
xum
Inj
5m
g/m
l2
ml
Sed
ativ
esan
dTr
anq
uil
iser
sEa
stIn
dia
38.5
4
Dia
zep
amEl
cion
CR
Cap
10m
g10
Sed
ativ
esan
dTr
anq
uil
iser
sR
anba
xy4.
130.
00
245
Lora
zep
amA
tiva
nTa
b1
mg
10Se
dat
ives
and
Tran
qu
ilis
ers
Wye
th5.
660.
00
Lora
zep
amA
tiva
nTa
b2
mg
10Se
dat
ives
and
Tran
qu
ilis
ers
Wye
th0.
00
Flu
ph
enaz
ine
An
aten
sol
Inj.
Inj
25m
g/m
l1
ml
vial
Sed
ativ
esan
dTr
anq
uil
iser
sN
ich
olas
Pira
mal
12.9
90.
00
Flu
ph
enaz
ine
An
aten
sol
Inj.
Tab
1m
g10
Sed
ativ
esan
dTr
anq
uil
iser
sN
ich
olas
Pira
mal
0.00
Phen
obar
bito
ne
yes
Gar
den
alTa
b30
mg
10H
ypn
otic
sN
ich
olas
Pira
mal
0.00
40.1
7
Phen
obar
bito
ne
yes
Gar
den
alTa
b60
mg
10H
ypn
otic
sN
ich
olas
Pira
mal
38.4
0
Phen
obar
bito
ne
Gar
den
alSy
rup
20m
g/5
ml
60m
lH
ypn
otic
sN
ich
olas
Pira
mal
23.3
7
Phen
ytoi
n+
Phen
obar
bito
ne
yes
Gar
oin
Tab
100
mg
+50
mg
10A
nti
con
vuls
ants
Nic
hol
asPi
ram
al7.
0031
.54
Phen
ytoi
nSo
diu
mD
ilan
tin
Kap
seal
s10
0m
g10
0A
nti
con
vuls
ants
Pfize
r0.
0024
.04
Phen
ytoi
nSo
diu
mD
ilan
tin
Kap
seal
s25
mg
100
An
tico
nvu
lsan
tsPfi
zer
26.0
1Ph
enyt
oin
Sod
ium
yes
Dil
anti
nSy
rup
25m
g/m
l10
0m
lA
nti
con
vuls
ants
Pfize
r21
.28
Phen
ytoi
nSo
diu
m+
Eth
anol
yes
Dil
anti
nIn
j50
mg
+9.
5%v/
v2
ml
An
tico
nvu
lsan
tsPfi
zer
21.4
3
Phen
ytoi
n+
Phen
obar
bito
ne
Dil
anti
n–
PK
apse
als
100
mg
+32
mg
100
An
tico
nvu
lsan
tsPfi
zer
0.00
Phen
ytoi
nSo
diu
mye
sEp
soli
nTa
b10
0m
g10
0A
nti
con
vuls
ants
Cad
ila
4.21
0.00
Phen
ytoi
nSo
diu
mye
sEp
soli
nIn
j50
mg/
ml
50×
2m
lA
nti
con
vuls
ants
Cad
ila
0.00
Phen
ytoi
nSo
diu
mye
sEp
toin
Tab
50m
g50
An
tico
nvu
lsan
tsA
bbot
t8.
320.
00Ph
enyt
oin
Sod
ium
yes
Epto
inTa
b10
0m
g10
0A
nti
con
vuls
ants
Abb
ott
0.00
Phen
ytoi
nSo
diu
mEp
toin
Syru
p30
mg/
5m
l20
0m
lA
nti
con
vuls
ants
Abb
ott
0.00
Trih
exyp
hen
idyl
yes
Paci
tan
eTa
b2
mg
10N
euro
deg
ener
ativ
eD
isea
seW
yeth
6.70
0.00
Sour
ce:
For
1994
–200
4M
IMS
Ind
ia,
asci
ted
inSa
kth
ivel
2006
,fo
r20
05–0
8,D
rug
Tod
ay,
vari
ous
issu
es,
CIM
SIn
dia
,20
07Ju
ly–O
ctob
er,
and
IDR
Phar
mac
yTr
ipp
leC
omp
end
ium
,200
8,N
ovem
ber
07–J
anu
ary
08.
246
Tabl
eB
.3Pr
ice
chan
ges
tod
rugs
for
infe
ctio
ns
and
infe
stat
ion
s
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
Cef
tria
xon
eso
diu
mM
onoc
efIn
j12
5m
gV
ial
An
tibi
otic
sA
rist
o−2
.58
1.82
Cef
tria
xon
eso
diu
mye
sM
onoc
efIn
j25
0m
gV
ial
An
tibi
otic
sA
rist
o6.
76
Cef
tria
xon
eso
diu
mM
onoc
efIn
j50
0m
gV
ial
An
tibi
otic
sA
rist
o5.
24
Cef
tria
xon
eso
diu
mye
sM
onoc
efIn
j1
gmV
ial
An
tibi
otic
sA
rist
o2.
93
Cef
tria
xon
eso
diu
mM
onoc
efIn
j2
gmV
ial
An
tibi
otic
sA
rist
o2.
94
Cef
pod
oxim
ep
roxe
til
Mon
ocef
–O
Tab
100
mg
6A
nti
biot
ics
Ari
sto
−0.6
0
Cef
pod
oxim
ep
roxe
til
Mon
ocef
–O
Tab
200
mg
6A
nti
biot
ics
Ari
sto
−0.6
0
Cef
pod
oxim
ep
roxe
til
Mon
ocef
–O
Dry
syru
p50
mg/
5m
l30
ml
An
tibi
otic
sA
rist
o−1
.81
Cef
pod
oxim
ep
roxe
til
Mon
ocef
–O
Dry
syru
p10
0m
g/5
ml
30m
lA
nti
biot
ics
Ari
sto
−1.7
6
Cef
tria
xon
eso
diu
mye
sO
fram
axIn
j25
0m
gV
ial
An
tibi
otic
sR
anba
xy−0
.17
0.00
Cef
tria
xon
eso
diu
mO
fram
axIn
j50
0m
gV
ial
An
tibi
otic
sR
anba
xy0.
00
Cef
tria
xon
eso
diu
mye
sO
fram
axIn
j1
gmV
ial
An
tibi
otic
sR
anba
xy0.
00
Pen
icil
lin
-Gp
otye
sPe
nti
ds
–20
0Ta
b20
0,00
0i.
u6
An
tibi
otic
sN
ich
olas
Pira
mal
−0.0
56.
06
Pen
icil
lin
-Gp
otye
sPe
nti
ds
–40
0Ta
b40
0,00
0i.
u6
An
tibi
otic
sN
ich
olas
Pira
mal
6.25
247Pe
nic
illi
n-G
pot
yes
yes
Pen
tid
s–
600
Tab
600,
000
i.u
4A
nti
biot
ics
Nic
hol
asPi
ram
al6.
35
Ben
zath
ine
Pen
icil
lin
-Gye
sye
sPe
nco
mIn
j60
0,00
0i.
u5
vial
sA
nti
biot
ics
Ale
mbi
c0.
58−1
.27
Ben
zath
ine
Pen
icil
lin
-Gye
sye
sPe
nco
mIn
j1,
200,
000i
.u5
vial
sA
nti
biot
ics
Ale
mbi
c−1
.21
Ben
zath
ine
Pen
icil
lin
-Gye
sye
sPe
nid
ure
LA6
Inj
600,
000
i.u
Via
lA
nti
biot
ics
Wye
th0.
00
Ben
zath
ine
Pen
icil
lin
-Gye
sye
sPe
nid
ure
LA12
Inj
1,20
0,00
0i.
uV
ial
An
tibi
otic
sW
yeth
0.00
Ben
zath
ine
Pen
icil
lin
-Gye
sye
sPe
nid
ure
LA24
Inj
2,40
0,00
0i.
uV
ial
An
tibi
otic
sW
yeth
0.00
Eryt
hro
myc
inye
sye
sEr
yth
roci
nTa
b25
0m
g10
An
tibi
otic
sPfi
zer
8.57
−33.
62Er
yth
rom
ycin
yes
yes
Eryt
hro
cin
Tab
500
mg
10A
nti
biot
ics
Pfize
r−3
4.26
Eryt
hro
myc
inye
sye
sEl
toci
nTa
b25
0m
g10
An
tibi
otic
sIP
CA
3.03
−36.
08Er
yth
rom
ycin
yes
yes
Elto
cin
Tab
500
mg
10A
nti
biot
ics
IPC
A−5
8.39
Eryt
hro
myc
inye
sye
sEl
toci
nD
rysy
rup
125
mg/
5m
l30
ml
An
tibi
otic
sIP
CA
−34.
32C
efot
axim
eye
sye
sC
lafo
ran
Inj
250
mg
Via
lA
nti
biot
ics
San
ofi-
Ave
nti
s2.
220.
00
Cef
otax
ime
yes
yes
Cla
fora
nIn
j50
0m
gV
ial
An
tibi
otic
sSa
nofi
-A
ven
tis
0.00
Cef
otax
ime
yes
Cla
fora
nIn
j1
gmV
ial
An
tibi
otic
sSa
nofi
-A
ven
tis
0.00
Ch
lora
mp
hen
icol
yes
Rec
lor
Cap
250
mg
10A
nti
biot
ics
Nic
hol
asPi
ram
al0.
0015
.63
Ch
lora
mp
hen
icol
yes
Rec
lor
Cap
500
mg
6A
nti
biot
ics
Nic
hol
asPi
ram
al14
.86
Ch
lora
mp
hen
icol
yes
Ch
loro
myc
etin
Cap
500
mg
6A
nti
biot
ics
Pfize
r5.
7324
.14
Ch
lora
mp
hen
icol
yes
Ch
loro
myc
etin
Palm
itat
esu
sp12
5m
g/5
ml
60m
lA
nti
biot
ics
Pfize
r0.
00C
hlo
ram
ph
enic
olC
hlo
rom
ycet
inK
apse
al25
0m
g10
An
tibi
otic
sPfi
zer
24.2
5A
mox
icil
lin
+C
loxa
cill
inye
sye
sN
ovac
lox
Cap
s25
0m
g+
250
mg
9A
nti
biot
ics
Cip
la7.
19−5
2.65
Am
oxic
illi
n+
Clo
xaci
llin
yes
Nov
aclo
xP-
Tab
125
mg
+12
5m
g15
An
tibi
otic
sC
ipla
−51.
70
Am
oxic
illi
n+
Clo
xaci
llin
yes
Nov
aclo
x25
0In
j12
5m
g+
125
mg
Via
lA
nti
biot
ics
Cip
la0.
00
248
Tabl
eB
.3(C
onti
nu
ed)
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
Am
oxic
illi
n+
Clo
xaci
llin
yes
yes
Nov
aclo
x50
0In
j25
0m
g+
250
mg
Via
lA
nti
biot
ics
Cip
la−1
.54
Am
oxic
illi
n+
Clo
xaci
llin
yes
yes
Nov
aclo
x10
00In
j50
0m
g+
500
mg
Via
lA
nti
biot
ics
Cip
la−1
.58
Am
oxic
illi
n+
Clo
xaci
llin
yes
Nov
aclo
xN
eon
ate
Inj
50m
g+
25m
g2
ml
vial
An
tibi
otic
sC
ipla
0.00
Am
oxic
illi
n+
Clo
xaci
llin
+La
ctic
Aci
dB
acil
lus
yes
yes
Nov
aclo
x–
LBC
ap25
0m
g+
250
mg
+60
mil
lion
cell
s
6A
nti
biot
ics
Cip
la−1
.58
Am
oxic
illi
nye
sye
sN
ovam
oxC
ap25
0m
g15
An
tibi
otic
sC
ipla
8.67
0.00
Am
oxic
illi
nye
sye
sN
ovam
oxC
ap50
0m
g6
An
tibi
otic
sC
ipla
0.00
Am
oxic
illi
nye
sye
sN
ovam
oxD
rysy
rup
125
mg/
5m
l30
ml
An
tibi
otic
sC
ipla
0.00
Am
oxic
illi
nye
sye
sN
ovam
oxD
rysy
rup
125
mg/
5m
l60
ml
An
tibi
otic
sC
ipla
0.00
Am
oxic
illi
nye
sN
ovam
ox(D
T)
Tab
125
mg
15A
nti
biot
ics
Cip
la0.
00
Am
oxic
illi
nye
sye
sN
ovam
ox(D
T)
Tab
250
mg
15A
nti
biot
ics
Cip
la0.
00
Am
pic
illi
nye
sye
sC
amp
icil
inC
ap25
0m
g10
An
tibi
otic
sC
adil
a10
.90
24.3
2A
mp
icil
lin
yes
yes
Cam
pic
ilin
Cap
500
mg
10A
nti
biot
ics
Cad
ila
−25.
22A
mp
icil
lin
yes
yes
Cam
pic
ilin
Dry
syru
p12
5m
g/5
ml
40m
lA
nti
biot
ics
Cad
ila
0.00
Am
pic
illi
nye
sye
sC
amp
icil
inD
rysy
rup
125
mg/
5m
l60
ml
An
tibi
otic
sC
adil
a7.
42A
mp
icil
lin
yes
Cam
pic
ilin
P-D
rop
s10
0m
g/m
l10
ml
An
tibi
otic
sC
adil
a0.
00A
mp
icil
lin
yes
Cam
pic
ilin
Inj
250
mg
Via
lA
nti
biot
ics
Cad
ila
0.00
Am
pic
illi
nye
sye
sC
amp
icil
inIn
j50
0m
gV
ial
An
tibi
otic
sC
adil
a0.
00A
mp
icil
lin
yes
yes
Bac
ipen
Cap
250
mg
4A
nti
biot
ics
Ale
mbi
c0.
00A
mp
icil
lin
yes
yes
Bac
ipen
Cap
500
mg
4A
nti
biot
ics
Ale
mbi
c0.
00
249
Am
pic
illi
nye
sye
sB
acip
enIn
j50
0m
gV
ial
An
tibi
otic
sA
lem
bic
0.00
Am
oxic
illi
n+
Clo
xaci
llin
yes
yes
Sup
rim
oxC
ap25
0m
g+
250
mg
15A
nti
biot
ics
Rex
cel/
Ran
baxy
3.89
−56.
36
Am
oxic
illi
n+
Clo
xaci
llin
yes
Sup
rim
oxP-
Tab
125
mg
+12
5m
g10
An
tibi
otic
sR
exce
l/R
anba
xy−5
1.48
Am
ph
oter
icin
Bye
sFu
ngi
zon
eIn
trav
enou
sIn
j50
mg
Via
lA
nti
fun
gals
Nic
hol
asPi
ram
al7.
500.
00
Clo
fazi
min
eye
sH
anse
pra
nC
ap50
mg
10A
nti
lep
roti
csN
ich
olas
Pira
mal
7.85
0.00
Clo
fazi
min
eye
sH
anse
pra
nC
ap10
0m
g10
An
tile
pro
tics
Nic
hol
asPi
ram
al0.
00
Meb
end
azol
eye
sM
ebex
Tab
100
mg
6A
nth
elm
inti
csan
dot
her
anti
-in
fest
ive
dru
gs
Cip
la4.
91
Meb
end
azol
eye
sM
ebex
Susp
100
mg/
5m
l30
ml
An
thel
min
tics
and
oth
eran
ti-i
nfe
stiv
ed
rugs
Cip
la6.
66
Meb
end
azol
eM
ebex
Gra
nn
ule
s20
0m
g/5
mg
5gm
Sach
ets
An
thel
min
tics
and
oth
eran
ti-i
nfe
stiv
ed
rugs
Cip
la7.
20
Meb
end
azol
e+
Pyra
nte
lPa
moa
te
yes
Meb
exPl
us
Tab
150
mg
+10
0m
g2
An
thel
min
tics
and
oth
eran
ti-i
nfe
stiv
ed
rugs
Cip
la0.
00−1
.66
Met
ron
idaz
ole
yes
yes
Flag
ylTa
b20
0m
g10
An
ti-
amoe
bics
,an
ti-g
iard
iasi
s
Nic
hol
asPi
ram
al2.
52−1
.92
Met
ron
idaz
ole
yes
yes
Flag
ylTa
b40
0m
g10
An
ti-
amoe
bics
,an
ti-g
iard
iasi
s
Nic
hol
asPi
ram
al−1
.74
250
Tabl
eB
.3(C
onti
nu
ed)
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
Met
ron
idaz
ole
yes
Flag
ylSu
sp20
0m
g/5
ml
30m
lA
nti
-am
oebi
cs,
anti
-gia
rdia
sis
Nic
hol
asPi
ram
al−5
.13
Met
ron
idaz
ole
yes
Flag
ylSu
sp20
0m
g/5
ml
60m
lA
nti
-am
oebi
cs,
anti
-gia
rdia
sis
Nic
hol
asPi
ram
al−4
.56
Met
ron
idaz
ole
+Fu
razo
lid
one
yes
yes
Flag
yl–
FTa
b40
0m
g+
100
mg
10A
nti
-dia
rrh
orea
lsN
ich
olas
Pira
mal
3.55
Met
ron
idaz
ole
+Fu
razo
lid
one
yes
yes
Flag
yl–
FSu
sp10
0m
g+
30m
g/5
ml
60m
lA
nti
-dia
rrh
orea
lsN
ich
olas
Pira
mal
7.40
Met
ron
idaz
ole
+D
ilox
anid
eFu
roat
e
yes
yes
Flag
yl–
DF
Tab
400
mg
+50
0m
g15
An
ti-d
iarr
hor
eals
Nic
hol
asPi
ram
al−0
.09
Met
ron
idaz
ole
yes
yes
Ari
stog
ylTa
b20
0m
g10
An
ti-a
moe
bics
,an
ti-g
iard
iasi
sA
rist
o4.
74−1
.09
Met
ron
idaz
ole
yes
yes
Ari
stog
ylTa
b40
0m
g10
An
ti-a
moe
bics
,an
ti-g
iard
iasi
sA
rist
o−1
.27
Met
ron
idaz
ole
yes
Ari
stog
ylSu
sp10
0m
g/5
ml
60m
lA
nti
-am
oebi
cs,
anti
-gia
rdia
sis
Ari
sto
−1.1
7
Met
ron
idaz
ole
+Fu
razo
lid
one
+Si
met
hic
one
yes
yes
Ari
stog
yl–
FTa
b40
0m
g+
100
mg
+50
mg
10A
nti
-am
oebi
cs,
anti
-gia
rdia
sis
Ari
sto
0.00
Met
ron
idaz
ole
+Fu
razo
lid
one
yes
Ari
stog
yl–
FSu
sp10
0m
g+
30m
g/5
ml
60m
lA
nti
-am
oebi
cs,
anti
-gia
rdia
sis
Ari
sto
−1.3
2
Met
ron
idaz
ole
+D
ilox
anid
eFu
roat
e+
Sim
eth
icon
e
yes
yes
Ari
stog
ylPl
us
Tab
400
mg
+50
0m
g+
100
mg
10A
nti
-am
oebi
cs,
anti
-gia
rdia
sis
Ari
sto
−1.1
7
Cip
rofl
oxac
inye
sye
sC
ipro
win
Tab
250
mg
10Q
uin
olon
esA
lem
bic
0.00
0.00
251
Cip
rofl
oxac
inye
sye
sC
ipro
win
Tab
500
mg
10Q
uin
olon
esA
lem
bic
0.00
Cip
rofl
oxac
inye
sC
ipro
win
Tab
750
mg
10Q
uin
olon
esA
lem
bic
0.00
Cip
rofl
oxac
inye
sC
ipro
win
Infu
sion
100
mg/
50m
l10
0m
lQ
uin
olon
esA
lem
bic
0.00
Cip
rofl
oxac
in+
Trin
idaz
ole
yes
yes
Cip
row
in–
TZ
–25
0Ta
b25
0m
g+
300
mg
10A
nti
-d
iarr
hor
eals
Ale
mbi
c0.
00
Cip
rofl
oxac
in+
Trin
idaz
ole
yes
Cip
row
in–
TZ
–50
0Ta
b50
0m
g+
600
mg
10A
nti
-d
iarr
hor
eals
Ale
mbi
c0.
00
Cip
rofl
oxac
in+
Ben
zalk
oniu
mch
lori
de
yes
yes
Cip
row
inE/
ED
rop
sD
rop
s3
mg
+0.
012%
v/v/
ml
5m
lA
nti
-in
fect
ive
pre
pA
lem
bic
0.00
Cip
rofl
oxac
inye
sC
iplo
xTa
b10
0m
g10
Sulp
hon
amid
esan
dot
her
Bac
t.
Cip
la3.
38−0
.83
Cip
rofl
oxac
inye
sye
sC
iplo
xTa
b25
0m
g10
Sulp
hon
amid
esan
dot
her
Bac
t.
Cip
la−0
.80
Cip
rofl
oxac
inye
sye
sC
iplo
xTa
b50
0m
g10
Sulp
hon
amid
esan
dot
her
Bac
t.
Cip
la−0
.80
Cip
rofl
oxac
inye
sC
iplo
xTa
b75
0m
g10
Sulp
hon
amid
esan
dot
her
Bac
t.
Cip
la−0
.80
Cip
rofl
oxac
inye
sC
iplo
xIn
fusi
onIn
fusi
on10
0m
g/50
ml
100
ml
Sulp
hon
amid
esan
dot
her
Bac
t.
Cip
la0.
00
Cip
rofl
oxac
inye
sye
sC
iplo
x–
OD
Tab
500
mg
5Su
lph
onam
ides
and
oth
erB
act.
Cip
la0.
00
Cip
rofl
oxac
inye
sC
iplo
xTa
b10
0m
g5
Sulp
hon
amid
esan
dot
her
Bac
t.
Cip
la0.
00
Sour
ce:
For
1994
–200
4M
IMS
Ind
ia,
asci
ted
inSa
kth
ivel
2006
,fo
r20
05–0
8,D
rug
Tod
ay,
vari
ous
issu
es,
CIM
SIn
dia
,20
07Ju
ly–O
ctob
er,
and
IDR
Phar
mac
yTr
ipp
leC
omp
end
ium
,200
8,N
ovem
ber
07–J
anu
ary
08.
252
Tabl
eB
.4Pr
ice
chan
ges
tod
rugs
for
mal
aria
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
Ch
loro
qu
ine
yes
Emq
uin
Tab
250
mg
10A
nti
mal
aria
lsM
erck
7.29
−16.
14C
hlo
roq
uin
eye
sEm
qu
inTa
b25
0m
g10
00A
nti
mal
aria
lsM
erck
0.00
Ch
loro
qu
ine
yes
Emq
uin
D.S
.50
0m
g20
×5
An
tim
alar
ials
Mer
ck−3
.07
Ch
loro
qu
ine
yes
Emq
uin
Susp
160
mg/
10m
l60
ml
An
tim
alar
ials
Mer
ck1.
97
Ch
loro
qu
ine
yes
Emq
uin
Inj
64.5
mg/
ml
15×
30m
lA
nti
mal
aria
lsM
erck
9.19
Ch
loro
qu
ine
yes
Mel
ubr
inTa
b25
0m
g10
An
tim
alar
ials
Ran
baxy
−2.5
80.
00C
hlo
roq
uin
eye
sN
ivaq
uin
eTa
b25
0m
g10
An
tim
alar
ials
Nic
hol
asPi
ram
al−1
6.13
Ch
loro
qu
ine
yes
Niv
aqu
ine
Susp
80.6
5m
g/5
ml
60m
lA
nti
mal
aria
lsN
ich
olas
Pira
mal
−7.2
9
Ch
loro
qu
ine
yes
yes
Niv
aqu
ine
Inj
40m
g/m
l2
ml
amp
An
tim
alar
ials
Nic
hol
asPi
ram
al20
.33
Ch
loro
qu
ine
yes
yes
Niv
aqu
ine
Inj
40m
g/m
l5
mla
mp
An
tim
alar
ials
Nic
hol
asPi
ram
al5.
88
Ch
loro
qu
ine
yes
yes
Niv
aqu
ine
Inj
40m
g/m
l30
ml
An
tim
alar
ials
Nic
hol
asPi
ram
al5.
41
Mefl
oqu
ine
Mefl
iam
Tab
250
mg
6A
nti
mal
aria
lsC
ipla
0.00
Mefl
oqu
ine
Faci
tal
Tab
250
mg
6A
nti
mal
aria
lsC
adil
a0.
00Q
uin
ine
sulp
hat
eye
sK
un
enTa
b30
0m
g10
An
tim
alar
ials
Mer
rin
d0.
00Q
uin
ine
sulp
hat
eK
un
enTa
b60
0m
g10
An
tim
alar
ials
Mer
rin
d0.
00
Sour
ce:
For
1994
–200
4M
IMS
Ind
ia,
asci
ted
inSa
kth
ivel
2006
,fo
r20
05–0
8,D
rug
Tod
ay,
vari
ous
issu
es,
CIM
SIn
dia
,20
07Ju
ly–O
ctob
er,
and
IDR
Phar
mac
yTr
ipp
leC
omp
end
ium
,200
8,N
ovem
ber
07–J
anu
ary
08.
253
Tabl
eB
.5Pr
ice
chan
ges
tod
rugs
for
HIV
/AID
S
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
Zid
ovu
din
eye
sZi
dov
irC
ap10
0m
g10
An
tire
torv
iral
sC
ipla
−7.6
70.
00Zi
dov
ud
ine
yes
Zid
ovir
Cap
100
mg
100
An
tire
torv
iral
sC
ipla
0.00
Zid
ovu
din
eye
sZi
dov
irC
ap30
0m
g10
An
tire
torv
iral
sC
ipla
0.00
Zid
ovu
din
eye
sZi
dov
irC
ap30
0m
g60
An
tire
torv
iral
sC
ipla
0.00
Zid
ovu
din
eZi
dov
irSy
rup
50m
g/m
l10
0m
lA
nti
reto
rvir
als
Cip
la−3
3.33
Zid
ovu
din
eZi
dom
axC
ap10
0m
g10
An
tire
torv
iral
sA
lkem
0.00
Zid
ovu
din
eye
sZi
dom
axTa
b30
0m
g10
An
tire
torv
iral
sA
lkem
0.00
Zid
ovu
din
eZy
dow
inC
ap10
0m
g10
An
tire
torv
iral
sZy
du
sV
acci
care
0.00
Zid
ovu
din
eye
sZy
dow
inTa
b30
0m
g10
An
tire
torv
iral
sZy
du
sV
acci
care
0.00
Stav
ud
ine
yes
Stav
irC
ap30
mg
10A
nti
reto
rvir
als
Cip
la0.
00St
avu
din
eye
sSt
avir
Tab
40m
g10
An
tire
torv
iral
sC
ipla
0.00
Lam
ivu
din
e+
Zid
ovu
din
eye
sC
ombi
vir
Tab
150
mg
+ 300
mg
10A
nti
reto
rvir
als
GSK
0.00
Lam
ivu
din
e+
Zid
ovu
din
eye
sD
uov
irTa
b15
0m
g+ 30
0m
g
60A
nti
reto
rvir
als
Cip
la0.
00
Lam
ivu
din
e+
Zid
ovu
din
eye
sLa
mu
zid
Tab
150
mg
+ 300
mg
10A
nti
reto
rvir
als
Zyd
us
Vac
cica
re0.
00
Lam
ivu
din
e+
Zid
ovu
din
eye
sZi
dol
amTa
b15
0m
g+ 30
0m
g
10A
nti
reto
rvir
als
Gen
ix−2
3.64
Sour
ce:
For
1994
–200
4M
IMS
Ind
ia,
asci
ted
inSa
kth
ivel
2006
,fo
r20
05–0
8,D
rug
Tod
ay,
vari
ous
issu
es,
CIM
SIn
dia
,20
07Ju
ly–O
ctob
er,
and
IDR
Phar
mac
yTr
ipp
leC
omp
end
ium
,200
8,N
ovem
ber
07–J
anu
ary
08.
254
Tabl
eB
.6Pr
ice
chan
ges
tod
rugs
for
Tube
rcu
losi
s
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
Rif
amp
icin
+Is
onia
zid
yes
yes
Rim
paz
idTa
b45
0m
g+
300
mg
10A
nti
tube
rcu
losi
sC
adil
aH
ealt
h12
.39
0.00
Rif
amp
icin
+Is
onia
zid
yes
yes
Rim
acta
zid
450/
300
Tab
450
mg
+30
0m
g20
×4
An
titu
berc
ulo
sis
Nov
arti
s−1
2.17
Rif
amp
icin
+Is
onia
zid
yes
yes
Rim
acta
zid
Dis
ped
100
mg
+50
mg
10A
nti
tube
rcu
losi
sN
ovar
tis
−12.
19
Rif
amp
icin
+Is
onia
zid
yes
yes
Rim
acta
zid
Plu
sTa
b60
0m
g+
300
mg
25×
4A
nti
tube
rcu
losi
sN
ovar
tis
−12.
13
Rif
amp
icin
yes
yes
Rim
acta
ne
Cap
300
mg
4A
nti
tube
rcu
losi
sN
ovar
tis
2.90
0.00
Rif
amp
icin
yes
yes
Rim
acta
ne
Tab
450
mg
20×
4A
nti
tube
rcu
losi
sN
ovar
tis
−11.
07Et
ham
buto
l+
INH
yes
Myc
onex
800
Tab
800
mg
+30
0m
g10
An
titu
berc
ulo
sis
LeSa
nte
0.00
4.17
Eth
ambu
tol+
INH
yes
Inab
uto
lFo
rte
Tab
800
mg
+30
0m
g10
An
titu
berc
ulo
sis
Th
emis
Ch
emic
als
9.96
0.00
Eth
ambu
tol+
INH
yes
Com
bun
exTa
b80
0m
g+
300
mg
10A
nti
tube
rcu
losi
sLu
pin
13.4
50.
00
Pyra
zin
amid
eye
sP-
Zid
eTa
b50
0m
g10
An
titu
berc
ulo
sis
LeSa
nte
0.00
0.00
Pyra
zin
amid
eye
sP-
Zid
eTa
b75
0m
g11
An
titu
berc
ulo
sis
LeSa
nte
0.00
0.00
Pyra
zin
amid
eye
sP-
Zid
eTa
b10
00m
g12
An
titu
berc
ulo
sis
LeSa
nte
0.00
0.00
Pyra
zin
amid
eye
sPZ
A-C
iba
Tab
500
mg
10A
nti
tube
rcu
losi
sN
ovar
tis
7.56
0.00
Pyra
zin
amid
eye
sPZ
A-C
iba
Tab
750
mg
10A
nti
tube
rcu
losi
sN
ovar
tis
0.00
Pyra
zin
amid
eye
sPZ
A-C
iba
Tab
1000
mg
10A
nti
tube
rcu
losi
sN
ovar
tis
0.00
Pyra
zin
amid
ePZ
A-C
iba
Susp
5%10
0m
lA
nti
tube
rcu
losi
sN
ovar
tis
0.00
Stre
pto
myc
inye
sye
sA
mbi
stry
n-S
Inj
0.75
gmvi
alA
nti
tube
rcu
losi
sN
ich
olas
Pira
mal
8.96
−7.3
1St
rep
tom
ycin
yes
yes
Am
bist
ryn
-SIn
j1.
00gm
vial
An
titu
berc
ulo
sis
Nic
hol
asPi
ram
al−8
.15
Sour
ce:
For
1994
–200
4M
IMS
Ind
ia,
asci
ted
inSa
kth
ivel
2006
,fo
r20
05–0
8,D
rug
Tod
ay,
vari
ous
issu
es,
CIM
SIn
dia
,20
07Ju
ly–O
ctob
er,
and
IDR
Phar
mac
yTr
ipp
leC
omp
end
ium
,200
8,N
ovem
ber
07–J
anu
ary
08.
255
Tabl
eB
.7Pr
ice
chan
ges
tod
rugs
for
alim
enta
ry,m
usc
ulo
-ske
leta
ld
isor
der
s,h
orm
ones
,an
dge
nit
o-u
rin
ary
syst
em
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
Nal
idix
icA
cid
yes
yes
Gra
mon
egTa
b50
0m
g8
An
tid
iarr
hoe
als
Rex
tar
−0.4
10.
00N
alid
ixic
Aci
dye
sG
ram
oneg
Syru
p30
0m
g/5
ml
30m
lA
nti
dia
rrh
oeal
sR
exta
r0.
00
Nal
idix
icA
cid
+M
etro
nid
a-zo
le
yes
Gra
mon
eg–
MSy
rup
150
mg
+10
0m
g/5
ml
30m
lA
nti
dia
rrh
oeal
sR
anba
xy0.
00
Nal
idix
icA
cid
+M
etro
nid
a-zo
le
yes
yes
Gra
mon
eg–
MTa
b30
0m
g+
200
mg
8A
nti
dia
rrh
oeal
sR
anba
xy0.
00
Nor
flox
acin
+Ti
nid
azol
eye
sye
sG
ram
oneg
–T
NTa
b40
0m
g+
600
mg
10A
nti
dia
rrh
oeal
sR
anba
xy0.
00
Nal
idix
icA
cid
yes
Neg
adix
Tab
Kid
125
mg
10U
rin
ary
anti
-in
fect
ives
CFL
Phar
ma
−0.3
80.
00
Nal
idix
icA
cid
+M
etro
nid
a-zo
le
yes
yes
Neg
adix
–M
Tab
300
mg
+20
0m
g6
Uri
nar
yan
ti-i
nfe
ctiv
esC
FLPh
arm
a0.
00
Nal
idix
icA
cid
+M
etro
nid
a-zo
le
yes
Neg
adix
–M
Susp
150
mg
+10
0m
g60
ml
Uri
nar
yan
ti-i
nfe
ctiv
esC
FLPh
arm
a0.
00
Oxy
toci
nye
sPi
toci
nIn
j10
i.u
.1
amp
Dru
gsac
tin
gon
ute
rus
Pfize
r0.
7720
.51
Gli
ben
clam
ide
yes
Eugl
uco
nTa
b5
mg
10H
yper
and
hyp
ogly
caem
ics
Nic
hol
asPi
ram
al8.
3533
.33
Gli
ben
clam
ide
yes
Dao
nil
Tab
5m
g10
Hyp
eran
dh
ypog
lyca
emic
sSa
nofi
-Ave
nti
s6.
810.
00
256
Tabl
eB
.7(C
onti
nu
ed)
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
Fru
sem
ide
yes
yes
Fru
sen
exTa
b40
mg
10D
iure
tics
and
An
tid
iure
tics
Gen
o−1
.03
0.00
Fru
sem
ide
yes
Fru
sen
exTa
b10
0m
g10
Diu
reti
csan
dA
nti
diu
reti
csG
eno
0.00
Fru
sem
ide
yes
yes
Lasi
xTa
b40
mg
10D
iure
tics
and
An
tid
iure
tics
San
ofi-A
ven
tis
−1.6
6
Fru
sem
ide
yes
Lasi
xTa
bH
igh
dos
e10
Diu
reti
csan
dA
nti
diu
reti
csSa
nofi
-Ave
nti
s0.
00
Fru
sem
ide
yes
yes
Lasi
xIn
j10
mg/
2m
l2
ml
Am
pD
iure
tics
and
An
tid
iure
tics
San
ofi-A
ven
tis
1.41
Fru
sem
ide
yes
yes
Lasi
xIn
jH
igh
dos
e10
mg
5×
25m
lD
iure
tics
and
An
tid
iure
tics
San
ofi-A
ven
tis
0.00
Fru
sem
ide
+A
mil
orid
eye
sFr
um
ilTa
b40
mg
+5
mg
10D
iure
tics
and
An
tid
iure
tics
Gen
o8.
240.
00
Spir
onol
acto
ne
yes
yes
Ald
acto
ne
Tab
25m
g10
Diu
reti
csan
dA
nti
diu
reti
csR
PG4.
34−6
.04
Spir
onol
acto
ne
yes
Ald
acto
ne
Tab
100
mg
10D
iure
tics
and
An
tid
iure
tics
RPG
−8.1
7
Spir
onol
acto
ne
+H
ydro
flu
me-
thia
zid
e
yes
yes
Ald
acti
de
Tab
25m
g+
25m
g10
Diu
reti
csan
dA
nti
diu
reti
csR
PG0.
00
Ibu
pro
fen
yes
yes
Bru
fen
Tab
200
mg
10N
on-S
tero
idan
ti-i
nlm
.D
rugs
Abb
ott
4.66
0.00
Ibu
pro
fen
yes
yes
Bru
fen
Tab
400
mg
10N
on-S
tero
idan
ti-i
nlm
.D
rugs
Abb
ott
0.00
257
Ibu
pro
fen
yes
Bru
fen
Tab
600
mg
10N
on-S
tero
idan
ti-i
nlm
.Dru
gsA
bbot
t0.
00
Ibu
pro
fen
+Pa
race
tam
olye
sye
sC
ombi
flam
Tab
400
mg
+32
5m
g10
Non
-Ste
roid
anti
-in
lm.D
rugs
San
ofi-A
ven
tis
7.16
−1.6
7
Ibu
pro
fen
+Pa
race
tam
olye
sC
ombi
flam
Susp
100
mg
+16
2.5
mg/
5m
l60
ml
Non
-Ste
roid
anti
-in
lm.D
rugs
San
ofi-A
ven
tis
−1.6
2
Insu
lin
NPH
yes
yes
Act
rap
idIn
j40
i.u
.10
ml
Hyp
eran
dh
ypog
lyca
emic
sA
bbot
t3.
990.
00
Insu
lin
NPH
yes
yes
Act
rap
idM
CIn
j40
i.u
.10
ml
Hyp
eran
dh
ypog
lyca
emic
sA
bbot
t0.
00
Insu
lin
NPH
yes
yes
Len
tard
Inj
40i.
u./
ml
10m
lT
hro
idan
dan
tith
roid
dru
gsA
bbot
t1.
240.
00
Insu
lin
NPH
yes
yes
Ilet
in–
LIn
j40
i.u
./m
l10
ml
Th
roid
and
anti
thro
idd
rugs
Eli
Lill
y0.
00
Insu
lin
NPH
yes
yes
Ilet
in–
NPH
Inj
40i.
u./
ml
10m
lT
hro
idan
dan
tith
roid
dru
gsEl
iLi
lly
0.00
Insu
lin
NPH
yes
yes
Ilet
in–
RIn
j40
i.u
./m
l10
ml
Th
roid
and
anti
thro
idd
rugs
Eli
Lill
y0.
00
Pred
nis
olon
eye
sye
sW
ysol
one
Tab
5m
g10
Cor
tico
ster
oid
san
dre
late
dd
rugs
Wye
th−5
.10
0.00
Pred
nis
olon
eye
sye
sW
ysol
one
Tab
10m
g10
Cor
tico
ster
oid
san
dre
late
dd
rugs
Wye
th0.
00
Pred
nis
olon
eye
sW
ysol
one
Tab
20m
g10
Cor
tico
ster
oid
san
dre
late
dd
rugs
Wye
th0.
00
Pred
nis
olon
eye
sW
ysol
one
Tab
30m
g10
Cor
tico
ster
oid
san
dre
late
dd
rugs
Wye
th0.
00
Pred
nis
olon
eye
sW
ysol
one
Tab
40m
g10
Cor
tico
ster
oid
san
dre
late
dd
rugs
Wye
th0.
00
258
Tabl
eB
.7(C
onti
nu
ed)
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
Mag
nes
ium
+ye
sPe
pti
cain
eLi
qu
idC
ombi
nat
ion
120
ml
Gas
tro-
inte
stin
alse
dat
ives
and
Ulc
erd
rugs
Pfize
r3.
440.
00
Mag
nes
ium
+ye
sSo
laci
dTa
bC
ombi
nat
ion
10G
astr
o-in
test
inal
sed
ativ
esan
dU
lcer
dru
gs
Dey
’sPh
arm
a10
.60
25.0
0
Mag
nes
ium
+ye
sSo
laci
dSy
rup
Com
bin
atio
n17
0m
lG
astr
o-in
test
inal
sed
ativ
esan
dU
lcer
dru
gs
Dey
’sPh
arm
a19
.40
Mag
nes
ium
+ye
sSo
laci
dSy
rup
Com
bin
atio
n34
0m
lG
astr
o-in
test
inal
sed
ativ
esan
dU
lcer
dru
gs
Dey
’sPh
arm
a18
.42
Mag
nes
ium
+ye
sSo
laci
d–
OSu
spC
ombi
nat
ion
170
ml
Gas
tro-
inte
stin
alse
dat
ives
and
Ulc
erd
rugs
Dey
’sPh
arm
a14
.28
Not
e:T
he
+sy
mbo
lat
the
end
ofa
dru
gn
ame
den
otes
form
ula
tion
sm
ade
from
mor
eth
anth
ree
dru
gs.
Wh
ile
all
the
dru
gsw
ere
con
sid
ered
for
the
anal
ysis
,it
was
con
sid
ered
app
rop
riat
eto
lim
itth
eli
stin
gto
thre
ed
rugs
for
this
stu
dy.
Sour
ce:
For
1994
–200
4M
IMS
Ind
ia,
asci
ted
inSa
kth
ivel
2006
,fo
r20
05–0
8,D
rug
Tod
ay,
vari
ous
issu
es,
CIM
SIn
dia
,20
07Ju
ly–O
ctob
er,
and
IDR
Phar
mac
yTr
ipp
leC
omp
end
ium
,200
8,N
ovem
ber
07–J
anu
ary
08.
259
Tabl
eB
.8Pr
ice
chan
ges
tod
rugs
for
nu
trit
ion
and
resp
irat
ory
syst
em
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
Vit
amin
Aye
sye
sR
ovig
onTa
bV
itam
inA
10,0
00i.
u+
Vit
amin
E25
mg
10V
itam
ins
Nic
hol
asPi
ram
al0.
440.
00
Salm
eter
olSe
robi
dIn
hal
er25
mcg
/m
eter
edd
ose
200
md
iB
ron
chos
pas
mC
ipla
3.40
0.00
Salm
eter
olSe
robi
dR
otah
aler
30B
ron
chos
pas
mC
ipla
0.00
Salm
eter
olSe
robi
dR
otac
ap50
mcg
30B
ron
chos
pas
mC
ipla
0.00
Salm
eter
olSa
lmet
erIn
hal
er25
mcg
/m
eter
edd
ose
Bro
nch
osp
asm
DR
L−0
.67
0.00
Eph
edri
ne
+T
heo
ph
ylli
ne
+p
hen
obar
bito
ne
yes
yes
Asm
apax
Dep
otTa
b50
mg
+65
mg
+30
mg
10B
ron
chos
pas
mN
ich
olas
Pira
mal
−0.3
4−1
.63
Eph
edri
ne
+T
heo
ph
ylli
ne
+p
hen
obar
bito
ne
yes
yes
Ale
rgin
Tab
20m
g+
100
mg
+15
mg
10B
ron
chos
pas
mC
ipla
7.36
0.00
Iron
+(S
alts
/com
ple
x)ye
sA
nem
idox
Cap
Com
bin
atio
n3
×10
An
aem
ia;
Neu
trop
enia
Mer
ck14
.18
−1.3
2
Iron
+(S
alts
/com
ple
x)Im
fero
nLi
qu
idC
ombi
nat
ion
200
ml
An
aem
ia;
Neu
trop
enia
Shre
ya4.
367.
35
Iron
+(S
alts
/com
ple
x)Im
fero
nC
apC
ombi
nat
ion
15A
nae
mia
;N
eutr
open
iaSh
reya
64.4
7
260
Tabl
eB
.8(C
onti
nu
ed)
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
Iron
dex
tran
+V
itam
inB
-12
+Fo
lic
acid
yes
Imfe
ron
Inj
50m
gof
elem
enta
lir
on+
12,5
00m
cg+
2.5
mg/
ml
2m
lA
nae
mia
;N
eutr
open
iaSh
reya
−6.4
3
Iron
dex
tran
+V
itam
inB
-12
+Fo
lic
acid
yes
Imfe
ron
Inj
50m
gof
elem
enta
lir
on+
12,5
00m
cg+
2.5
mg/
ml
10m
lA
nae
mia
;N
eutr
open
iaSh
reya
−0.8
0
Iron
dex
tran
+V
itam
inB
-12
yes
Imfe
ron
B–
12In
j50
mg
ofel
emen
tal
iron
+50
0m
cg/m
l
2m
lA
nae
mia
;N
eutr
open
iaSh
reya
0.00
Iron
dex
tran
+V
itam
inB
-12
+Fo
lic
acid
yes
Imfe
ron
F–
12In
j50
mg
ofel
emen
tal
iron
+50
0m
cg+
2.5
mg/
ml
20×
2m
lA
nae
mia
;N
eutr
open
iaSh
reya
12.4
0
Bu
des
onid
ePu
lmic
ort
Inh
aler
100
mcg
100
dos
esB
ron
chos
pas
mre
laxa
nts
Ast
raZe
nec
a8.
9338
.51
Bu
des
onid
ePu
lmic
ort
Inh
aler
100
mcg
400
dos
esB
ron
chos
pas
mre
laxa
nts
Ast
raZe
nec
a0.
00
Salb
uta
mol
yes
yes
Salm
aplo
nTa
b2
mg
10B
ron
chos
pas
mre
laxa
nts
Kh
and
elw
al4.
06−6
8.00
261
Salb
uta
mol
yes
yes
Salm
aplo
nTa
b4
mg
10B
ron
chos
pas
mre
laxa
nts
Kh
and
elw
al−7
0.40
Salb
uta
mol
yes
yes
Salb
etol
Tab
2m
g10
Bro
nch
osp
asm
rela
xan
tsFD
C2.
570.
00
Salb
uta
mol
yes
yes
Salb
etol
Tab
4m
g10
Bro
nch
osp
asm
rela
xan
tsFD
C0.
00
Car
boh
ydra
te+
yes
Ferr
adol
Food
Pow
der
Com
bin
atio
n20
0gm
sTo
nic
s;ap
pet
ite
stim
ula
nts
Pfize
r−2
.06
0.00
Car
boh
ydra
te+
yes
Ferr
adol
Food
Pow
der
Com
bin
atio
n45
0gm
sTo
nic
s;ap
pet
ite
stim
ula
nts
Pfize
r0.
00
Am
ino
acid
+G
lyci
ne
+So
rbit
ol
Ast
ymin
–3
Infu
sion
81.2
mg
+10
mg
+50
mg/
ml
200
ml
Ton
ics;
app
etit
est
imu
lan
tsTa
blet
Ind
ia11
.75
Am
ino
acid
+G
lyci
ne
+So
rbit
ol
Ast
ymin
–3
Am
p81
.2m
g+
10m
g+
50m
g/m
l
20m
lTo
nic
s;ap
pet
ite
stim
ula
nts
Tabl
etIn
dia
8.31
L-is
oleu
cin
e+A
stym
in–
SNIn
fusi
onC
ombi
nat
ion
200
ml
Ton
ics;
app
etit
est
imu
lan
tsTa
blet
Ind
ia10
.27
L-is
oleu
cin
e+ye
sA
stym
inSy
rup
Com
bin
atio
n11
0m
lTo
nic
s;ap
pet
ite
stim
ula
nts
Tabl
etIn
dia
21.3
7
L-is
oleu
cin
e+ye
sA
stym
inSy
rup
Com
bin
atio
n20
0m
lTo
nic
s;ap
pet
ite
stim
ula
nts
Tabl
etIn
dia
22.9
9
Vit
amin
A+
yes
yes
Ast
ymin
Fort
eC
apC
ombi
nat
ion
10×
2To
nic
s;ap
pet
ite
stim
ula
nts
Tabl
etIn
dia
2.05
13.5
2
Vit
amin
C+
yes
Ast
ymin
–C
Dro
ps
Com
bin
atio
n15
ml
Ton
ics;
app
etit
est
imu
lan
tsTa
blet
Ind
ia19
.89
Mag
nes
ium
+A
stym
in-M
Fort
eC
apC
ombi
nat
ion
10To
nic
s;ap
pet
ite
stim
ula
nts
Tabl
etIn
dia
16.9
8
Dex
tros
e+Le
clyt
ePo
wd
erC
ombi
nat
ion
30gm
sM
iner
alan
dp
aren
tera
ln
utr
itio
nal
sup
pl.
Alb
ert
Dav
id0.
000.
00
Dex
tros
e+Le
clyt
e–
GIn
jC
ombi
nat
ion
500
ml
Plas
ma
exp
and
ers
Alb
ert
Dav
id−3
9.20
262
Tabl
eB
.8(C
onti
nu
ed)
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
Dex
tros
e+Le
clyt
e–
MIn
jC
ombi
nat
ion
500
ml
Plas
ma
exp
and
ers
Alb
ert
Dav
id−3
9.20
Dex
tros
e+Le
clyt
e–
PIn
jC
ombi
nat
ion
500
ml
Plas
ma
exp
and
ers
Alb
ert
Dav
id−3
9.20
Dex
tros
e+Le
clyt
e–
RIn
jC
ombi
nat
ion
500
ml
Plas
ma
exp
and
ers
Alb
ert
Dav
id0.
00
Dex
tros
e+Le
clyt
e–
WPo
wd
erC
ombi
nat
ion
27.5
gms
Min
eral
and
par
ente
ral
nu
trit
ion
alsu
pp
l.
Alb
ert
Dav
id0.
00
Cal
ciu
mC
arbo
nat
e+
Vit
amin
D3
Oss
ivit
eTa
b0.
625
g+10
0i.
u.
10M
iner
alan
dp
aren
tera
ln
utr
itio
nal
sup
pl.
Wye
th5.
620.
00
Cal
ciu
mC
arbo
nat
e+
Vit
amin
D3
Oss
ivit
eTa
b1.
25g+
200
i.u
.10
Min
eral
and
par
ente
ral
nu
trit
ion
alsu
pp
l.
Wye
th0.
00
Vit
amin
A+
yes
yes
Fili
bon
Cap
Com
bin
atio
n50
Min
eral
and
par
ente
ral
nu
trit
ion
alsu
pp
l.
Wye
th2.
900.
00
Dex
trom
eth
rop
han
+G
rili
nct
us
Syru
pC
ombi
nat
ion
100
ml
Exp
ecto
ran
ts,
Cou
ghSu
pp
r.,
Dec
onge
stan
ts
Fran
coIn
dia
n4.
6753
.66
Dex
trom
eth
rop
han
+G
rili
nct
us
Syru
pC
ombi
nat
ion
450
ml
Exp
ecto
ran
ts,
Cou
ghSu
pp
r.,
Dec
onge
stan
ts
Fran
coIn
dia
n25
.00
Terb
uta
lin
e+
Bro
mh
exci
ne
Gri
lin
ctu
sB
MSy
rup
2.5
mg
+8
mg/
5m
l10
0m
lEx
pec
tora
nts
,C
ough
Sup
pr.
,D
econ
gest
ants
Fran
coIn
dia
n25
.00
Terb
uta
lin
e+
Bro
mh
exci
ne
Gri
lin
ctu
sB
MPe
adsy
rup
1.5
mg
+4
mg/
5m
l30
ml
Exp
ecto
ran
ts,
Cou
ghSu
pp
r.,
Dec
onge
stan
ts
Fran
coIn
dia
n16
.86
263
Terb
uta
lin
e+
Bro
mh
exci
ne
yes
Gri
lin
ctu
sB
MTa
b2.
5m
g+
8m
g/5
ml
10Ex
pec
tora
nts
,Cou
ghSu
pp
r.,D
econ
gest
ants
Fran
coIn
dia
n43
.40
Terb
uta
lin
e+B
ro-Z
edex
Syru
pC
ombi
nat
ion
100
ml
Exp
ecto
ran
ts,C
ough
Sup
pr.
,Dec
onge
stan
tsW
ockh
ard
t5.
690.
00
Terb
uta
lin
e+B
ro-Z
edex
Liq
uic
apC
ombi
nat
ion
6Ex
pec
tora
nts
,Cou
ghSu
pp
r.,D
econ
gest
ants
Woc
khar
dt
0.00
Ch
lorp
hen
iram
ine
+A
mm
oniu
mch
lori
de
+So
diu
mci
trat
e
Piri
ton
Exp
ecto
ran
tLi
qu
id2.
5m
g+
125
mg
+55
mg/
5m
l
120
ml
Exp
ecto
ran
ts,c
ough
sup
pre
ssan
ts,m
uco
lyti
csan
dd
econ
gest
ants
GSK
5.42
0.00
Ch
lorp
hen
iram
ine
+A
mm
oniu
mch
lori
de
+So
diu
mci
trat
e
Piri
ton
Exp
ecto
ran
tLi
qu
id2.
5m
g+
125
mg
+55
mg/
5m
l
460
ml
Exp
ecto
ran
ts,c
ough
sup
pre
ssan
ts,m
uco
lyti
csan
dd
econ
gest
ants
GSK
3.00
Ch
lorp
hen
iram
ine
+C
odei
ne
Cor
exSy
rup
4m
g+
10m
g/5
ml
50m
lEx
pec
tora
nts
,cou
ghsu
pp
ress
ants
,mu
coly
tics
and
dec
onge
stan
ts
Pfize
r−0
.24
24.2
7
Ch
lorp
hen
iram
ine
+C
odei
ne
Cor
exSy
rup
4m
g+
10m
g/5
ml
100
ml
Exp
ecto
ran
ts,c
ough
sup
pre
ssan
ts,m
uco
lyti
csan
dd
econ
gest
ants
Pfize
r24
.00
Dex
trom
eth
orp
han
+C
hlo
rph
enir
amin
e+
Men
thol
Cor
ex–
DX
Syru
p10
mg
+4
mg
+0.
1m
g/5
ml
50m
lEx
pec
tora
nts
,cou
ghsu
pp
ress
ants
,mu
coly
tics
and
dec
onge
stan
ts
Pfize
r30
.23
Dex
trom
eth
orp
han
+C
hlo
rph
enir
amin
e+
Men
thol
Cor
ex–
DX
Syru
p10
mg
+4
mg
+0.
1m
g/5
ml
100
ml
Exp
ecto
ran
ts,c
ough
sup
pre
ssan
ts,m
uco
lyti
csan
dd
econ
gest
ants
Pfize
r30
.50
Not
e:T
he
+sy
mbo
lat
the
end
ofa
dru
gn
ame
den
otes
form
ula
tion
sm
ade
from
mor
eth
anth
ree
dru
gs.
Wh
ile
all
the
dru
gsw
ere
con
sid
ered
for
the
anal
ysis
,it
was
con
sid
ered
app
rop
riat
eto
lim
itth
eli
stin
gto
thre
ed
rugs
for
this
stu
dy.
Sour
ce:
For
1994
–200
4M
IMS
Ind
ia,
asci
ted
inSa
kth
ivel
2006
,fo
r20
05–0
8,D
rug
Tod
ay,
vari
ous
issu
es,
CIM
SIn
dia
,20
07Ju
ly–O
ctob
er,
and
IDR
Phar
mac
yTr
ipp
leC
omp
end
ium
,200
8,N
ovem
ber
07–J
anu
ary
08.
264
Tabl
eB
.9Pr
ice
chan
ges
tod
rugs
for
ENT,
skin
,an
dsu
rgic
alan
aest
het
ics
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
Lign
ocai
ne+
yes
Xyl
ocai
ne
cA
dre
nal
ine
Inj
Com
bin
atio
n30
ml
An
aest
het
ics
Ast
raZe
nec
a6.
4443
.95
Lign
ocai
ne
+M
eth
ylp
arab
enye
sX
yloc
ain
ec
Ad
ren
alin
eTo
pic
al4%
42.7
mg/
ml
+1
mg/
ml
30m
lA
nae
sth
etic
sA
stra
Zen
eca
51.4
2
Lign
ocai
ne
+M
eth
ylp
arab
en+
Sod
ium
chlo
rid
e
yes
Xyl
ocai
ne
1%In
j10
.7m
g+
1m
g+
6m
g/m
l
30m
lA
nae
sth
etic
sA
stra
Zen
eca
47.5
1
Lign
ocai
ne
+M
eth
ylp
arab
enye
sX
yloc
ain
e1%
Inj
21.3
mg
+1
mg
+6
mg/
ml
30m
lA
nae
sth
etic
sA
stra
Zen
eca
35.4
0
Lign
ocai
ne
+M
eth
ylp
arab
en+
Prop
ylp
arab
en
Xly
ocai
ne
Jell
y2%
Gel
21.3
mg
+0.
61m
g+
0.27
mg/
ml
30gm
sA
nae
sth
etic
sA
stra
Zen
eca
35.9
0
Lign
ocai
ne
+Pr
opyl
ene
glyc
olye
sX
yloc
ain
eO
int
5%O
intm
ent
5%w
/w+
25%
w/w
20gm
sA
nae
sth
etic
sA
stra
Zen
eca
43.9
5
Lign
ocai
ne
+Et
han
olX
yloc
ain
eSp
ray
Spra
y10
0m
g+
28.2
9%v/
vp
erm
l
500
md
An
aest
het
ics
Ast
raZe
nec
a0.
00
Lign
ocai
ne
+M
eth
ylp
arab
enX
yloc
ain
eSp
ray
100
mg
+28
.29%
v/v
per
ml
800
md
An
aest
het
ics
Ast
raZe
nec
a0.
00
Lign
ocai
ne
+M
eth
ylp
arab
en+
Prop
ylp
arab
en
yes
Vis
cou
s2%
Vis
cou
s21
.3m
g+
0.61
mg
+0.
27m
g/m
l
100
ml
An
aest
het
ics
Ast
raZe
nec
a50
.99
Lign
ocai
ne
+So
diu
mch
lori
de
yes
Xyl
ocar
dV
ial
21.3
mg
+6
mg/
ml
50m
lV
entr
icu
lar
arrh
yth
mia
sA
stra
Zen
eca
50.9
6
265
Lign
ocai
ne
+D
extr
ose
yes
Xyl
ocai
ne
Hea
vy5%
Inj
53.5
mg
+75
mg
25×
2m
lSp
inal
anae
sth
esia
Ast
raZe
nec
a0.
00
Lign
ocai
ne
+G
luco
seye
sG
esic
ain
Hea
vy5%
Inj
5%+
7.5%
25×
2m
lSp
inal
anae
sth
esia
Nic
hol
asPi
ram
al5.
51
Lign
ocai
ne
yes
Ges
icai
nc
Ad
ren
alin
e2%
Inj
2%30
ml
An
aest
het
ics
Nic
hol
asPi
ram
al9.
990.
00
Lign
ocai
ne
yes
Ges
icai
nIn
j2%
30m
lA
nae
sth
etic
sN
ich
olas
Pira
mal
0.00
Lign
ocai
n+
Car
boxy
-m
eth
ylce
llu
lose
Ges
icai
nJe
lly
2%G
el2%
+3.
5%30
ml
An
aest
het
ics
Nic
hol
asPi
ram
al0.
00
Ligo
cain
eye
sG
esic
ain
Oin
t5%
Oin
tmen
t5%
10gm
An
aest
het
ics
Nic
hol
asPi
ram
al5.
49
Ligo
cain
eye
sG
esic
ain
Top
ical
4%SO
LN
Soln
4%30
ml
An
aest
het
ics
Nic
hol
asPi
ram
al5.
49
Ket
amin
eye
sK
etm
inIn
j10
mg/
ml
10m
lA
nae
sth
etic
sT
hem
isM
edic
are
−3.5
80.
00
Ket
amin
eye
sK
etm
inIn
j50
mg/
ml
2m
lA
nae
sth
etic
sT
hem
isM
edic
are
0.00
Ket
amin
eye
sK
etal
arIn
j10
mg
20m
lA
nae
sth
etic
sPfi
zer
0.00
0.00
Ket
amin
eye
sK
etal
arIn
j50
mg
2m
lA
nae
sth
etic
sPfi
zer
0.00
Ket
amin
eye
sK
etal
arIn
j50
mg
10m
lA
nae
sth
etic
sPfi
zer
0.00
Lign
ocai
ne+
yes
Ote
k-A
C+
Dro
ps
Com
bin
atio
n5
ml
An
ti-i
nfe
ctiv
ep
rep
.FD
C7.
8828
.42
Ch
lora
mp
hen
icol
Ch
loro
myc
etin
Ap
lica
ps
Ap
lica
ps
(eye
)25
0mg
50A
nti
-in
fect
ive
pre
pPfi
zer
27.4
8
Ch
lora
mp
hen
icol
+B
enzo
cain
eC
hlo
rom
ycet
inD
rop
s(e
ye)
5%w
/v+
1%w
/v5
ml
An
ti-i
nfe
ctiv
ep
rep
Pfize
r0.
00
Ch
lora
mp
hen
icol
+B
enzo
cain
e+
Prop
ylen
egl
ycol
Ch
loro
myc
etin
Dro
ps
(ear
)5%
w/v
+1%
w/v
+q
.s
5m
lA
ura
lPr
epar
atio
ns
Pfize
r24
.49
Gen
tam
ycin
+B
enza
lkon
ium
yes
yes
Gen
ticy
nEy
e/Ea
rD
rop
sG
enta
myc
in0.
3%5
ml
Au
ral
Prep
arat
ion
sN
ich
olas
Pira
mal
0.27
266
Tabl
eB
.9(C
onti
nu
ed)
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
Gen
tam
ycin
+B
enza
lkon
ium
yes
yes
Gen
ticy
nE/
ED
rop
s0.
3%+
0.04
%5
ml
An
ti-i
nfe
ctiv
ep
rep
All
erga
n3.
260.
00
Gen
tam
ycin
+ye
sye
sG
enti
cyn
BEy
e/Ea
rD
rop
sC
ombi
nat
ion
5m
lA
nti
-in
flam
ator
y/A
nti
-all
ergi
cN
ich
olas
Pira
mal
0.00
Gen
tam
ycin
+ye
sye
sG
enti
cyn
HC
Dro
ps
Com
bin
atio
n5
ml
An
ti-i
nfl
amat
ory/
An
ti-a
ller
gic
Nic
hol
asPi
ram
al0.
00
Flu
tica
son
eZo
flu
tC
ream
0.05
%5
gmTo
pic
alst
eroi
dPr
epC
ipla
1.22
0.00
Flu
tica
son
eZo
flu
tC
ream
0.05
%10
gmTo
pic
alst
eroi
dPr
epC
ipla
0.00
Flu
tica
son
eZo
flu
tLo
tion
0.05
%10
ml
Top
ical
ster
oid
Prep
Cip
la0.
00Fl
uti
caso
ne
Zofl
ut
Oin
tmen
t0.
05%
10gm
Top
ical
ster
oid
Prep
Cip
la0.
00N
itro
fura
zon
eFu
raci
n-S
Cre
am0.
02%
20gm
sTo
pic
alst
eroi
dPr
epG
SK0.
00−2
8.87
Nit
rofu
razo
ne
Fura
cin
-SC
ream
0.02
%50
0gm
sTo
pic
alst
eroi
dPr
epG
SK−4
.28
Cro
tam
iton
+H
ydro
cort
ison
eC
roto
rax-
HC
Cre
am10
%+
0.25
%10
gms
Top
ical
ster
oid
Prep
Nic
hol
asPi
ram
al0.
180.
00
Cro
tam
iton
Cro
tora
xC
ream
10%
20gm
sTo
pic
alst
eroi
dPr
epN
ich
olas
Pira
mal
0.00
Cro
tam
iton
Cro
tora
xLo
tion
10%
60m
lTo
pic
alst
eroi
dPr
epN
ich
olas
Pira
mal
0.00
Hep
arin
+B
enzy
ln
icot
inat
eB
epar
ine
Cre
am50
.i.u
+3
mg/
g15
gmM
isc.
skin
pre
p.
Bio
logi
cal
E8.
450.
20
Sod
ium
dia
triz
oate
+M
eglu
min
ean
tim
onat
e
yes
Uro
grafi
n60
%/7
6%In
j16
00+
1040
0m
g20
ml
Dia
gnos
tic
Age
nts
Ger
man
Rem
edie
s18
.19
0.00
Sod
ium
dia
triz
oate
+M
eglu
min
ean
tim
onat
e
yes
Uro
grafi
n60
%/7
6%In
j20
00+
1320
0m
g20
ml
Dia
gnos
tic
Age
nts
Ger
man
Rem
edie
s0.
00
267
Bu
piv
acai
ne
yes
Mar
cain
eIn
j0.
50%
20m
lSu
rgic
alan
tiba
cter
ials
Nic
hol
asPi
ram
al2.
380.
00
Bu
piv
acai
ne
Mar
cain
eH
yper
bari
cIn
j1%
2m
lSu
rgic
alan
tiba
cter
ials
Nic
hol
asPi
ram
al0.
00
Bu
piv
acai
ne
+So
diu
mC
hlo
rid
e+
Met
hya
lp
arab
en
yes
Sen
sorc
ain
eIn
j0.
25%
2.64
+8
+1
mg/
ml
20m
lSu
rgic
alan
tiba
cter
ials
Ast
raZe
nec
a8.
4464
.98
Bu
piv
acai
ne
+So
diu
mC
hlo
rid
e+
Met
hyl
par
aben
yes
Sen
sorc
ain
eIn
j0.
25%
5.28
+8
+1
mg/
ml
20m
lSu
rgic
alan
tiba
cter
ials
Ast
raZe
nec
a0.
00
Bu
piv
acai
ne
+D
extr
ose
mon
ohyd
rate
yes
Sen
sorc
ain
eH
eavy
Inj
5+
80m
g/m
l5
×4
ml
Surg
ical
anti
bact
eria
lsA
stra
Zen
eca
0.00
Bu
piv
acai
ne
+ye
sSe
nso
rcai
ne
0.5%
wit
hA
dre
nal
ine
Inj
Com
bin
atio
n20
ml
Surg
ical
anti
bact
eria
lsA
stra
Zen
eca
0.00
Bec
lom
eth
ason
ed
ipro
pio
nat
eB
ecla
te–
200
Inh
aler
200
mg
200
md
Loca
lre
acta
nts
onth
en
ose
Cip
la1.
970.
00
Bec
lom
eth
ason
ed
ipro
pio
nat
eye
sB
ecla
teIn
hal
erIn
hal
er50
mcg
200
dos
esLo
cal
reac
tan
tson
the
nos
e
Cip
la0.
00
Bec
lom
eth
ason
ed
ipro
pio
nat
eB
ecla
teIn
hal
erIn
hal
er10
0m
cg20
0d
oses
Loca
lre
acta
nts
onth
en
ose
Cip
la0.
00
Bec
lom
eth
ason
ed
ipro
pio
nat
eB
ecla
teR
otac
aps
Inh
aler
100
mcg
3×
10Lo
cal
reac
tan
tson
the
nos
e
Cip
la0.
00
Bec
lom
eth
ason
ed
ipro
pio
nat
eB
ecla
teR
otac
aps
Inh
aler
200
mcg
30Lo
cal
reac
tan
tson
the
nos
e
Cip
la0.
00
Bec
lom
eth
ason
ed
ipro
pio
nat
e+
Ch
inof
orm
Bec
late
Rot
acap
sIn
hal
er40
0m
cg30
Loca
lre
acta
nts
onth
en
ose
Cip
la0.
00
268
Tabl
eB
.9(C
onti
nu
ed)
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
Bec
lom
eth
ason
ed
ipro
pio
nat
eB
ecla
te-C
Cre
am0.
025%
w/w
+3%
15gm
Top
ical
ster
oid
Prep
Cip
la0.
00
Bec
lom
eth
ason
ed
ipro
pio
nat
e+
Neo
myc
in
Bec
late
-NC
ream
0.02
5%+
0.5%
15gm
Top
ical
ster
oid
Prep
Cip
la0.
00
Bec
lom
eth
ason
ed
ipro
pio
nat
e+
Sali
cycl
icac
id
yes
Bec
late
-SO
intm
ent
0.1%
+3%
15gm
Top
ical
ster
oid
Prep
Cip
la0.
00
Atr
opin
e+
Pred
nis
olon
+C
hlo
robu
tan
ol
yes
Atr
isol
onD
rop
s1%
+0.
25%
+0.
5%
5m
lA
nti
-in
flam
mat
ory
and
anti
-all
ergi
cp
rep
.
Inta
s2.
310.
00
Not
e:T
he
+sy
mbo
lat
the
end
ofa
dru
gn
ame
den
otes
form
ula
tion
sm
ade
from
mor
eth
anth
ree
dru
gs.
Wh
ile
all
the
dru
gsw
ere
con
sid
ered
for
the
anal
ysis
,it
was
con
sid
ered
app
rop
riat
eto
lim
itth
eli
stin
gto
thre
ed
rugs
for
this
stu
dy.
Sour
ce:
For
1994
–200
4M
IMS
Ind
ia,
asci
ted
inSa
kth
ivel
2006
,fo
r20
05–0
8,D
rug
Tod
ay,
vari
ous
issu
es,
CIM
SIn
dia
,20
07Ju
ly–O
ctob
er,
and
IDR
Phar
mac
yTr
ipp
leC
omp
end
ium
,200
8,N
ovem
ber
07–J
anu
ary
08.
269
Tabl
eB
.10
Pric
ech
ange
sto
dru
gsfo
rca
nce
ran
dot
her
rela
ted
trea
tmen
ts
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
All
opu
rin
olye
sZy
lori
cTa
b10
0m
g10
Gou
tG
SK4.
8013
.64
All
opu
rin
olZy
lori
cTa
b30
0m
g10
Gou
tG
SK0.
00B
leom
ycin
yes
Ble
ocin
Inj
15m
gV
ial
Car
cin
o-ch
emot
her
apeu
tic
Dru
gs
Kh
and
elw
al0.
85−9
.62
Ch
lora
mbu
cil
Leu
kera
nTa
b2
mg
25C
arci
no-
chem
oth
erap
euti
cD
rugs
GSK
8.87
0.00
Ch
lora
mbu
cil
Leu
kera
nTa
b5
mg
25C
arci
no-
chem
oth
erap
euti
cD
rugs
GSK
0.00
Cyc
lop
hos
ph
amid
eye
sEn
dox
an-A
sta
Tab
50m
g10
Car
cin
o-ch
emot
her
apeu
tic
Dru
gs
Ger
man
Rem
edie
s3.
640.
00
Cyc
lop
hos
ph
amid
eye
sEn
dox
an-A
sta
Inj
200
mg
Via
lC
arci
no-
chem
oth
erap
euti
cD
rugs
Ger
man
Rem
edie
s0.
00
Cyc
lop
hos
ph
amid
eye
sEn
dox
an-A
sta
Inj
500
mg
Via
lC
arci
no-
chem
oth
erap
euti
cD
rugs
Ger
man
Rem
edie
s0.
00
Cyc
lop
hos
ph
amid
eEn
dox
an-A
sta
Inj
1gm
Via
lC
arci
no-
chem
oth
erap
euti
cD
rugs
Ger
man
Rem
edie
s0.
00
Dox
oru
bici
nye
sD
oxor
ubi
cin
-M
eiji
nIn
j10
mg
Via
lC
arci
no-
chem
oth
erap
euti
cD
rugs
Kh
and
elw
al1.
100.
00
270
Tabl
eB
.10
(Con
tin
ued
)
Cat
ego
ryD
PC
ON
LE
MB
ran
dFo
rmSt
ren
gth
Qty
Th
erap
euti
cgr
ou
pC
om
pan
yP
rice
chan
ge%
Dru
gn
ame/
Yea
r19
9520
0319
94–2
004
2005
–200
8
Dox
oru
bici
nye
sD
oxor
ubi
cin
-M
eiji
nIn
j50
mg
Via
lC
arci
no-
chem
oth
erap
euti
cD
rugs
Kh
and
elw
al0.
00
Etop
sid
e+
Ben
zyl
alco
hol
+Et
hyl
alco
hol
yes
Etos
idIn
j10
0m
g+
150
mg
+30
%/5
ml
5m
lC
arci
no-
chem
oth
erap
euti
cD
rugs
Cip
la−0
.91
0.00
Etop
sid
e+
Ben
zyl
alco
hol
+Et
hyl
alco
hol
yes
Etos
idC
ap10
0m
g+
150
mg
+30
%/5
ml
4C
arci
no-
chem
oth
erap
euti
cD
rugs
Cip
la0.
00
Flu
orou
raci
lFl
ura
cil
Cap
250
mg
10C
arci
no-
chem
oth
erap
euti
cD
rugs
Bio
chem
0.71
0.00
Flu
orou
raci
lFl
ura
cil
Inj
500
mg
10m
l/2
×5
ml
Car
cin
o-ch
emot
her
apeu
tic
Dru
gs
Bio
chem
107.
40
Hep
arin
+B
enzy
ln
icot
inat
e
Th
rom
bop
hop
Oin
t50
00i.
u+
0.2/
100
g20
gmC
arci
no-
chem
oth
erap
euti
cD
rugs
Ger
man
Rem
edie
s0.
000.
00
Hep
arin
Th
rom
bop
hop
Gel
20,0
00i.
u/
100
g20
gmC
arci
no-
chem
oth
erap
euti
cD
rugs
Ger
man
Rem
edie
s0.
00
271
Met
hot
rexa
teye
sN
eotr
exat
eTa
b2.
5m
g10
Car
cin
o-ch
emot
her
apeu
tic
Dru
gs
GSK
0.00
6.20
Met
hot
rexa
teye
sB
iotr
exat
eTa
b2.
5m
g10
Car
cin
o-ch
emot
her
apeu
tic
Dru
gs
Bio
chem
1.04
−6.0
8
Met
hot
rexa
teye
sB
iotr
exat
eIn
j50
mg
2m
lC
arci
no-
chem
oth
erap
euti
cD
rugs
Bio
chem
0.00
Tam
oxif
enye
sM
amof
enTa
b10
mg
10C
arci
no-
chem
oth
erap
euti
cD
rugs
Kh
and
elw
al0.
004.
62
Tam
oxif
enye
sN
olva
dex
Tab
10m
g50
Car
cin
o-ch
emot
her
apeu
tic
Dru
gs
Ast
raZe
nec
ca2.
840.
00
Vin
cris
tin
e+ye
sC
ytoc
rist
inIn
jC
ombi
nat
ion
1m
lC
arci
no-
chem
oth
erap
euti
cD
rugs
Cip
la1.
086.
67
Not
e:T
he
+sy
mbo
lat
the
end
ofa
dru
gn
ame
den
otes
form
ula
tion
sm
ade
from
mor
eth
anth
ree
dru
gs.
Wh
ile
all
the
dru
gsw
ere
con
sid
ered
for
the
anal
ysis
,it
was
con
sid
ered
app
rop
riat
eto
lim
itth
eli
stin
gto
thre
ed
rugs
for
this
stu
dy.
Sour
ce:
For
1994
–200
4M
IMS
Ind
ia,
asci
ted
inSa
kth
ivel
2006
,fo
r20
05–0
8,D
rug
Tod
ay,
vari
ous
issu
es,
CIM
SIn
dia
,20
07Ju
ly–O
ctob
er,
and
IDR
Phar
mac
yTr
ipp
leC
omp
end
ium
,200
8,N
ovem
ber
07–J
anu
ary
08.
Appendix C
Sensitivity test: Case 1
Payment schedule for the lowest income category remains unchanged. For theother categories, the co-payments are raised from Rs. 25 to Rs. 30 and from Rs. 50to Rs. 60. The Safety Net threshold is also raised from Rs. 1125 to Rs. 1350 andfrom Rs. 2000 to Rs. 2400.
272
273
Tabl
eC
.1En
titl
emen
tsof
Ind
iaH
ealt
hca
rds
ata
glan
ce
S.N
oIn
com
ep
.a.
Cat
ego
ryC
olo
ur
Co
-pay
men
tp
erp
resc
rip
tio
nSa
fety
Net
Th
resh
old
Co
-pay
men
t(p
ost
Safe
tyN
et)
per
pre
scri
pti
on
(Rs.
)(R
s.)
(Rs.
)(R
s.)
1N
one
S-C
ard
Bro
wn
Nil
N.A
.N
il2
<15
,000
B1-
Car
dR
edN
ilN
.AN
il3
15,0
01–4
0,00
0B
2-C
ard
Yell
ow10
500
Nil
415
,001
–40,
000
A1-
Car
dW
hit
e/Ye
llow
1050
0N
il5
40,0
01–1
00,0
00A
2-C
ard
Wh
ite/
Purp
le30
1350
106
40,0
01–1
00,0
00M
1-C
ard
Purp
le30
1350
107
>10
0,00
0A
3-C
ard
Wh
ite/
Gre
en60
2400
308
>10
0,00
0M
2-C
ard
Gre
en60
2400
30
Not
e:T
he
thre
shol
dw
ould
kick
inat
40p
resc
rip
tion
sfo
rB
2an
dA
1C
ateg
orie
s,at
45p
resc
rip
tion
sfo
rM
1an
dA
2ca
tego
ries
,an
dat
50p
resc
rip
tion
sfo
rM
2an
dA
3ca
tego
ries
.So
urce
:Au
thor
.
274
Tabl
eC
.2C
alcu
lati
ng
hea
lth
and
med
icin
eex
pen
dit
ure
(Rs.
)
Cat
ego
ryP
op
ula
tio
nH
ealt
h(m
on
thly
)M
edic
ine
(mo
nth
ly)
(Mil
lio
n.)
Per
cap
ita
(Rs.
)To
tal
Rs.
(Mil
lio
n.)
Per
cap
ita
(Rs.
)To
tal
Rs.
(Mil
lio
n.)
Ru
ral
798
4435
,112
28.1
622
,471
.68
Urb
an34
271
24,2
8239
.76
13,5
97.9
2To
tal
(In
dia
)11
4059
,394
36,0
69.6
Bas
edo
nth
eab
ove
Tab
leH
ealt
h(y
earl
y)M
edic
ine
(yea
rly)
Ru
ral
421,
344
269,
660.
2U
rban
291,
384
163,
175
Tota
l(I
nd
ia)
712,
728
432,
835.
2Pe
rp
erso
n62
5.2
379.
68Pe
rfa
mil
y31
2618
98.4
Sour
ce:A
uth
ores
tim
ates
base
don
GO
I(2
007c
,200
7f).
275
Tabl
eC
.3A
nn
ual
exp
end
itu
reon
med
icin
esu
nd
ercu
rren
tan
dp
rop
osed
mod
els
S.N
o.
Cat
ego
ryE
stim
ated
po
pu
lati
on
(mil
lio
n)
Est
imat
edn
o.
of
card
s(m
illi
on
)
Tota
ld
rug
exp
end
itu
re–
Ind
ia(R
s.m
illi
on
)
Tota
lo
ut-
of-
po
cket
co-p
aym
ents
(Rs.
mil
lio
n)
Go
vern
men
tco
ntr
ibu
tio
n(R
s.m
illi
on
)
Ave
rage
OO
Pm
ed.
exp
per
fam
ily
(Rs.
)
Ave
rage
ou
t-o
f-p
ock
etd
rug
exp
end
itu
rep
erfa
mil
y(R
s.)
(cu
rren
t)(p
rop
ose
d)
(pro
po
sed
)(p
rop
ose
d)
(cu
rren
t)1
23
45
67
=(5
−6)
89
1S-
Car
d40
40.0
015
,187
.20
15,1
87.2
018
98.4
2B
1-C
ard
350
86.5
013
2,88
80
132,
888
018
98.4
3B
2-C
ard
450
85.5
017
0,85
642
,750
128,
106
500
1898
.44
A1-
Car
d5
2.50
1,89
8.4
1,25
064
8.4
500
1898
.45
A2-
Car
d5
2.50
1,89
8.4
3,71
2.5
014
8518
98.4
6M
1-C
ard
190
38.0
072
,139
.256
,430
15,7
09.2
1485
1898
.47
A3-
Car
d5
2.50
1,89
8.4
6,60
00
2640
1898
.48
M2-
Car
d95
19.0
036
,069
.650
,160
026
4018
98.4
Tota
l11
4027
6.50
432,
835
160,
903
271,
933
582
1898
.410
0%37
.17
62.8
3
Not
e:A
t5
per
cen
t,17
.5m
illi
onel
der
lyp
opu
lati
onw
ould
beis
sued
wit
h8.
75m
illi
onB
1-C
ard
s.A
t5
mem
bers
per
fam
ily,
332.
5m
illi
onp
opu
lati
onw
ould
beis
sued
wit
h66
.5m
illi
onB
1-C
ard
s(A
ged
).A
t5
per
cen
tof
450
mil
lion
ofB
2-p
opu
lati
on,
22.5
mil
lion
eld
erly
pop
ula
tion
wou
ldbe
issu
edw
ith
11.2
5m
illi
onB
1-C
ard
s(A
ged
)T
hu
s,th
en
um
ber
ofca
rds
issu
edin
B1
cate
gory
wou
ldbe
hig
her
and
inB
2w
ould
belo
wer
than
stra
igh
tfo
rwar
dd
ivid
ing
the
tota
lp
opu
lati
onby
5in
thos
eca
tego
ries
.So
urce
:Au
thor
esti
mat
esba
sed
onG
OI
(200
7c,2
007f
).
276
Tabl
eC
.4Es
tim
ates
ofto
tal
out-
of-p
ocke
tm
edic
ine
exp
end
itu
re(R
s.m
illi
on)
and
pop
ula
tion
grou
ps
(mil
lion
)
Yea
rTo
tal
0–4
(fac
tor
1.2)
5–64
(fac
tor
1)65
+(f
acto
r4.
5)To
tal
OO
Pm
ed.
exp
Tota
lO
OP
med
exp
Incl
.5%
CA
GR
Po
pu
lati
on
Po
pu
lati
on
Med
.Ex
p.
Po
pu
lati
on
Med
.Ex
p.
Po
pu
lati
on
Med
.Ex
p.
12
34
56
78
9(4
+6
+8)
10
2006
1140
126.
557
,635
956.
536
3,16
457
.097
,388
518,
187
518,
187.
320
0711
6012
7.6
58,1
3797
3.8
369,
732
58.6
100,
122
527,
991
554,
390.
120
0811
8112
7.5
58,0
9199
3.2
377,
098
60.2
102,
855
538,
045
593,
194.
120
0912
0112
7.3
58,0
0010
11.2
383,
932
62.5
106,
785
548,
717
635,
208.
920
1012
2012
6.9
57,8
1810
28.5
390,
501
64.7
110,
544
558,
862
679,
300.
720
1112
3712
6.2
57,4
9910
44.0
396,
386
66.8
114,
132
568,
016
724,
948.
920
1212
5412
5.4
57,1
3410
59.6
402,
309
69.0
117,
891
577,
334
773,
682.
520
1312
7112
4.6
56,7
7010
75.3
408,
270
71.2
121,
649
586,
689
825,
530.
520
1412
8712
4.8
56,8
6110
88.8
413,
396
73.4
125,
408
595,
665
880,
068.
120
1513
0312
5.1
56,9
9811
02.3
418,
521
75.6
129,
167
604,
686
938,
066.
4
Sour
ce:A
uth
ores
tim
ates
base
don
Un
ited
Nat
ion
s(2
005a
);an
dG
OI
(200
7c,2
007f
).
277
Tabl
eC
.5Es
tim
ates
ofto
tal
out-
of-p
ocke
the
alth
exp
end
itu
re(R
s.m
illi
on)
and
pop
ula
tion
grou
ps
(mil
lion
)
Yea
rTo
tal
0–4
(fac
tor
1.2)
5–64
(fac
tor
1)65
+(f
acto
r4.
5)To
tal
OO
Ph
ealt
hex
p.
Tota
lO
OP
hea
lth
exp
.in
cl.
5%C
AG
RP
op
ula
tio
nP
op
ula
tio
nH
ealt
hex
p.
Po
pu
lati
on
Hea
lth
exp
.P
op
ula
tio
nH
ealt
hex
p.
12
34
56
78
9(4
+6
+8)
10
2006
1140
126.
594
,905
956.
559
8,00
457
160,
364
853,
273
853,
273
2007
1160
127.
695
,731
973.
860
8,82
058
.616
4,86
586
9,41
691
2,88
620
0811
8112
7.5
95,6
5699
3.2
620,
949
60.2
169,
367
885,
971
976,
783
2009
1201
127.
395
,506
1011
.263
2,20
262
.517
5,83
890
3,54
51,
045,
967
2010
1220
126.
995
,205
1028
.564
3,01
864
.718
2,02
792
0,25
11,
118,
570
2011
1237
126.
294
,680
1,04
465
2,70
966
.818
7,93
593
5,32
41,
193,
737
2012
1254
125.
494
,080
1059
.666
2,46
269
194,
125
950,
667
1,27
3,98
420
1312
7112
4.6
93,4
8010
75.3
672,
278
71.2
200,
314
966,
072
1,35
9,36
020
1412
8712
4.8
93,6
3010
88.8
680,
718
73.4
206,
504
980,
851
1,44
9,16
420
1513
0312
5.1
93,8
5511
02.3
689,
158
75.6
212,
693
995,
706
1,54
4,66
7
Sour
ce:A
uth
ores
tim
ates
base
don
Un
ited
Nat
ion
s(2
005a
);an
dG
OI
(200
7c,2
007f
).
278
Tabl
eC
.6Pr
ojec
ted
dis
trib
uti
onof
tota
lh
ealt
hex
pen
dit
ure
(Rs.
mil
lion
)
Yea
rC
urr
ent
situ
atio
nP
rop
ose
dp
rogr
amm
e
Tota
lO
OP
hea
lth
exp
.in
cl.
5%C
AG
R
Est
imat
edto
tal
hea
lth
exp
.(T
HE
)
Pu
bli
ch
ealt
hex
p.(
PH
E)
Tota
lO
OP
hea
lth
exp
.G
DP
esti
mat
esP
HE
as%
of
GD
P
−72%
−100
%62
.83%
37.1
7%
2006
853,
273
1,18
5,10
174
4,55
144
0,55
139
,743
,850
1.87
2007
912,
886
1,26
7,89
879
6,56
847
1,32
945
,453
,590
1.75
2008
976,
783
1,35
6,64
385
2,32
350
4,32
050
,916
,870
1.67
2009
1,04
5,96
71,
452,
731
9,12
6,92
540,
040
57,3
61,8
801.
5920
101,
118,
570
1,55
3,57
09,
760,
4557
7,52
564
,612
,270
1.51
2011
1,19
3,73
71,
657,
968
1,04
1,63
461
6,33
472
,713
,230
1.43
2012
1,27
3,98
41,
769,
422
1,11
1,65
665
7,76
781
,814
,440
1.36
2013
1,35
9,36
01,
888,
000
1,18
6,15
370
1,84
692
,075
,660
1.29
2014
1,44
9,16
42,
012,
728
1,26
4,51
574
8,21
310
3,58
5,11
81.
2220
151,
544,
667
2,14
5,37
11,
347,
849
797,
522
116,
533,
257
1.16
Sour
ce:A
uth
ores
tim
ates
base
don
GO
I(2
005b
,200
7c);
and
IMF
(200
8).
Appendix D
Sensitivity test: Case 2
Co-payment for the lowest income category is raised to Rs. 15 and Safety Netthreshold raised to Rs. 750. The payment schedule for the other categoriesremains unchanged.
279
280
Tabl
eD
.1En
titl
emen
tsof
Ind
iaH
ealt
hca
rds
ata
glan
ce
S.N
oIn
com
ep
.a.
Cat
ego
ryC
olo
ur
Co
-pay
men
tp
erp
resc
rip
tio
nSa
fety
Net
Th
resh
old
Co
-pay
men
t(p
ost
Safe
tyN
et)
per
pre
scri
pti
on
(Rs.
)(R
s.)
(Rs.
)(R
s.)
1N
one
S-C
ard
Bro
wn
Nil
N.A
.N
il2
<15
,000
B1-
Car
dR
edN
ilN
.AN
il3
15,0
01–4
0,00
0B
2-C
ard
Yell
ow15
750
Nil
415
,001
–40,
000
A1-
Car
dW
hit
e/Ye
llow
1575
0N
il5
40,0
01–1
00,0
00A
2-C
ard
Wh
ite/
Purp
le25
1125
156
40,0
01–1
00,0
00M
1-C
ard
Purp
le25
1125
157
>10
0,00
0A
3-C
ard
Wh
ite/
Gre
en50
2000
258
>10
0,00
0M
2-C
ard
Gre
en50
2000
25
Not
e:T
he
thre
shol
dw
ould
kick
inat
40p
resc
rip
tion
sfo
rB
2an
dA
1C
ateg
orie
s,at
45p
resc
rip
tion
sfo
rM
1an
dA
2ca
tego
ries
,an
dat
50p
resc
rip
tion
sfo
rM
2an
dA
3ca
tego
ries
.So
urce
:Au
thor
.
281
Tabl
eD
.2C
alcu
lati
ng
hea
lth
and
med
icin
eex
pen
dit
ure
(Rs.
)
Cat
ego
ryP
op
ula
tio
n(M
illi
on
)H
ealt
h(m
on
thly
)M
edic
ine
(mo
nth
ly)
Ind
ia11
40P
erca
pit
a(R
s.)
Tota
lR
s.(M
illi
on
.)P
erca
pit
a(R
s.)
Tota
lR
s.(M
illi
on
.)
Ru
ral
798
4435
,112
28.1
622
,471
.68
Urb
an34
271
24,2
8239
.76
13,5
97.9
2To
tal
(In
dia
)59
,394
36,0
69.6
Bas
edo
nth
eab
ove
Tab
leH
ealt
h(y
earl
y)M
edic
ine
(yea
rly)
Ru
ral
421,
344
269,
660.
2U
rban
291,
384
163,
175
Tota
l(I
nd
ia)
712,
728
432,
835.
2Pe
rp
erso
n62
5.2
379.
68Pe
rfa
mil
y31
2618
98.4
Sour
ce:A
uth
ores
tim
ates
base
don
GO
I(2
007c
,200
7f).
282
Tabl
eD
.3A
nn
ual
exp
end
itu
reon
med
icin
esu
nd
ercu
rren
tan
dp
rop
osed
mod
els
S.N
o.
Cat
ego
ryE
stim
ated
po
pu
lati
on
(mil
lio
n)
Est
imat
edn
o.o
fca
rds
(mil
lio
n)
Tota
ld
rug
exp
end
itu
re–
Ind
ia(R
s.m
illi
on
)
Tota
lo
ut-
of-
po
cket
co-p
aym
ents
(Rs.
mil
lio
n)
Go
vern
men
tco
ntr
ibu
tio
n(R
s.m
illi
on
)
Ave
rage
ou
t-o
f-p
ock
etco
-pay
men
tsp
erfa
mil
y(R
s.)
Ave
rage
ou
t-o
f-p
ock
etd
rug
exp
end
itu
rep
erfa
mil
y(R
s.)
(cu
rren
t)(p
rop
ose
d)
(pro
po
sed
)(p
rop
ose
d)
(cu
rren
t)1
23
45
67
=(5
−6)
89
1S-
Car
d40
40.0
015
,187
.20
15,1
87.2
018
98.4
2B
1-C
ard
350
86.5
013
2,88
80
132,
888
018
98.4
3B
2-C
ard
450
85.5
017
0,85
664
,125
106,
731
750
1898
.44
A1-
Car
d5
2.50
1,89
8.4
1,87
523
.475
018
98.4
5A
2-C
ard
52.
501,
898.
430
93.7
50
1238
1898
.46
M1-
Car
d19
038
.00
72,1
39.2
47,0
2525
,114
.212
3818
98.4
7A
3-C
ard
52.
501,
898.
45,
500
022
0018
98.4
8M
2-C
ard
9519
.00
36,0
69.6
41,8
000
2200
1898
.4To
tal
1100
236.
5043
2,83
516
3,41
926
9,41
669
118
98.4
100%
37.7
662
.24
Not
e:A
t5
per
cen
t,17
.5m
illi
onel
der
lyp
opu
lati
onw
ould
beis
sued
wit
h8.
75m
illi
onB
1-C
ard
s(A
ged
).A
t5
mem
bers
per
fam
ily,
332.
5m
illi
onp
opu
lati
onw
ould
beis
sued
wit
h66
.5m
illi
onB
1-C
ard
s.A
t5
per
cen
tof
450
mil
lion
ofB
2-p
opu
lati
on,2
2.5
mil
lion
eld
erly
pop
ula
tion
wou
ldbe
issu
edw
ith
11.2
5m
illi
onB
1-C
ard
s(A
ged
).T
hu
s,th
en
um
ber
ofca
rds
issu
edin
B1
cate
gory
wou
ldbe
hig
her
and
inB
2w
ould
belo
wer
than
stra
igh
tfor
war
dd
ivid
ing
the
tota
lp
opu
lati
onby
5in
thos
eca
tego
ries
.So
urce
:Au
thor
base
don
GO
I(2
007c
,200
7f).
283
Tabl
eD
.4Es
tim
ates
ofto
tal
out-
of-p
ocke
tm
edic
ine
exp
end
itu
re(R
s.m
illi
on)
and
pop
ula
tion
grou
ps
(mil
lion
)
0–4
(fac
tor
1.2)
5–64
(fac
tor
1)65
+(f
acto
r4.
5)Y
ear
Tota
lp
op
ula
tio
nP
op
ula
tio
nM
ed.E
xp
.P
op
ula
tio
nM
ed.E
xp
.P
op
ula
tio
nM
ed.E
xp
.
Tota
lO
OP
med
.ex
p.
Tota
lO
OP
med
.ex
p.
Incl
.5%
CA
GR
12
34
56
78
9(4
+6
+8)
10
2006
1140
126.
557
,635
956.
536
3,16
457
.097
,388
518,
187
518,
187
2007
1160
127.
658
,137
973.
836
9,73
258
.610
0,12
252
7,99
155
4,39
020
0811
8112
7.5
58,0
9199
3.2
377,
098
60.2
102,
855
538,
045
593,
194
2009
1201
127.
358
,000
1011
.238
3,93
262
.510
6,78
554
8,71
763
5,20
920
1012
2012
6.9
57,8
1810
28.5
390,
501
64.7
110,
544
558,
862
679,
301
2011
1237
126.
257
,499
1044
.039
6,38
666
.811
4,13
256
8,01
672
4,94
920
1212
5412
5.4
57,1
3410
59.6
402,
309
69.0
117,
891
577,
334
773,
683
2013
1271
124.
656
,770
1075
.340
8,27
071
.212
1,64
958
6,68
982
5,53
120
1412
8712
4.8
56,8
6110
88.8
413,
396
73.4
125,
408
595,
665
880,
068
2015
1303
125.
156
,998
1102
.341
8,52
175
.612
9,16
760
4,68
693
8,06
6
Sour
ce:A
uth
ores
tim
ates
base
don
Un
ited
Nat
ion
s(2
005a
);an
dG
OI
(200
7c,2
007f
).
284
Tabl
eD
.5Es
tim
ates
ofto
tal
out-
of-p
ocke
the
alth
exp
end
itu
re(R
s.m
illi
on)
and
pop
ula
tion
grou
ps
(mil
lion
)
0–4
(fac
tor
1.2)
5–64
(fac
tor
1)65
+(f
acto
r4.
5)Y
ear
Tota
lp
op
ula
tio
nP
op
ula
tio
nH
/car
eex
pP
op
ula
tio
nH
/Cex
pP
op
ula
tio
nH
/Cex
p
Tota
lO
OP
hea
lth
exp
Tota
lO
OP
hea
lth
exp
Incl
.5%
CA
GR
12
34
56
78
9(4
+6
+8)
10
2006
1140
126.
594
,905
956.
559
8,00
457
.016
0,36
485
3,27
385
3,27
320
0711
6012
7.6
95,7
3197
3.8
608,
820
58.6
164,
865
869,
416
912,
886
2008
1181
127.
595
,656
993.
262
0,94
960
.216
9,36
788
5,97
197
6,78
320
0912
0112
7.3
95,5
0610
11.2
632,
202
62.5
175,
838
903,
545
1,04
5,96
720
1012
2012
6.9
95,2
0510
28.5
643,
018
64.7
182,
027
920,
251
1,11
8,57
020
1112
3712
6.2
94,6
8010
44.0
652,
709
66.8
187,
935
935,
324
1,19
3,73
720
1212
5412
5.4
94,0
8010
59.6
662,
462
69.0
194,
125
950,
667
1,27
3,98
420
1312
7112
4.6
93,4
8010
75.3
672,
278
71.2
200,
314
966,
072
1,35
9,36
020
1412
8712
4.8
93,6
3010
88.8
680,
718
73.4
206,
504
980,
851
1,44
9,16
420
1513
0312
5.1
93,8
5511
02.3
689,
158
75.6
212,
693
995,
706
1,54
4,66
7
Sour
ce:A
uth
ores
tim
ates
base
don
Un
ited
Nat
ion
s(2
005a
);an
dG
OI
(200
7c,2
007f
).
285
Tabl
eD
.6Pr
ojec
ted
dis
trib
uti
onof
tota
lh
ealt
hex
pen
dit
ure
(Rs.
mil
lion
)(2
006–
2015
)
Yea
rC
urr
ent
situ
atio
nP
rop
ose
dp
rogr
amm
e
Tota
lO
OP
hea
lth
exp
incl
.5%
CA
GR
Est
imat
edto
tal
hea
lth
exp
(TH
E)
Pu
bli
ch
ealt
hex
p(P
HE
)To
tal
OO
Ph
ealt
hex
pG
DP
esti
mat
esP
HE
as%
of
GD
P
−72%
−100
%62
.24%
37.7
6%
2006
853,
273
1,18
5,10
173
7,66
144
7,44
039
,743
,850
1.86
2007
912,
886
1,26
7,89
878
9,19
847
8,70
045
,453
,590
1.74
2008
976,
783
1,35
6,64
384
4,43
751
2,20
650
,916
,870
1.66
2009
1,04
5,96
71,
452,
731
904,
247
548,
485
57,3
61,8
801.
5820
101,
118,
570
1,55
3,57
096
7,01
358
6,55
764
,612
,270
1.50
2011
1,19
3,73
71,
657,
968
1,03
1,99
562
5,97
372
,713
,230
1.42
2012
1,27
3,98
41,
769,
422
1,10
1,37
066
8,05
381
,814
,440
1.35
2013
1,35
9,36
01,
888,
000
1,17
5,17
771
2,82
292
,075
,660
1.28
2014
1,44
9,16
42,
012,
728
1,25
2,81
475
9,91
410
3,58
5,11
81.
2120
151,
544,
667
2,14
5,37
11,
335,
377
809,
994
116,
533,
257
1.15
Sour
ce:A
uth
ores
tim
ates
base
don
GO
I(2
005b
,200
7c);
and
IMF
(200
8).
Notes
2 The WTO and the TRIPS Agreement
1. Pharmaceutical sector inquiry: Preliminary report submitted on 28 November2008 found up to 1300 patents filed EU-wide on a single medicine. We havetermed this act as excessive patenting.
3 The Global Pharmaceutical Industry andDeveloping New Drugs
1. Product with annual sales of more than a billion dollars.2. According to Pammolli and Riccaboni (2007), the off-shoring of manufacture
by the US pharmaceutical firms increased five times between 1996 and 2004.
4 Development of India’s Pharmaceutical Industry
1. Certain drugs are reserved for manufacture by the SSI, for which to qualify,the total outlay must not exceed Rs. 10 million ($222,000). This limit iscurrently in the process of being increased to Rs. 50 million ($1.15 million).
2. The actual drug or salt used in the formulation (e.g. the drug Paracetamolused in Panadol).
3. Filed to obtain approvals for bulk drugs.4. Filed to obtain approvals for generic versions of formulations.5. No breakdown of the export value of each drug was available separately. The
value of the whole item was used in calculation.6. Item no. 211 had four drugs, of which patents on all but paclitaxel had
expired. Paclitaxel is a natural molecule, thus a product patent would notbe applicable to it per se. However, considering that a patent on its ‘methodof working’ exists in South Africa till 2013, the whole item was included inthe examination, as its export may be affected by the new patent regime inIndia.
7. Foreign Exchange Regulation Act (FERA).8. The significance of this period is that it covers the period of restrictive mea-
sures of the 1970s as well as the period following economic reforms in1991.
9. For the years obtained from the IMF database and average for each periodderived.
10. The FDI confidence index was not available for 2006.
5 TRIPS and the Indian Patents Regime
1. The High Court is the highest court in a state/province. The Supreme Court isthe apex court of India.
286
Notes 287
2. Defined as mastering the ability to read patents ‘in such a way that you canbypass someone’s invention’, and ‘to write patents in such a way that nobodycan bypass you’ (Mashelkar 2003).
3. Indian Network for People Living with HIV/AIDS, the Manipur Network ofPositive People, and the Lawyers Collective.
4. (Chapter XVI, Section 84(1)).5. As noted earlier, Roche has a patent on Taraceva in India.
6 Price Controls and Drug Affordability in India:Policy Options
1. Author calculations based on CIMS (2007).2. List of drugs under price control.3. Under Section (2) of the Essential Commodities Act, medicines are consid-
ered essential commodities.4. As listed in Schedule – I appended to the DPCO – 1970.5. Transfer pricing refers to companies charging their subsidiary significantly at
a higher price for a product than otherwise available.6. The All India Drug Action Network (AIDAN), the Medico Friends Circle
(MFC), the Low Cost Standard Therapeutics (LOCOST), and the Jan SwasthyaSahyog.
7. The 354 drugs on the NLEM list minus the 15 drugs currently under pricecontrol.
8. Dispensed as received, that is without breaking the packs or taking out smallquantities from bottles and so on.
9. CIMS, Drug Today, and IDR are the reference books used by medicalpractitioners to prescribe medicines.
10. Uttar Pradesh is the most populous state in India.11. Emails to Sakthivel were not replied. (on record with the author).12. Email from the TGA on record with the author.
7 Health Insurance in India
1. The Union Government contributes 75 per cent and the states 25 per cent.2. Organisation for Economic Co-operation and Development.3. Denotes holders of a Pensioner Concession Card; Australian Seniors
Health Card; Health Care Card; or DVA White, Gold, or Orange Card.(http://www.pbs.gov.au/html/consumer/pbs/about). These cards are meanstested, which means that people with assets above the government thresholdwould be ineligible.
8 Broadening Access to Medicines andHealthcare in India
1. While the official estimates suggest 233 million population lives below thepoverty line in India, experts such as Patnaik (2010) find considerable dis-crepancies and inconsistencies in the methodology used in the estimates and
288 Notes
claim the actual figure to be significantly higher. Our estimate of 350 millionfor the BPL population may be closer to reality.
2. The expression used in drug evaluation literature.3. The yoga practitioners would be excluded for two reasons. First, under yogic
therapies, no medicine is dispensed. The main focus is on physical exercisesand body postures. Two, there is no framework in place for validation of theyogic claims or for qualifications.
4. Includes the Department of Veterans Affairs-issued Pensioner ConcessionCards and Commonwealth Seniors Health Cards. The Department of HumanServices through Centrelink also issues a range of Health Care Cards andother types of concession cards, such as Disability Support Pension Card.
5. Consumer Price Index.6. Wholesale Price Index used in India.7. Over the age of 65 years.8. Adjusted up from 1991 figures of 38.8 million for disabled in Government of
India (2003b, p. 98).9. Under the proposal, the year would mean Indian accounting year (April–
March) because it would be easier for budgetary planning and accountingpurposes.
10. Medicines specifically listed under the 20-day Rule (e.g. for chronic diseasessuch as HIV/AIDS).
11. Based on Government of India (2007f).12. Total out-of-pocket payments/total number of IndiaHealthcards.13. Rs. 141,419/150 (sum of all cards except S and B1 categories).14. Employees’ State Insurance Scheme (ESIS).15. Central Government Health Scheme (CGHS).
9 Is TRIPS Appropriate for Developing Countries?
1. The German Parliament until 1945.2. It is assumed that each product would have identical demand functions.3. Oxfam (2002) estimates, the poor countries would contribute $40 billion
annually in TRIPS-inflicted additional costs.4. Deliberate use of this figure rather than the recent estimates of $1.3 billion,
because the actual outlay is less than half of the new estimates and thedeveloping countries would be actually paying additional costs.
5. See Chapter 5 for more details.6. Rector, Imperial College, London.
10 Which Way Ahead?
1. Around 100 world’s largest pharmaceutical companies based in the US, EU,and Japan.
2. Such as 1300 patents on a single drug noted earlier in the chapter.
References
A T Kearney 2004, ‘FDI Confidence Index’, Global Business Policy Council, vol. 7,October.
———2005, ‘FDI Confidence Index’, Global Business Policy Council, vol. 8,December.
———2007, New Concerns in an Uncertain World: The 2007 A.T. Kearney ForeignDirect Investment confidence index, Global Business Policy Council, Vienna, VA.
Abbott, FM 1998, ‘The enduring enigma of TRIPS: A challenge for the world eco-nomic system’, Journal of International Economic Law, vol. 1, no. 4, pp. 497–521.
———2003, The Competition Provisions in the TRIPS Agreement: Implications forTechnology Transfer, Paper presented to WIPO–WTO Joint Workshop: Intellec-tual Property Rights and Transfer of Technology, Geneva, 17 November.
———2005, ‘The WTO medicines decision: World pharmaceutical trade and theprotection of pubic health’, American Journal of International Law, vol. 99, no. 2,pp. 317–58.
Abegunde, D & Stanciole, A 2006, ‘An estimation of the economic impactof chronic noncommunicable diseases in selected countries’, Working paper,World Health Organization, Geneva, 30 May, viewed 23 January 2009,http://www.who.int/chp/working_paper_growth%20model29may.pdf.
Acharya, A & Ranson, MK 2005, ‘Health care financing for the poor: Community-based health insurance schemes in Gujarat’, Economic and Political Weekly,vol. 40, no. 38, pp. 4141–50.
Aderibigbe, MR 1990, ‘The Nigerian patent system and the new industrial policy’,World Patent Information, vol. 12, no. 2, pp. 95–9.
Adikibi, OT 1988, ‘The multinational corporation and monopoly of patents inNigeria’, World Development, vol. 16, no. 4, pp. 511–26.
Aggarwal, A 2004, ‘Strategic approach to strengthening the international compet-itiveness in the knowledge based industries: The Indian pharmaceutical indus-try’, Discussion paper RIS-DP # 80/2004, Research and Information System forthe Non-Aligned and Other Developing Countries, New Delhi.
Ahuja, R & Narang, A 2005, ‘Emerging trends in health insurance for low-incomegroups’, Economic and Political Weekly, vol. 40, no. 38, pp. 4151–7.
Aiyer, S 2006, ‘Indian MNCs: Indian companies hunt for assets abroad to acquireglobal scale’, India Today, vol. 31, no. 44, pp. 38–48.
Alexander, J 2007, ‘ICMR launches medical innovation fund to support novelinitiative in drug research’, Pharmabiz, 20 February.
Alsegård, E 2004, ‘Global pharmaceutical patents after the Doha Declaration:What lies in the future?’, SCRIPT-ed, vol. 1, no. 1, 23 February.
Angell, M 2004, The Truth About the Drug Companies: How They Deceive Us andWhat To Do About It, Random House, New York.
Ashton, TS 1964, The Industrial Revolution: 1760–1830, Oxford University Press,London, UK.
289
290 References
Australian Bureau of Statistics 2006, ‘Population projections, Australia, 2004to 2101’, viewed 23 June 2008, http://www.abs.gov.au/ausstats/[email protected]/ProductsbyCatalogue/5A9C0859C5F50C30CA25718C0015182F?OpenDocument.
Australian Institute of Health and Welfare 2005, Health system expenditure on dis-ease and injury in Australia, 2000–01, Health and Welfare expenditure seriesno. 21, 2nd edn, Canberra.
Austrom, D & Howard, P 1994, ‘Speeding drugs to market: Strategies forre-engineering’, Scrip Magazine, October, pp. 50–2.
Babu, G 2007, ‘Cadila Pharma to launch SEZ in the third quarter of 2008’,Pharmabiz, 11 May.
Baker, BK 2008, ‘Ending drug registration apartheid: Taming data exclusivityand patent/registration Linkage’, American Journal of Law & Medicine, vol. 34,no. 2/3, pp. 303–44.
Balasubramaniam, K 2002, ‘Access to medicines: Patents, prices and public pol-icy – consumer perspectives’, in P Drahos & R Mayne (eds), Global IntellectualProperty Rights: Knowledge, Access and Development, Palgrave Macmillan, NewYork, pp. 90–107.
Ballance, R, Pogány, J & Forstner, H 1992, The World’s Pharmaceutical Industries:An International Perspective on Innovation, Competition and Policy, United NationsIndustrial Development Organization and Edward Elgar Publishing, Aldershot,England.
Barry, M 2003, ‘Presidential address: Diseases without borders – Globalization’schallenge to the American society of tropical medicine and hygiene: A call forpublic advocacy and activism’, The American Journal of Tropical Medicine andHygiene, vol. 69, no. 1, pp. 3–7.
Barton, J 2001, ‘Differentiated pricing of patented products’, rev. edn, Work-ing paper no. 63, Indian Council for Research on International EconomicRelations, New Delhi, November.
———2003, Preserving the Global Scientific and Technological Commons, Paperpresented to Science and Technology Diplomacy Initiative and the ICTSD-UNCTAD Project on IPRs and Sustainable Development Policy Dialogue on aProposal for an International Science and Technology Treaty, Room 25, Palaisdes Nations, Geneva, 11 April, viewed 23 February 2006, http://stdev.unctad.org/capacity/Barton.doc.
Barton, JH & Maskus, KE 2004, ‘Economic perspectives on a multilateral agree-ment on open access to basic science and technology’, SCRIPT-ed, vol. 1, no. 3,pp. 367–87.
Berndt, ER, Glennerster, R, Kremer, MR, Lee, J, Levine, R & Weizsäcker, G2005, ‘Advanced purchase commitments for a malaria vaccine: Estimatingcosts and effectiveness’, Discussion paper no. PEPP/2, Suntory and ToyotaInternational Centres for Economics and Related Disciplines, London Schoolof Economics and Political Science, London, April, viewed 14 March 2006,http://sticerd.lse.ac.uk/dps/pepp/pepp02.pdf.
Berry, A 2005, ‘Third-world medicine: A new way of developing drugs forneglected diseases of the poor world’, The Economist, 14 April.
Bhagat, M 1982, Aspects of Drug Industry in India, Centre for Education andDocumentation, Bombay.
References 291
Bidwai, P 2007, ‘Novartis patents case far from dead’, Transnational Insti-tute, viewed 3 December 2008, http://www.tni.org/detail_page.phtml?act_id=17188.
Bisserbe, N 2006, ‘It’s jungle out there’, Economic Times, 15 October.Blech, J 2006, Inventing Disease and Pushing Pills: Pharmaceutical Companies and
the Medicalisation of Normal Life, Routledge, London and New York.Blendon, RJ, Schoen, C, DesRoches, CM, Osborn, R, Scoles, KL & Zapert, K 2002,
‘Inequities in health’, Health Affairs, vol. 21, no. 3, pp. 182–91.Bloomberg 2006, ‘Pfizer investors to suffer from halting of Lipitor replace-
ment: Big M&A to come?’, Seeking Alpha, no. 4, December, viewed27 January 2009, http://seekingalpha.com/article/21659-pfizer-investors-to-suffer-from-halting-of-lipitor-replacement-big-m-a-to-come.
Boldrin, M & Levine, D 2005, The Pharmaceutical Industry, University ofCalifornia, viewed 23 February 2006, http://levine.sscnet.ucla.edu/papers/ip.ch.9.m1004.pdf.
Bower, DJ & Sulej, JC 2007, ‘The Indian challenge: The evolution of a success-ful new global strategy in the pharmaceutical industry’, Technology Analysis &Strategic Management, vol. 19, no. 5, pp. 611–24.
Braee, R 2001, New Zealand Pharmaceutical Pricing and Reimbursement Policies,European Commission, Brussels.
Brown, P 2004, ‘Fiddling with prices’, Scrip Magazine, June, pp. 3–4.Bureau of National Affairs 2001, ‘Rewriting TRIPS could hurt research: Pharma-
ceutical industry strongly warns WTO’, WTO Reporter, 20 September.Cai, Q & Salmon, JW 2005, ‘What role may pharmaeconomics play in phar-
maceutical pricing and reimbursement in China?’, Journal of PharmaceuticalFinance, Economics & Policy, vol. 14, no. 1, pp. 51–75.
Caplow, T, Hicks, L & Wattenberg, B 2006, The First Measured Century, PublicBroadcasting Services, Arlington, VA, viewed November 2006, http://www.pbs.org/fmc/book/2work4.htm.
Central Drug Research Institute (CDRI) 2008, New Drugs, Central DrugResearch Institute, Lucknow, viewed 12 April 2008, http://www.cdriindia.org/newdrugs.htm.
Chadha, A 2006, ‘Destination India for the pharmaceutical industry’, The DelhiBusiness Review, vol. 7, no. 1, pp. 1–8.
Chataway, J, Tait, J & Wield, D 2007, ‘Frameworks for pharmaceutical innova-tion in developing countries: The case of Indian pharma’, Technology Analysis& Strategic Management, vol. 19, no. 5, pp. 697–708.
Chataway, M 2000, ‘A radical idea for how pharma can help the developingworld’, Scrip Magazine, October, pp. 21–5.
Chaturvedi, K 2005, ‘Policy and technology co-evolution in the Indian phar-maceutical industry’, DPP Working paper no. 50, Development Policy andPractice, Faculty of Technology, The Open University, Walton Hall, MiltonKeynes, December.
Chaudhuri, S 2005, The WTO and India’s Pharmaceutical Industry: Patent Protection,TRIPS and Developing Countries, Oxford University Press, New Delhi.
Chaudhuri, S, Goldberg, P & Jia, P 2003, ‘The effects of extending intellec-tual property rights protection to developing countries: A case study of theIndian pharmaceutical market’, Working paper no. 10159, National Bureau ofEconomic Research, Cambridge, MA, December.
292 References
Chin, J & Grossman, G 1990, ‘Intellectual property rights and north-southtrade’, in RW Jones & AO Krueger (eds), The Political Economy of InternationalTrade: Essays in Honor of Robert E. Baldwin, Basil-Blackwell, Cambridge, MA,pp. 90–107.
CIMS 2007, CIMS, vol. 98, no. 3, Bio Gard Publishers, Bangalore, July–October.Cipla 2005, Annual Report 2004–05, Cipla Pharmaceuticals, Mumbai.———2008, Annual Report 2007–08, Cipla Pharmaceuticals, Mumbai.Clements, PJ 2007–08, ‘The Hatch-Waxman Act and the conflict between
antitrust law and patent law’, IDEA: The Intellectual Property Law Review, vol. 48,no. 3, pp. 381–407.
Clift, C 2007, ‘Data protection and data exclusivity in pharmaceuticals and agro-chemicals’, in A Krattiger, RT Mahoney, L Nelsen, JA Thomson, AB Bennett,K Satyanarayana, GD Graff, C Fernandez and SP Kowalski (eds), IntellectualProperty Management in Health and Agricultural Innovation: A Handbook of BestPractices, MIHR, Oxford, UK and PIPRA, Davis, USA, vol. 2.
Cole, JH 2001, ‘Patents and copyrights: Do the benefits exceed the costs?’, Journalof Libertarian Studies, vol. 15, no. 4, pp. 79–105.
Collier, R 2009, ‘Drug development cost estimates hard to swallow’, CanadianMedical Association Journal, vol. 180, no. 3, 3 February.
Commission on Intellectual Property Rights 2002, ‘Integrating intellectual prop-erty rights and development policy’, London, September, viewed 5 June 2005,http://www.iprcommission.org/papers/pdfs/final_report/CIPRfullfinal.pdf.
Commission on Intellectual Property Rights Innovation and Public Health2006, Public Health: Innovation and Intellectual Property Rights, World HealthOrganization, Geneva.
Commission on Macroeconomics and Health 2001, Macroeconomics and Health:Investing in Health for Economic Development, World Health Organization,Geneva.
Congressional Budget Office (CBO) 1998, Pricing and Competition in the Phar-maceutical Market: How Increased Competition from Generic Drugs Has AffectedPrices and Returns in the Pharmaceutical Industry, Congressional Budget Office,Government of the United States, Washington, DC.
Cornish, WR 1989, Intellectual Property: Patents, Copyrights, Trademarks and AlliedRights, Sweet and Maxwell, London.
Correa, CM 2002a, ‘Pro-competitive measures under TRIPS to promote tech-nology diffusion in developing countries’, in P Drahos and R Mayne (eds),Global Intellectual Property Rights: Knowledge, Access and Development, PalgraveMacmillan, New York, pp. 40–60.
———2002b, ‘Unfair competition under the TRIPS agreement: Protection ofdata submitted for the registration of pharmaceuticals’, Chicago Journal ofInternational Law, vol. 3, no. 1, pp. 69–86.
———2006, ‘Implications of bilateral free trade agreements on access tomedicines’, Bulletin of the World Health Organization, vol. 84, no. 5, pp. 399–404.
Cruddas, J & Gannon, Z 2009, A bitter pill to swallow: Drugs for people not justfor profit, Compass, London, 26 August.
Cutler, DM 2007, ‘The demise of the blockbuster?’, The New England Journal ofMedicine, vol. 356, no. 13, pp. 1292–3.
Cygnus 2005, Industry Insight: Indian Pharmaceuticals, Cygnus Business Consult-ing & Research, Hyderabad.
References 293
———2007, Quarterly Performance Analysis of Companies (October–December 2006):Indian Pharmaceutical Industry, Cygnus Business Consulting & Research,Hyderabad.
Danzon, P 2001, Differential Pricing: Reconciling R&D, IP and Access, paperpresented to WHO/WTO Workshop on Differential Pricing and Financ-ing of Essential Drugs, Hosbjor, Norway, 8–11 April, viewed 14 October2004, http://www.wto.org/english/tratop_e/trips_e/hosbjor_presentations_e/12danzon_e.pdf.
Danzon, PM, Epstein, A & Nicholson, S 2007, ‘Mergers and acquisitions in thepharmaceutical and biotech industries’, Managerial and Decision Economics,vol. 28, no. 4–5, pp. 307–28.
Darbourne, A 2003, ‘Access to medicines: Worlds apart’, Scrip Magazine, February,pp. 36–8.
Das, SC, Mandal, M & Mandal, SC 2007, ‘A critical study on availability andprice variation between different brands: Impact on access to medicines’, IndianJournal of Pharmaceutical Sciences, vol. 69, no. 1, pp. 160–3.
David, P 1993, ‘Intellectual property institutions and the panda’s thumb: Patents,copyrights, and trade secrets in economic theory and history’, in M Wallerstein,M Mogee and R Schoen (eds), Global Dimensions of Intellectual Property Rights inScience and Technology, National Academy Press, Washington, DC, pp. 19–61.
Davis, M 1994, ‘Patents in healthcare: Subsidy and victimisation?’, Scrip Magazine,December, pp. 6–8.
Deardof, A 1992, ‘Welfare effects of global patent protection’, Economica, vol. 59,no. 233, pp. 35–51.
Deloitte Recap 2009, ‘Biotech database’, Deloitte Recap LLC, viewed 28 January2009, http://www.deloitte.com/.
DeNavas-Walt, C, Proctor, BD & Smith, J 2007, Income, Poverty, and Health Insur-ance Coverage in the United States: 2006, US Census Bureau, U.S Department ofCommerce, Economics and Statistics Administration.
Department of Health 2005, ‘Reimbursement of “standard” branded genericmedicines: A further consultation’, viewed 17 July 2007, http://www.dh.gov.uk/en/Consultations/Closedconsultations/DH_4121799.
DiMasi, JA 1991, The Cost of Innovation in the Pharmaceutical Industry:New Drug R&D Cost Estimates, Pharmaceutical Manufacturers Association,Washington, DC.
———2001, ‘New drug development in the United States from 1963 to 1999’,Clinical Pharmacology & Therapeutics, vol. 69, no. 5, May, pp. 286–96.
DiMasi, JA & Grabowski, HG 2007, ‘The cost of biopharmaceutical R&D:Is biotech different?’, Managerial and Decision Economics, vol. 28, no. 4–5,pp. 469–79.
DiMasi, JA, Hansen, RW & Grabowski, HG 2003, ‘The price of innovation: Newestimates of drug development costs’, Journal of Health Economics, vol. 22, no. 2,pp. 151–85.
Dongre, RCK 1982, Shrimad Bhagwad-Rahasya [The Secret of God], MaanasPrakashan, New Delhi.
Dr Reddy’s 2004, ‘Address by Dr. K Anji Reddy’, Pharmacophore 2004, Inter-national Symposium, Innovating Drugs: Emerging Perspectives, Hyderabad,16–17 January, viewed 10 January 2006, http://www.drreddys.com/coverview/pdf/speeches/Pharmacophore2004_address.pdf.
294 References
———2005, Annual Report 2004–2005, Dr Reddy’s Labs, viewed 15 September2005, http://www.drreddys.com/investors/pdf/annualreport2005.pdf.
———2008, ‘API-product list’, viewed 18 September 2008, http://www.drreddys.com/gchemicals/api_productlist.htm.
Drahos, P 2002a, ‘Introduction’, in P Drahos & R Mayne (eds), Global IntellectualProperty Rights: Knowledge, Access and Development, Palgrave Macmillan, NewYork, pp. 1–12.
———2002b, ‘Negotiating intellectual property rights: Between coercion anddialogue’, in P Drahos & R Mayne (eds), Global Intellectual Property Rights:Knowledge, Access and Development, Palgrave Macmillan, New York, pp. 161–82.
Drahos, P & Braithwaite, J 2002, ‘Intellectual property, corporate strategy, glob-alisation: TRIPS in context’, Wisconsin International Law Journal, vol. 20, no. 3,pp. 451–80.
Drahos, P, Faunce, T, Goddard, M & Henry, D 2004, ‘The FTA and the PBS:A Submission to the Senate Select Committee on the US-Australia Free TradeAgreement’, Government of Australia, Canberra.
Drahos, P 2008, ‘ “Trust me”: Patent offices in developing countries’, AmericanJournal of Law & Medicine, vol. 34, no. 2, pp. 151–74.
Drohan, M 1996, ‘Canada can take heart from earlier WTO ruling: Backgrounderfor countries in danger of being pushed around by large neighbours, decisionbacking Venezuela over U.S. was special’, The Globe and Mail, 13 March, p. A12.
Drug Today 2005, Drug Today, vol. 12, no. 3, January–March.———2007, Drug Today, vol. 15, no. 2, October–December.Duckett, SJ 2004, ‘Drug policy down under: Australia’s Pharmaceutical Benefits
Scheme’, Health Care Financing Review, vol. 25, no. 3, pp. 55–67.Dukes, G 2006, The Law and the Ethics of the Pharmaceutical Industry, Elsevier,
Amsterdam.Dunkley, G 2001, The Free Trade Adventure: The Uruguay Round and Globalism –
A Critique, Melbourne University Press, Melbourne.Dutta, A 2005, ‘Free entry in the market for drugs in India: Implications for social
welfare’, MIT, viewed 22 February 2006, http://econ-www.mit.edu/graduate/candidates/download_res.php?id=254.
Economic Research Foundation 2006, ‘Government health expenditure in India:A benchmark study undertaken for the MacArthur Foundation’, viewed 1 July2008, http://www.macroscan.org/anl/oct06/pdf/Health_Expenditure.pdf.
EFPIA 2006, The Pharmaceutical Industry in Figures, European Federation of Phar-maceutical Industries and Associations, Brussels, viewed 22 November 2006,http://www.efpia.org/6_publ/infigures2006.pdf.
———2008, The Pharmaceutical Industry in Figures, European Federation ofPharmaceutical Industries and Associations, Brussels, viewed 3 August 2008,http://www.efpia.eu/Content/Default.asp?PageID=559&DocID=4883.
Elliott, R 2008, Delivery Past Due: Agreement Between Rwanda and Canadian GenericPharmaceutical Company Represents Historic First Use of WTO Rules on CompulsoryLicensing For Export, But Could Be Last, Paper presented to XVII Interna-tional AIDS Conference, Mexico City, 3–8 August, viewed 2 January 2008,http://www.aids2008.org/Pag/Abstracts.aspx?SID=290&AID=15940.
Ellis, RP, Alam, M & Gupta, I 2000, ‘Health insurance in India: Prognosis andprospectus’, Economic and Political Weekly, vol. 35, no. 4, pp. 207–17.
References 295
Embassy of the United States 2008, ‘IPR toolkit India: Patents’, viewed 28 October2008, http://newdelhi.usembassy.gov/iprpatents.html.
Essentialdrugs 2004, ‘India-drug: Total number of drug units in India’, Essen-tial Drugs, viewed 5 October 2004, http://www.essentialdrugs.org/indiadrug/archive/200401/msg00032.php.
EurActiv 2005, ‘Review of EU pharmaceutical legislation’, 11 February, viewed12 December 2008, http://www.euractiv.com/en/health/new-medicines-legislation/article-117531.
European Commission 2008, Pharmaceutical Sector Inquiry: PreliminaryReport, European Commission, Brussels, 28 November, viewed 10 Decem-ber 2008, http://ec.europa.eu/comm/competition/sectors/pharmaceuticals/inquiry/preliminary_report.pdf.
European Generic Medicines Association 2007, ‘Generic market shares acrossEurope in 2006’, viewed 5 July 2007, http://www.egagenerics.com/doc/fac-GxMktEur_2006.pdf.
European Parliament 2007, ‘Written declaration’, 0022/2007, 26 February,viewed 13 January 2009, http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//NONSGML+WDECL+P6-DCL-2007-0022+0+DOC+PDF+V0//EN&language=EN.
Federal Trade Commission 2003, ‘To Promote Innovation: The Proper Balance ofCompetition and Patent Law and Policy’, Washington, DC, 28 October, viewed15 October 2008, http://www.ftc.gov/opa/2003/10/cpreport.shtm.
Ferreiro, A 2000, ‘Private health insurance in India: Would its implementationaffect the poor?’, in D Peters, GNV Ramana & KS Rao (eds), Private Health Insur-ance and Public Health Goals in India: Report on a National Seminar, World Bank,New Delhi, pp. 79–83.
FICCI 2005, Competitiveness of the Indian Pharmaceutical Industry in the NewProduct Patent Regime: FICCI Report for National Manufacturing Competi-tiveness Council (NMCC), Federation of Indian Chambers of Commerce andIndustry, New Delhi.
———2007, ‘Govt to Frame India Innovation Act to Spur Research and Innova-tion: Kapil Sibal’, Federation of Indian Chambers of Commerce and Industry,New Delhi.
FierceBiotech 2006, ‘Dr. Reddy’s to buy betapharm in $570M deal’,viewed 3 February 2007, http://www.fiercebiotech.com/story/dr-reddy-s-to-buy-betapharm-in-570m-deal/2006-02-16.
Finger, JM 2002, ‘Implementing the Uruguay Round Agreements’, in P Lloyd &C Milner (eds), The World Economy: Global Trade Policy 2001, Blackwell Publish-ing, Oxford, UK, pp. 7–18.
Finger, JM & Schuler, P 2001, ‘Implementation of Uruguay round commit-ments: The development challenge’, World Bank Policy Research Workingpaper no. 2215, World Bank, Washington DC, viewed 23 June 2003, http://econ.worldbank.org/external/default/main?ImgPagePK=64202990&entityID=000094946_01013005324822&pagePK=64210502&theSitePK=544849&piPK=64210520.
Flink, JJ 1990, ‘Henry Ford and the triumph of the automobile’, in W Caroll &J Pursell (eds), Technology in America: A History of Individuals and Ideas, MIT Press,Cambridge, MA.
296 References
Food and Drug Administration (FDA) 2008, Electronic Orange Book: Approved DrugProducts with Therapeutic Equivalence Evaluations, Food and Drug Administra-tion, Government of the United States of America, viewed 2 December 2008,http://www.fda.gov/cder/ob/docs/querytn.htm.
Foroohar, R 2006, ‘A new drug deal’, Newsweek, December 2005–February 2006,p. 78.
Frank, R & Hensley, S 2002, ‘Pfizer to buy Pharmacia for $60 billion in stock’, TheWall Street Journal, 15 July, p. 1.
Galpalli, N 2004, ‘GATT agreement: Effect on drug prices in India’,Pharmainfo.net, viewed 18 February 2005, http://pharmainfo.net/subjects-viewpage-pageid-82.html.
Gambardella, A 1995, Science and Innovation: The US Pharmaceutical IndustryDuring the 1980s, Cambridge University Press, New York.
Gambardella, A, Orsenigo, L & Pammolli, F 2000, Global Competitiveness inPharmaceuticals: A European Perspective, Report Prepared for the DirectorateGeneral Enterprise of the European Commission, Brussels.
Garg, CC 2000, ‘Implications of current experiences of health insurance in India’,in D Peters, GNV Ramana & KS Rao (eds), Private Health Insurance and PublicHealth Goals in India: Report on a National Seminar, World Bank, New Delhi,pp. 3–42.
Gassmann, O, Reepmeyer, G & von Zedtwitz, M 2004, Leading PharmaceuticalInnovation: Trends and Drivers for Growth in the Pharmaceutical Industry, Springer-Verlag, Berlin.
———2008, Leading Pharmaceutical Innovation: Trends and Drivers for Growth inthe Pharmaceutical Industry, 2nd edn, Springer-Verlag, Berlin.Gehl Sampath, P2006, ‘India’s product patent protection regime: Less or more of “Pills for thePoor”?’, The Journal of World Intellectual Property, vol. 9, no. 6, pp. 694–726.
Genepharm 2005, Annual Report, Genepharm Australasia, Melbourne.General Insurance Corporation of India 2008, ‘History in brief’, viewed 9 July
2008, http://gicofindia.in/en/.Generic Handbook 2007, Generic Handbook, 2nd edn, VOI Consulting, New
Orleans.Global-Challenges 2008, ‘AIDS: Third world: 1999–2008: Global issues of the
twenty-first century and United Nations challenges’, viewed 20 September2008, http://www.global-challenges.org/30aids-thirdworld.html.
Global Forum for Health Research 1999, ‘The 10/90 report on health research’,Global Forum for Health Research, Geneva, viewed 4 January 2009, http://www.globalforumhealth.org/filesupld/1090_report_99/99ex_summary.PDF.
———2004, The 10/90 Gap in Health Research, Global Forum for Health Research,Geneva, viewed 4 January 2009, http://www.globalforumhealth.org/filesupld/1090_report_03_04/109004_chap_5.pdf.
Goddard, M, Hauck, K, Preker, A & Smith, PC 2006, ‘Priority setting in health: Apolitical economy perspective’, Health Economics, Policy and Law, vol. 1, no. 1,pp. 79–90.
Goozner, M 2004, The $800 Million Pill: The Truth Behind the Cost of New Drugs,University of California, Berkeley and Los Angeles, CA.
Government of Australia 2006, Expenditure and Prescriptions Twelve Months to 30June 2006, Department of Health and Ageing, Canberra, Australia.
References 297
———2007a, Australian Regulation of Prescription Medical Products, Ther-apeutic Goods Administration, Department of Health and Ageing,Canberra.
———2007b, Pharmaceutical Benefits Scheme (PBS) Reform, Therapeutic GoodsAdministration, Department of Health and Ageing, Canberra.
———2008, ‘What is intellectual property? an introduction to intellec-tual property’, viewed 10 December 2008, http://www.ipaustralia.gov.au/ip/introduction.shtml.
———2010, Overview of the PBS Safety Net?, Medicare Australia, Canberra, viewed27 January 2010, http://www.medicareaustralia.gov.au/public/services/scripts/pbs.jsp.
Government of Canada 2008, How Does the PMPRB Review the Pricing Infor-mation For All Patented Medicines Sold in Canada?, Patented Medicine PricesReview Board, Ottawa, viewed 27 August 2008, http://www.pmprb-cepmb.gc.ca/english/view.asp?x=272#16.
Government of India (GOI) 1952, First Five-Year Plan (1952–57), Planning Com-mission of India, New Delhi.
———1957, Second Five-Year Plan (1957–1962), Planning Commission of India,New Delhi.
———1972, The Patent Act 1970, Office of the Controller General of Patents,Designs and Trade Marks, Kolkata.
———1977, Drug Policy – 1977, Department of Chemicals and Petrochemicals,Ministry of Chemicals and Fertilizers, New Delhi.
———1980, Sixth Five-Year Plan (1980–85), Planning Commission of India, NewDelhi.
———1986, Drug Policy – 1986, Department of Chemicals and Petrochemicals,Ministry of Chemicals and Fertilizers, New Delhi.
———1994, Drug Policy – 1994, Department of Chemicals and Petrochemicals,Ministry of Chemicals and Fertilizers, New Delhi.
———1995, Drugs (Price Control) Order 1995, Department of Chemicals andPetrochemicals, Ministry of Chemicals and Fertilizers, Government of India,New Delhi.
———1999, The Patents (Amendment) Act, 1999, no. 17 of 1999, 26 March 1999,http://ipindia.nic.in/ipr/patent/patact_99.PDF.
———2002a, National Health Policy – 2002, Ministry of Health and FamilyWelfare, Government of India, New Delhi.
———2002b, The Patents (Amendment) Act, 2002, no. 38 of 2002, 25 June 2002,http://ipindia.nic.in/ipr/patent/patentg.pdf.
———2002c, Pharmaceutical Policy – 2002, Press Information Bureau, Govern-ment of India, viewed 16 January 2003, http://pib.nic.in/archive/Ireleng/Iyr2002/rfeb2002/15022002/r1502200212.html.
———2002d, Pharmaceutical Policy – 2002, Department of Chemicals andPetrochemicals, Ministry of Chemicals and Fertilizers, New Delhi.
———2003a, Functions of NPPA, National Pharmaceutical Pricing Authority,Government of India, New Delhi.
———2003b, Health Information of India 2000 & 2001, Central Bureau of HealthIntelligence, Directorate General of Health Services, Ministry of Health &Family Welfare, New Delhi.
298 References
———2003c, Statistical Pocket Book – India 2002, Central Statistical Organisation,Ministry of Statistics and Programme Implementation, New Delhi.
———2004, National Common Minimum Programme of the Government of India,Government of India, New Delhi.
———2005a, Draft – National Pharmaceuticals Policy: 2006, Department of Chem-icals and Petrochemicals, Ministry of Chemicals and Fertilizers viewed 12February 2006, http://chemicals.nic.in/npp_circulation_latest.pdf.
———2005b, National Health Accounts 2001–02, National Health Accounts Cell,Ministry of Health and Family Welfare, New Delhi.
———2005c, The Patents (Amendment) Act, 2005, no. 15 of 2005, 5 April2005, viewed 16 November 2005, http://patentoffice.nic.in/ipr/patent/patent_2005.pdf.
———2005d, Pharmaceuticals, Department of Chemicals and Petrochemicals,viewed 12 December 2005, http://chemicals.nic.in/pharma1.htm.
———2005e, Report of the National Commission on Macroeconomics and Health,National Commission on Macroeconomics and Health, Ministry of Health andFamily Welfare, New Delhi.
———2005f, Seventh Report on Availability and Price Management of Drugs andPharmaceuticals, Standing Committee on Chemicals and Fertilizers (2005–06),Department of Chemicals and Petrochemicals, Ministry of Chemicals andFertilizers, New Delhi.
———2006a, Annual Report 2005–2006, Department of Chemicals andPetrochemicals, Ministry of Chemicals and Fertilizers, New Delhi.
———2006b, Census of India 2001: Population Projections for India and States2001–2026, Technical Group on Population Projections, Office of the RegistrarGeneral, New Delhi.
———2006c, (Draft) Towards Faster and More Inclusive Growth: An Approach to the11th Five-Year Plan, Planning Commission, New Delhi.
———2006d, Household Assets Holding, Indebtedness, Current Borrowings and Repay-ments of Social Groups in India: All-India Debt and Investment Survey, NSS 59thRound, no. 503 (59/18.2/4), National Sample Survey Organisation, Ministry ofStatistics & Programme Implementation, New Delhi.
———2006e, Morbidity, Health Care and the Condition of the Aged, NSS 60th Round,507 (60/25.0/1), National Sample Survey Organisation, Ministry of Statisticsand Programme Implementation, New Delhi.
———2006f, National Health Profile 2006, Central Bureau of Health Intelligence,Directorate General of Health Services, Ministry of Health and Family Welfare,New Delhi.
———2006g, ‘Notice for termination of exclusive marketing right EMR/1/2002’,The Patent Office Journal, no. 7, 17 February.
———2006h, Reduction in Prices of Certain Categories of Medicines (Promised),Department of Chemicals and Petro-Chemicals, Ministry of Chemicals andFertilizers, New Delhi, viewed 23 September 2008, http://chemicals.nic.in/ReductionList112006.pdf.
———2006i, Sectors Attracting Highest FDI Inflows, Department of Industrial Policyand Promotion, Ministry of Commerce & Industry, Government of India, NewDelhi.
———2006j, Selected Socio-economic Statistics India, Central Statistical Organisa-tion, Ministry of Statistics and Programme, New Delhi.
References 299
———2007a, ‘Actual reduction in prices of medicines as on 14 May 2007’, Depart-ment of Chemicals and Petrochemicals, Ministry of Chemicals and Fertilizers,New Delhi.
———2007b, Drugs and Pharmaceutical Exports (Commodity-wise), DirectorateGeneral Commercial Intelligence and Statistics (DGCIS), Kolkata.
———2007c, National Family Health Survey 2005–06 (NFHS-3), Ministry of Healthand Family Welfare, New Delhi.
———2007d, Report of the Special Subject Group: Unshackling Indian Industry, PrimeMinister’s Council on Trade and Industry, New Delhi.
———2007e, Report of the Working Group on Drugs and Pharmaceuticals for the 11thFive-Year Plan (2007–2012), Planning Commission of India, New Delhi.
———2007f, Statistical Pocket Book India, Combined Issue 2006 & 2007, 45thedn, Central Statistical Organisation, Ministry of Statistics and ProgrammeImplementation, New Delhi.
———2008a, Annual Report, Department of Scientific & Industrial Research,Ministry of Science and Technology, New Delhi.
———2008b, ‘Mainstreaming of ISM&H practitioners and bare-foot doctors’,viewed 23 June 2008, http://populationcommission.nic.in/ISM&H.htm.
———2009, ‘Annual Report’, Department of Pharmaceuticals, Ministry of Chem-icals and Fertilizers, New Delhi.
———2010, ‘List of Drugs Approved for Marketing in India’, Central Drugs Stan-dard Control Organisation, Directorate General of Health Services, Ministry ofHealth and Family Welfare, New Delhi.
Government of the United States 2008, The Orphan Drug Act (as Amended),SEC. 526 [360bb](a)(2), U.S. Food and Drug Administration, Washington, DC,viewed 24 August 2008, http://www.fda.gov/orphan/oda.htm.
Grabowski, H 2002, ‘Patents, innovation and access to new pharmaceuticals’,Journal of International Economic Law, vol. 5, no. 4, pp. 849–60.
———2005, ‘Increasing R&D incentives for neglected diseases: Lessons from theOrphan Drug Act’, in KE Maskus & JH Reichman (eds), International PublicGoods and Transfer of Technology under a Globalized Intellectual Property Regime,Cambridge University Press, New York, pp. 457–80.
Graf von der Schulenburg, JM 2007, Valuing Pharmaceutical Innovation inthe European Union: The German Perspective, Leibniz University, Hannover,Germany, Presentation, viewed 7 May 2008, http://www.lse.ac.uk/collections/LSEHealth/eventsAndSeminars/MerckSeminar2007/Workshopagendasandpresentations/ByMatthiasGrafvonderSchulenburg.pdf.
Gray, A & Matsebula, T 2003, ‘Drug pricing in South Africa- policy andpraxis’, Journal of Pharmaceutical Finance, Economics & Policy, vol. 12, no. 2,pp. 95–121.
Gupta, AS 2004, ‘Misplaced initiatives in the health sector’, People’s Democracy,vol. 28, no. 52.
Gupta, I & Trivedi, M 2005, ‘Social health insurance redefined: Health for allthrough coverage for all’, Economic and Political Weekly, vol. 40, no. 38,pp. 4132–40.
Hansen, R 1979, ‘The pharmaceutical development process: Estimates of devel-opment costs and times and the effects of proposed regulatory changes’, in RIChien (ed.), Issues in Pharmaceutical Economics, Lexington Books, D C Heath &Co, Lexington, MA.
300 References
Harten, C & Ballantyne, P 2004, ‘The impact of cost sharing within Canadianprovincial drug benefit programs: A review’, Journal of Pharmaceutical Finance,Economics & Policy, vol. 13, no. 1, pp. 35–53.
Harvey, K, Faunce, TA, Lokuge, B & Drahos, P 2004, ‘Will the Australia–UnitedStates Free Trade Agreement undermine the Pharmaceutical Benefits Scheme?’,The Medical Journal of Australia, vol. 181, no. 5, pp. 256–9.
Harvey, KJ 2005, ‘The Pharmaceutical Benefits Scheme 2003–2004’, Australia andNew Zealand Health Policy, vol. 2, no. 2.
Haub, C & Sharma, OP 2006, ‘India’s population reality: Reconciling change andtradition’, Population Bulletin, vol. 61, no. 3.
Hawthorne, F 2003, The Merck Druggernaut: The Inside Story of a PharmaceuticalGiant, John Wiley & Sons, Hoboken, New Jersey.
Hayek, FA 1988, The Fatal Conceit, University of Chicago Press, Chicago.Heinen, C & Perry, R 2006, ‘Big pharma’s Indian renaissance’, Scrip Magazine,
February, p. 33.Henry, D, Lopert, R & Lang, D 2001, Levelling the Playing Field: Using Evidence
to Determine ‘Fair’ Drug Prices, Paper presented to WHO/WTO Workshop onDifferential Pricing and Financing of Essential Drugs, Hosbjor, Norway, 8–11April, viewed 7 September 2005, http://www.wto.org/english/tratop_e/trips_e/hosbjor_presentations_e/37henry_e.pdf.
Hertz, AZ 1997, ‘Shaping the trident: Intellectual property under NAFTA, invest-ment protection agreements and at the World Trade Organization’, Canada-United States Law Journal, vol. 23, pp. 261–326.
Hesse, C 2002, ‘The rise of intellectual property, 700 B.C.–A.D. 2000: An idea inthe balance’, Daedalus, vol. 131, no. 2, pp. 26–45.
Hiddleston, S 2007, ‘No need to patent small changes’, Frontline, vol. 24, no. 5.Hoekman, B 2002, ‘The WTO: Functions and basic principles’, in B Hoekman,
A Mattoo & P English (eds), Development, Trade, and the WTO: A Handbook,The International Bank for Reconstruction and Development/The World Bank,Washington, DC.
Hofstede, G 2001, Culture’s Consequences: Comparing Values, Behaviors, Institutionsand Organizations Across Nations, Sage Publications, Thousand Oaks, Calif.
Hollis, A 2005, An Efficient Reward System for Pharmaceutical Innovation, Institute ofHealth Economics, Department of Economics, University of Calgary, Calgary.
Hope, J 2003, ‘Biotechnology project’, Open source, Research School of SocialSciences, Australian National University, Canberra, viewed 17 November 2006,http://rsss.anu.edu.au/∼janeth/Law.html.
House of Commons Health Committee 2005, The Influence of the PharmaceuticalIndustry, Government of the United Kingdom, London.
Hughes, JW, Moore, MJ & Snyder, EA 2002, ‘ “Napsterizing” pharmaceuticals:Access, innovation and consumer welfare’, Working paper no. 9229, NationalBureau of Economic Research, Cambridge, MA, October.
Humer, FB 2005, ‘Innovation in the pharmaceutical industry: Future prospects’,Talk to the Zuericher Volkswirtschaftliche Gesellschaft, Roche Pharmaceuticals,Zurich, 16 March.
Ibrahim, MIM & Bahri, S 2003, ‘Drug policies and pricing mechanism: TheMalaysian perspective’, Journal of Pharmaceutical Finance, Economics & Policy,vol. 12, no. 1, pp. 77–94.
References 301
IDR 2008, IDR Pharmacy Triple Compendium, Indian Drug Review, vol. 13,November 2007–January 2008.
IFPMA 2004, ‘Encouragement of New Clinical Drug Development: The Role ofData Exclusivity’, International Federation of Pharmaceutical ManufacturersAssociations, Geneva.
IMF 2008, ‘Report for selected countries and subjects’, World Economic OutlookDatabase, International Monetary Fund, Washington, DC, viewed 15 July 2008,http://www.imf.org/external/pubs/ft/weo/2008/01/weodata/weorept.aspx?sy=2006&ey=2013&scsm=1&ssd=1&sort=country&ds=.&br=1&c=534&s=NGDP_R%2CNGDP_RPCH%2CNGDP%2CNGDPD%2CNGDPPC%2CNGDPDPC%2CPPPGDP%2CPPPPC&grp=0&a=&pr.x=67&pr.y=2.
IMS Health 2004, IMS Lifecycle Incorporating R&D Focus, New Product Focus, andPatent Focus, CD, London, November.
INHATA 2008, ‘IQWiG – Institut für Qualität und Wirtschaftlichkeit imGesundheitswesen’, Global Networking for Effective Healthcare, viewed 30September 2008, http://www.inahta.org/Members/IQWiG/.
Insurance Regulatory and Development Authority (IRDA) 2007, Annual Report2005–06, Hyderabad.
———2008, Annual Report 2006–07, Hyderabad.Inter-Ministerial Consultative Committee (IMCC) 2007, Report on Steps to be Taken
by Government of India in the Context of Data Protection Provisions of Article 39.3of TRIPS Agreement, Department of Chemicals and Petrochemicals, Ministry ofChemicals and Fertilizers, Government of India, New Delhi.
IP-Watch 2006, ‘Pretest submitted to first patent filing of HIV/AIDS drug in India’,Intellectual Property Watch, Geneva, viewed 28 October 2008, http://www.ip-watch.org/weblog/index.php?p=254&print=1.
Jack, W & Lanjouw, JO 2005, ‘Financing pharmaceutical innovation: How muchshould poor countries contribute?’, The World Bank Economic Review, vol. 19,no. 1, January, pp. 45–67.
Jatania, P 2004, ‘In search of the sugar-coating: The new product patents regimewill decide the future of hundreds of leukaemia patients’, Indian Express, 19December.
Jeremy, D 2004, ‘Patents and Technology Transfer Between Nations: 1790–1851:Help, Hindrance or Irrelevance: Lessons from History’, paper presented to Intel-lectual Property Rights, Economic Development, and Social Welfare: What doesHistory tell us?, Ironbridge Gorge Museum, Coalbrookdale, 26 April.
Jorge, MF 2004, ‘TRIPS-plus provisions in trade agreements and their potentialadverse effects on public health’, Journal of Generic Medicines, vol. 1, no. 3,pp. 199–211.
Jyothi-Datta, PT 2006, ‘Roche gets product patent on Hepatitis C’, The HinduBusiness Line, 3 March.
Kamath, G 2004, ‘Is the pharma dream run over?’, Business World India,1 November.
———2007, ‘Beyond generics: Indian pharma companies are hiving off R&Dunits into separate companies in their quest for new drugs’, Business World,28 December.
Kamath, G & Krishnan, GS 2004, ‘Generics market: Creeping acquisition’,Business World, 2 August, p. 8.
302 References
Kassirer, JP 2005, On the Take: How Medicine’s Complicity with Big Business canEndanger your Health, Oxford University Press, New York.
Kaul, S 2004, ‘In better health than ever: Zydus Cadila prepares itself forthe challenges of the post WTO era’, Business India, 26 April–9 May,pp. 61–5.
Keayla, BK 1996, ‘New patent regime: Implications for domestic industry,research and development and consumers’, National Working Group on PatentLaws, Centre for Study on GATT Laws, New Delhi.
Khan, BZ 2002, ‘Intellectual property and economic development: Lessons fromAmerican and European history’, Study paper 1a, Commission on Intellec-tual Property Rights, viewed 24 October 2008, http:www.iprcommission.org/papers/word/study_papers/sp1a_khan_study.doc.
Khosla, R & Hunt, P 2008, Human Rights Guidelines for Pharmaceutical Compa-nies in Relation to Access to Medicines, Human Rights Centre, University ofEssex, viewed 1 February 2010, http://www.essex.ac.uk/human_rights_centre/research/rth/docs/Final_pharma_for_website.pdf.
Klein, N 2003, ‘Bush’s AIDS test’, The Nation, 27 October, p. 12.Knowledge at Wharton 2008, ‘An increasingly affluent Middle India is harder
to ignore’, India Knowledge@Wharton, viewed 12 July 2008, http://knowledge.wharton.upenn.edu/india/articlepdf/4303.pdf?CFID=74092837&CFTOKEN=85340977&jsessionid=9a3095fb819e56262155.
Koshy, S 1995, ‘The effects of TRIPS on Indian Patent Law: A pharmaceuticalperspective’, Boston University Journal of Science & Technology Law, vol. 1, no. 4,pp. 123–49.
KPMG 2006a, The Indian Pharmaceutical Industry: Collaboration for Growth, KPMGInternational, Mumbai.
KPMG 2006b, India Pharma Inc Competing Globally, KPMG International, Mumbai.Kremer, M 2002, ‘Pharmaceuticals and the developing world’, Journal of Economic
Perspectives, vol. 16, no. 4, pp. 67–90.Kremer, M & Glennerster, R 2004, Strong Medicine: Creating Incentives for Pharma-
ceutical Research on Neglected Diseases, Princeton University Press, Princeton.Kumar, R 2008, ‘Encourage innovation with holistic approach: Basheer’, The
Hindu Business Online, 13 October, viewed 31 October 2008, http://www.hindu.com/biz/2008/10/13/stories/2008101350051600.htm.
Labonte, R & Schrecker, T 2006, Globalization and Social Determinants of Health:Analytic and Strategic Review Paper, Institute of Population Health, Universityof Ottawa, 11 March, viewed 11 November 2008, http://www.who.int/social_determinants/resources/globalization.pdf.
Lacetera, N 2001, ‘Corporate governance and the governance of innovation: Thecase of the pharmaceutical industry’, Journal of Management and Governance,vol. 5, no. 1, pp. 29–59.
Lalitha, N 2002, ‘Indian pharmaceutical industry in WTO regime’, Economic andPolitical Weekly, vol. 37, no. 34, 24–30 August.
Lall, S 1974, ‘The international pharmaceutical industry and less-developed coun-tries, with special reference to India’, Oxford Bulletin of Economics and Statistics,vol. 36, no. 3, pp. 143–72.
Lanjouw, J 1998, ‘The Introduction of pharmaceutical product patents in India:Heartless exploitation of the poor and suffering?’, Working paper no. 6366,National Bureau of Economic Research, Cambridge, MA, January.
References 303
———2002a, ‘A new global patents regime for diseases: U.S, and interna-tional legal issues’, Harvard Journal of Law & Technology, vol. 16, no. 1, Fall,pp. 1–40.
———2002b, ‘Intellectual property and the availability of pharmaceuticals inpoor countries’, CGD Working paper no. 5, Centre for Global Development,April, viewed 24 May 2004, http://www.cgdev.org/content/publications/detail/2785.
Lanjouw, JO & Cockburn, IM 2001, ‘New pills for poor people? Empiricalevidence after GATT’, World Development, vol. 29, no. 2, pp. 265–89.
Lehman, B 2003, The Pharmaceutical Industry and the Patent System, Earth Insti-tute, Columbia University, viewed 12 June 2007, http://www.earthinstitute.columbia.edu/cgsd/documents/lehman.pdf.
Lewis, G, Class, S & Edery, E 2005, ‘Growth in moderation’, Scrip Magazine,February, pp. 28–33.
Lichtenberg, FR 2006, ‘Importation and innovation’, Working paper no. 12539,National Bureau of Economic Research, Cambridge, MA, September.
Light, DW 2005, ‘Making practical markets for vaccines’, PLoS Medicine, vol. 2,no. 10, p. 271.
Lippoldt, D 2006, ‘Intellectual property rights, pharmaceuticals and foreigndirect investment’, Policy brief, Groupe d’Economie Mondiale de SciencesPo., Paris, November, viewed 27 April 2008, http://gem.sciences-po.fr/content/publications/pdf/lippoldt_IPRs_Pharma_FDI1106.pdf.
Lleras-Muney, A & Lichtenberg, FR 2002, ‘The effect of education on medicaltechnology adoption: Are the more educated more likely to use new drugs?’,Working paper, no. 9185, National Bureau of Economic Research, Cambridge,MA, September.
Lloyd, I 2002, ‘R&D revolution remains just around the corner’, Scrip Magazine,February, pp. 72–3.
Lofgren, H 2005, ‘Purchase commitments: Big business bias or solution to the‘Neglected Disease’ dilemma?’, Australian Review of Public Affairs, 31 October,viewed 12 December 2005, http://www.australianreview.net/digest/2005/10/lofgren.html.
———2007, ‘Reshaping Australian drug policy: The dilemmas of genericmedicines policy’, Australia and New Zealand Health Policy, vol. 4, no. 11,pp. 1–4.
Macdonald, S 2002, ‘Exploring the hidden costs of patents’, in P Drahos &R Mayne (eds), Global Intellectual Property Rights: Knowledge, Access and Devel-opment, Palgrave Macmillan, New York, pp. 13–39.
Machlup, F 1958, An Economic Review of the Patent System: Study of the Subcom-mittee on Patents, Trademarks, and Copyrights of the Committee on the Judiciary,Presented to Eighty Fifth Congress, Study no. 15, United States Senate,Government of the United States, Washington, DC.
Machlup, F & Penrose, E 1950, ‘The patent controversy in the nineteenthcentury’, The Journal of Economic History, vol. 10, no. 1, pp. 1–29.
Madanmohan, TR & Krishnan, RT 2003, ‘Adaptive strategies in the Indianpharmaceutical industry’, International Journal of Technology and Management,vol. 25, no. 3–4, pp. 227–46.
Mahal, A 2000, ‘Private entry into health insurance in India: An assessment’,in D Peters, GNV Ramana & KS Rao (eds), Private Health Insurance and Public
304 References
Health Goals in India, Report on a National Seminar, World Bank, New Delhi,pp. 46–76.
———2002, ‘Health policy challenges for India: Private health insurance andlessons from the international experience’, in TN Srinivasan (ed.), Trade,Finance and Investment in South Asia, Social Science, New Delhi, pp. 395–463.
Malhotra, P 2008, ‘The impact of TRIPS on innovation and exports: A case studyof the pharmaceutical industry in India’, Indian Journal of Medical Ethics, vol. 5,no. 2, pp. 61–5.
Malhotra, P & Grewal, B 2008, ‘TRIPS-plus: Free trade agreements jeopardisingpublic health in developing nations’, in TV Hoa & C Harvie (eds), RegionalTrade Agreements in Asia, Edward Elgar, Cheltenham, UK, pp. 216–39.
Managing Intellectual Property 2007, ‘AIDS patent first in India’, Weekly News, 19December.
Mansfield, E 1986, ‘Patents and innovation: An empirical study’, ManagementScience, vol. 32, no. 2, pp. 173–81.
———1995, ‘Intellectual property protection, direct investment, technologytransfer: Germany, Japan and the United States’, Discussion paper no.27, International Finance Corporation, The World Bank, Washington, DC,September.
Mashelkar, RA 2003, ‘Whither India with the international patents regime?’,Chemical Business, April–June, pp. 77–92.
Maskus, K 2000a, ‘Intellectual Property Rights and Foreign Direct Investment’,Centre for International Economic Studies, University of Adelaide, Adelaide,Australia, May.
———2000b, ‘Regulatory standards in the WTO’, Working paper 00-1, Institutefor International Economics, Washington, January, viewed 16 November 2004,http://www.iie.com/publications/wp/wp.cfm?ResearchID=121.
Maskus, KE & Reichman, JH 2004, ‘The globalization of private knowledge goodsand the privatization of global public goods’, Journal of International EconomicLaw, vol. 7, no. 2, pp. 279–320.
Mathew, J 2006, ‘Ranbaxy eyes stake in marketing allies’, Economics Times, 12July, viewed 19 July 2006, http://economictimes.indiatimes.com/articleshow/1733416.cms.
———2008, ‘Cipla unveils Roche’s generic version of anti-infection drug’, Busi-ness Standard, 24 September.
Mathew, T & Torreblanca, M 2005, ‘India steps up to the plate’, Scrip Magazine,November, pp. 47–9.
Mathieu, MP (ed.) 2007, Parexel’s Bio/Pharmaceutical R&D Statistical Sourcebook2007/2008, Parexel International Coroporation, Waltham, MA, USA.
May, C & Sell, S 2006, Intellectual Property Rights: A Critical History, Lynne Rienner,Boulder, Colorado.
Mayne, R 2002, ‘The global campaign on patents and access to medicines: AnOxfam perspective’, in P Drahos & R Mayne (eds), Global Intellectual Prop-erty Rights: Knowledge, Access and Development, Palgrave Macmillan, New York,pp. 244–58.
———2005, ‘Regionalism, bilateralism, and ‘TRIPS Plus’ agreements: The threatto developing countries’, United Nations Development Program, OccasionalPaper no. 2005/18, viewed 6 September 2005, http://hdr.undp.org/docs/publications/background_papers/2005/HDR2005_Mayne_Ruth_18.pdf.
References 305
Mazumdar-Shaw, K 2007, ‘Biotechnology Partnering Opportunities with India’,paper presented to BioBreakfast, Melbourne Town Hall, 16 March.
McEwan, JG 2005, ‘Is the cure worse than the disease? An overview of the PatentReform Act of 2005’, The John Marshall Review of Intellectual Property Law, vol. 5,no. 1, pp. 55–77.
McLachlan, AJ, Ramzan, I & Milne, RW 2007, ‘Frequently asked questions aboutgeneric medicines’, Australian Prescriber, vol. 30, no. 2, pp. 41–3.
Medicines Australia 2008, ‘Global pharmaceutical industry: Facts at a glance’,Canberra, March, viewed 17 November 2008, http://www.medicinesaustralia.com.au/pages/images/Global%20-%20facts%20at%20a%20glance.pdf.
Medico Friends Circle 2006, ‘Submission to the Government of India: A balancedpharmaceutical policy’, Pune, 10 July, viewed 17 October 2008, http://www.mfcindia.org/PMdrugpricing.html.
MedIndia 2007, ‘Patents: Appellate board becomes functional’, MedIndia.com,Chennai, 10 April, viewed 28 May 2007, http://www.medindia.net/news/view_news_main.asp?x=19886.
Melethil, S 2005, ‘Patent issues in drug development: Perspectives of a pharma-ceutical scientist-attorney’, The American Association of Pharmaceutical Scientists(AAPS) Journal, vol. 7, no. 3, pp. E723–28.
Minwalla, S 2003, ‘Drug promotion in India’, Healthy Skepticism InternationalNews, vol. 21, no. 9, viewed 10 June 2008, http://www.healthyskepticism.org/publications/editions/2003/9.htm.
Misra, R, Chatterjee, R & Rao, S 2003, India Health Report, Oxford University Press,New Delhi.
Mokyr, J 1990, The Lever of Riches: Technological Creativity and Economic Progress,Oxford University Press, London.
Morag-Sela, T, Cohn, I, Kowalski, TJ, Jarecki-Black, J & Clyde-Watson, Z 2004,‘Intellectual property law in Israel, and US and European objections: Mar-ket exclusivity vs. data exclusivity’, Nature Biotechnology, vol. 22, no. 12,pp. 1591–2.
Moran, M 2001, ‘Bitter medicine: Why the developing world can’t get drugs’,On Line Opinion, 15 April, viewed 25 January 2006 http://www.onlineopinion.com.au/view.asp?article=1971.
———2005, ‘A breakthrough in R&D for neglected diseases: New ways toget the drugs we need’, PLOS, vol. 2, no. 9, viewed 12 December2005, http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0020302.
MSF 2008, ‘Pre-grant opposition victory in India’, Campaign for Access to Essen-tial Medicines, viewed 28 October 2008, http://www.msfaccess.org/main/access-patents/pre-grant-opposition-victory-in-india/.
Mueller, JM 2007a, ‘Taking TRIPS to India: Novartis, patent law, access tomedicines’, The New England Journal of Medicine, vol. 356, no. 6, pp. 541–3.
———2007b, ‘The tiger awakens: The tumultuous transformation of India’spatent system and the rise of Indian pharmaceutical innovation’, University ofPittsburgh Law Review, vol. 68, no. 3, pp. 491–641, viewed 24 April 2007, http://lawreview.law.pitt.edu/issues/68/68.3/Mueller.pdf.
Mukherjee, S 2005, ‘Pharmaceutical research and development in India – Lookingup?’, Business Briefing: Pharma Outsourcing, 11 March, pp. 98–103.
Mukreja, DN 2004, ‘Against all sceptics’, Business World, 16 August, pp. 29–34.
306 References
Murray, CJL & Lopez, AD (eds) 1996, The Global Burden of Disease: A Compre-hensive Assessment of Mortality and Disability from Diseases, Injuries, and RiskFactors in 1990 and Projected to 2020, Global Burden of Disease and Injury Series,Volume I, The Harvard School of Public Health on behalf of the World HealthOrganization and the World Bank, Cambridge, MA.
mX 2006, ‘Record deal ends tax row’, mX, 12 September, p. 11.Nagendranath, A & Chari, P 2002, Health Insurance in India: The Emerging
Paradigms, Paper presented to Insurance ’02: A Seminar on the EmergingIssues in the Indian Insurance Sector, IIFT-School of International BusinessManagement, New Delhi, 6 September.
Nanda, N 2006, Options for Using Competition Law/Policy Tools in Dealing withAnti-Competitive Practices in the Pharmaceutical Industry and the Heath DeliverySystem, Report Prepared for World Health Organization & Ministry of Healthand Family Welfare, Government of India, CUTS Centre for Competition,Investment and Economic Regulation (CUTS C-CIER), CUTS International,Jaipur.
Nanda, N & Khan, A 2005, ‘Competition policy for the pharmaceuticals sectorin India’, in P Mehta (ed.), Towards a Functional Competition Policy for India,Academic Foundation, New Delhi.
Nard, CA & Morriss, AP 2006, ‘Constitutionalizing patents: From Venice toPhiladelphia’, Review of Law & Economics, vol. 2, no. 2, pp. 223–321.
Narrain, S 2004, ‘A life-saving order’, Frontline, vol. 21, no. 15.———2005, ‘A costly prescription’, Frontline, vol. 22, no. 4.Narula, R 2004, ‘A recipe for litigation’, Scrip Magazine, June, p. 39.NIPER 2006, Impact of TRIPS on Pharmaceutical Prices, with Specific Focus on Generics
in India, National Institute of Pharmaceutical Education and Research, Depart-ment of Chemicals and Petrochemicals, Ministry of Chemicals and Fertilizers,Government of India, Mohali.
NISTADS 2005, Indian Patenting Activity in International and Domestic Patent System:Contemporary Scenario, National Institute of Science Technology and Develop-ment Studies, Office of the Principal Scientific Advisor to the Government ofIndia, New Delhi.
Nordmann, RM 1997, ‘A quarter century of monumental change’, Scrip Magazine,April, pp. 28–9.
North, DC 1968, ‘Source of productivity change in ocean shipping 1600–1850’,Journal of Political Economy, vol. 76, no. 5, September/October, pp. 953–70.
Novartis 2004, ‘Novartis India Analyst Meeting’, Novartis India, 16 July 2004.Nunnenkamp, P & Spatz, J 2003, ‘Intellectual property rights and foreign direct
investment: The role of industry and host-country characteristics’, Kiel Work-ing Paper no. 1167, Kiel Institute for World Economics, Kiel, Germany,June.
OECD 2001, Report on Competition and Regulation Issues in the Pharmaceu-tical Industry, Organisation for Economic Co-operation and Development,Paris.
———2008, Pharmaceutical Pricing Policies in a Global Market, Directoratefor Employment, Labour and Social Affairs, Organisation for EconomicCo-operation and Development, Paris.
OneIndia 2007, ‘Rs 750 Crore Rashtriya Swasthya Bima Yojana Launched’, viewed17 June 2008, http://news.oneindia.mobi/2007/10/03/451757.html.
References 307
OPPI 2003, ‘Pharmaceutical Industry in India: Fact Sheet – 2003’, Organisationof Pharmaceutical Producers of India, Mumbai, viewed 9 August 2005. http://www.indiaoppi.com/keystat.htm.
———2006, ‘Indian pharmaceutical industry: Fact sheet – 2004’, Organisationof Pharmaceutical Producers of India, viewed 12 February 2006, http://www.indiaoppi.com/keystat.htm.
Outterson, K 2008, ‘Should access to medicines and TRIPS flexibilities be lim-ited to specific diseases?’, American Journal of Law & Medicine, vol. 34, no. 2,pp. 317–38.
Oxfam 2002, Rigged Rules and Double Standards: Trade, Globalisation, and the FightAgainst Poverty, Oxfam International, London.
Palit, A & Nawani, S 2007, ‘Technological capability as a determinant of FDIinflows: Evidence from developing Asia and India’ Working paper no. 193,Indian Council for Research on International Economic Relations, New Delhi,April, viewed 23 September 2008, http://www.icrier.org/pdf/Working_Paper_193.pdf.
Pammolli, F & Riccaboni, M 2007, Innovation and Industrial Leadership: Lessonsfrom Pharmaceuticals, Center for Transatlantic Relations, The Johns HopkinsUniversity, Washington, DC.
Patent Lens 2009, ‘Initiative for open innovation’, Canberra, viewed 9 January2009, http://www.patentlens.net/daisy/patentlens/2973.html.
Patnaik, U 2010, ‘Trends in Urban Poverty Under Economic Reforms: 1993–94 to2004–05’, Economic and Political Weekly, vol. 45, no. 4, pp. 42–54.
Perlitz, U 2008, India’s Pharmaceutical Industry on Course for Globalisation,Deutsche Bank Research, Frankfurt, 9 April, viewed 11 August 2008, http://www.dbresearch.com/PROD/DBR_INTERNET_EN-PROD/PROD0000000000224095.pdf.
Pettypiece, S 2006, ‘Pfizer shops for drugs, profits’, Detroit Free Press, 1July, viewed 3 July 2006, http://www.freep.com/apps/pbcs.dll/article?AID=20060701/BUSIENESS06/607010363/1019/BUSINESS.
Pfizer 2005, Hatch-Waxman Economics: Balanced Incentives are the Key, Pfizer Inc,New York.
———2007, Annual Review, Pfizer Inc. New York.Phadke, A 2000, ‘End of drug control?’, India-Seminar, viewed 25 September 2008,
http://www.india-seminar.com/2000/489/489%20phadke.htm.Pharmaceutical & Drug Manufacturers 2005a, ‘Indian pharmaceutical indus-
try: An overview’, viewed 12 June 2005, http://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-industry/.
———2005b, ‘Number of units, pharma industry statistics’, viewed 3 November2005, http://www.pharmaceutical-drug-manufacturers.com/pharma-industry-statistics/.
PhRMA 2002, Annual Report, Pharmaceutical Research and Manufacturers ofAmerica, Washington, DC.
———2004, Industry Profile, Pharmaceutical Research and Manufacturers ofAmerica, Washington.
———2007, Annual Report, Pharmaceutical Research and Manufacturers ofAmerica, Washington, DC.
———2008a, Annual Report, Pharmaceutical Research and Manufacturers ofAmerica, Washington, DC.
308 References
———2008b, Pharmaceutical Industry Profile 2008, Pharmaceutical Research andManufacturers of America, Washington, DC.
Pogge, T 2008, ‘Access to medicines’, Public Health Ethics, vol. 1, no. 2, pp. 73–82.Posner, RA 2002, ‘The law and economics of intellectual property’, Daedalus,
vol. 131, no. 2, pp. 5–12.Pradhan, S 1983, International Pharmaceutical Marketing, Quorum Books,
Westport, CT.Prahalad, CK 2005, The Fortune at the Bottom of the Pyramid: Eradicating Poverty
Through Profits, Wharton School Publishing, Upper Saddle River, NJ.Public Citizen 2001, Rx R&D myths: The Case Against the Drug Industry’s Scare Card,
Public Citizen Congress Watch, Washington, DC, July, viewed 9 September2003, http://www.citizen.org/documents/ACFDC.PDF.
Pugatch, MP 2004, Intellectual Property and Pharmaceutical Data Exclusivity in theContext of Innovation and Market Access, paper presented to Dialogue on Ensur-ing Policy Options for Affordable Access to Essential Medicines, Bellagio, Italy,12–16 October.
Ram, P 2006, ‘India’s new TRIPS-Compliant patent regime: Between drug patentsand the right to health’, Chicago-Kent Journal of Intellectual Property, vol. 5, no. 2,Spring, pp. 195–206.
Rangnekar, D 2005, ‘No pills for poor people? Understanding the disembowel-ment of India’s patent regime’, Economic and Political Weekly, vol. 41, no. 5,pp. 409–17.
Raymus, P 2007, Review of Healthcare in India, Centre for Enquiry into Health andAllied Themes, New Delhi, January, viewed 1 July 2008, http://www.cehat.org/infocentre/r51tables1.pdf#page=373.
Reichman, JH 2000, ‘The TRIPS Agreement comes of age: Conflict of cooperationwith the developing countries?’, Case Western Reserve Journal of InternationalLaw, vol. 32, no. 3, pp. 441–70.
Reichmann, JH 1998, ‘Securing compliance with the TRIPS agreement after US vIndia’, Journal of International Economic Law, vol. 1, no. 4, pp. 586–601.
Reserve Bank of India (RBI) 2005, Exchange Control Manual: Foreign/FERA Com-panies and Foreign Nationals, Reserve Bank of India, Government of India,31 May, viewed 21 February 2007, http://www.rbi.org.in/upload/ECM/pdfs/Chapter11.pdf.
———2007, State Finances: A Study of Budgets of 2006–07, Reserve Bank of India,Government of India, New Delhi.
———2008, Annual Report 2007–08, Reserve Bank of India, Government of India,New Delhi.
Rhein, R 2001, ‘Canada keeps costs in check’, Scrip Magazine, February, pp. 24–5.Rogers, A 1994, ‘Patents in Argentina: Problems and paradoxes’, Scrip Magazine,
December, pp. 10–1.Roumeliotis, G 2006, ‘India set to overtake Italy in API production’, viewed 28
August 2006, http://www.in-pharmatechnologist.com/Materials-Formulation/India-set-to-overtake-Italy-in-API-production.
Roy, N & Madhiwala, N 2003, Surviving the Indian Pharmatical Jungle, Forum forMedical Ethics, Mumbai.
Ruston, G 1955, ‘On the origin of trademarks’, The Trade-Mark Reporter, vol. 45,no. 2, pp. 127–44.
Sachs, JD 2000, ‘A new map of the world’, The Economist, 22 June.
References 309
Sager, A & Socolar, D 2006, ‘Massachusetts health spending soars to $62.1billion in 2006: Spending here is world’s highest – 33% per person aboveUSA average, an unprecedented excess’, Boston University School of PublicHealth, Health Reform Program, Boston, 28 June, viewed 17 July 2007, http://dccwww.bumc.bu.edu/hs/Mass%20Health%20Spending%20Soars%20to%20$62%201%20Billion%20in%202006%20FINAL%2028June.pdf.
Sakthivel, S 2005, ‘Access to essential drugs and medicine’, Financing and Deliveryof Health Care Services in India, Commission on Macroeconomic and Health,and Ministry of Health and Family Welfare, New Delhi, pp. 185–212.
Santerre, RE & Vernon, JA 2005, ‘Assessing consumer gains from a drug price con-trol policy in the U.S.’, Working paper no. 11139, National Bureau of EconomicResearch, Cambridge, MA, February.
———2006, ‘Assessing consumer gains from a drug price control policy in theUnited States’, Southern Economic Journal, vol. 73, no. 1, pp. 233–45.
Sauer, C & Sauer, RM 2007, ‘Is it possible to have cheaper drugs and preserve theincentive to innovate? The benefits of privatizing the drug approval process’,Journal of Technology Transfer, vol. 32, no. 5, pp. 509–24.
Saunders, P 1999, ‘It’s time to call a halt to poor drug donation practice’, ScripMagazine, September, pp. 7–9.
Scherer, FM 2000, ‘The pharmaceutical industry’, in JP Newhouse (ed.), Handbookof Health Economics, Volume. I, Elsevier, Amsterdam, pp. 1297–336.
———2001, ‘The link between gross profitability and pharmaceutical R&Dspending’, Health Affairs, vol. 20, no. 5, September/October, pp. 216–20.
———2002, ‘A Note on Global Welfare in Pharmaceutical Patenting’, FederalReserve Bank of Philadelphia, Philadelphia, November, Working paper no.03–11, viewed 11 May 2007, <http://ssrn.com/abstract=570565>.
———2007, ‘Uncertainty and choice: The challenges of pharmaceutical effi-cacy, safety and cost’, Managerial and Decision Economics, vol. 28, no. 4–5,pp. 267–83.
Scherer, FM & Watal, J 2001, The Economics of Parallel Trade in Pharma-ceutical Products, Paper presented to WHO/WTO Workshop on DifferentialPricing and Financing of Essential Drugs, Hosbjor, Norway, 8–11 April,viewed 5 January 2004, http://www.wto.org/english/tratop_e/trips_e/hosbjor_presentations_e/hosbjor_presentations_e.htm.
Scherer, FM & Weisburst, S 1995, ‘Economic effects of strengthening pharmaceu-tical patent protection in Italy’, International Review of Industrial Property andCopyright Law, vol. 138, no. 26, pp. 1009–24.
Schiff, E 1971, Industrialisation Without National Patents: The Netherlands,1869–1912; Switzerland, 1850–1907, Princeton University Press, Princeton, NJ.
Schneider, F & Frey, BS 1985, ‘Economic and political determinants of foreigndirect investment’, World Development, vol. 13, no. 2, pp. 161–75.
Schreyoegg, J & Busse, R 2005, ‘Physician-drug budgets in Germany and effects onprescription behaviour’, Journal of Pharmaceutical Finance, Economics & Policy,vol. 14, no. 3, pp. 77–95.
Schweitzer, SO 1997, Pharmaceutical Economics and Policy, Oxford UniversityPress, New York.
Scott, A 2006, ‘Blockbuster drug numbers increase’, Chemical Week, vol. 168,no. 12, p. 31.
Scrip 2006, ‘Company partnerships’, Scrip 100, Informa Plc, London, p. 25.
310 References
Scrip News 2005a, ‘Canadian industry can expel firms for marketing offences’,Scrip News, no. 3114, 9 December.
———2005b, Indian proposal for generic prescribing opposed, Scrip News,vol. 3072, 15 July, p. 18.
———2005c, ‘US payers stand to benefit from targeted medicine’, Scrip News,vol. 3117, p. 13.
———2005d, ‘World’s scientists get $436 million to tackle diseases’, Scrip News,vol. 3069, p. 15.
Sen, A 2002, ‘How to judge globalism: Global links have spread knowledgeand raised average living standards, but the present version of globalismneedlessly harms the world’s poorest’, The American Prospect, vol. 13, no. 1,pp. A2–6.
Seyoum, B 1996, ‘The impact of intellectual property rights on foreign directinvestment’, Columbia Journal of World Business, vol. 31, no. 1, pp. 50–9.
Shadlen, K 2009, ‘Reforming and reinforcing the revolution: The post-TRIPSpolitics of patents in Latin America’, Working paper no. 09–02, Globaldevelopment and Environment Institute, Tufts University, April.
Shah, D 2003, Experience of India, Paper presented to The Role of Genericsand Local Industry in Attaining the MDGs in Pharmaceuticals andVaccines, World Bank, Washington, DC, 24–25 June, viewed 4 July2007, wbln0018.worldbank.org/HDNet/hddocs.nsf/9b2b70eeb6c333fb852568aa0073e2a1/dc5eece4d602253685256d4a004c41ce.
Shiva, V 2004, ‘TRIPS, human rights and the public domain’, The Journal of WorldIntellectual Property, vol. 7, no. 5, pp. 665–73.
Singh, K 2008, ‘NGO to seek compulsory licensing of cancer drugs’, EconomicTimes, 31 March.
Singleton, A 2006, ‘Can pharmaceuticals be developed without patents?’,Samizdata.net, London, 9 January, viewed 23 February 2006, http://www.samizdata.net/blog/archives/008450.html.
Sketris, I, Bowles, S & Manuel, R 2003, ‘Canadian public policies and practicesrelated to drug prices, utilization and expenditures’, Journal of PharmaceuticalFinance, Economics & Policy, vol. 12, no. 1, pp. 23–54.
Smith, SE 2000, Opening Up to the World: India’s Pharmaceutical Companies Pre-pare for 2005, Asia/Pacific Research Center, Institute for International Studies,Stanford University, Stanford.
So, AD 2004, ‘A fair deal for the future: Flexibilities under TRIPS’, Bulletin of theWorld Health Organization, vol. 82, no. 11, pp. 813–4.
Solow, RM 1957, ‘Technical change and the aggregate production’, The Review ofEconomics and Statistics, vol. 39, no. 3, August, pp. 312–20.
Srinivasan, S 2008, ‘How TRIPS benefits Indian industry and how it may notbenefit the Indian people’, Indian Journal of Medical Ethics, vol. V, no. 2,pp. 66–9.
Stiglitz, JE 2002a, ‘Globalism’s discontents: Integration with the global econ-omy works just fine when sovereign countries define the terms, it worksdisastrously when terms are dictated’, The American Prospect, vol. 13, no. 1,pp. A16–21.
———2002b, Globalization and its Discontents, W.W. Norton & Company,New York.
———2006, Making Globalization Work, W.W. Norton and Company, New York.
References 311
Stoate, N 2001/2002, ‘EU enlargement, the Bolar exemption and parallel imports:The consequences for market exclusivity’, Bio Science Law Review, vol. 5, no. 5,pp. 161–82.
Swain, N, Mishra, C, Jayasimha, K & Vijayalakshmi, S 2002, ‘Indian pharmaceu-tical industry: An analysis’, The Icfaian Journal of Management Research, vol. 1,no. 6, pp. 5–28.
Sweeny, K 2002, The Technological Revolution, Paper presented to Pharmaceuticalsin Australia: Access, Costs and Industry Development, Melbourne, 16September.
———2008, ‘Accounting for growth in the pharmaceutical benefits scheme’, PhDBook, Victoria University, Melbourne, Australia, April.
Tamilnadu Pharmaceutical Sciences Welfare Trust 2008, ‘Drugs approved by theDrugs Controller General (India) during January 1988 to August 2006’, viewed12 December 2008, http://www.pictrust.com/links/newdrugs.phtml.
Taylor, P 2005, ‘Sun pharma buys hungarian plant’, In-Pharmatechnologist, viewed9 September 2005, http://www.in-pharmatechnologist.com/news/news-ng.asp?id=61850-sun-generic-india-hungary.
The Economist 2005a, ‘Alternative medicine: Neglected diseases are fighting forattention’, The Economist, 16 June, pp. 8–9.
———2005b, ‘Health at a glance: OECD indicators’, The Economist, 16 June.The Expert Committee 2003, Report of the Expert Committee on a Comprehensive
Examination of Drug Regulatory Issues, Including the Problem of Spurious Drugs,Ministry of Health and Family Welfare, Government of India, New Delhi.
The Sen Committee 2005, Report: Task Force to Explore Options Other Than PriceControl for Achieving the Objective of Making Available Life-Saving Drugs at Rea-sonable Prices, Department of Chemicals and Petrochemicals, Government ofIndia, New Delhi.
The Seth Committee 2004, National List of Essential Medicines 2003, DirectorateGeneral of Health Services, Ministry of Health and Family Welfare, Govern-ment of India, New Delhi.
The Tribune 2004, ‘Government to cut prices of drugs’, The Tribune, 22 December.The Wharton School 2008, Eli Lilly’s Rajiv Gulati on Pharma’s Prospects in
India and China, The Wharton School, The University of Pennsylvania, 16October, viewed 18 October 2008, http://knowledge.wharton.upenn.edu/india/articlepdf/4325.pdf?CFID=75279634&CFTOKEN=29111060&jsessionid=a83096d931ea33394241.
Timmermans, K 2007, ‘Monopolizing clinical trial data: Implications and trends’,PLoS Medicine, vol. 4, no. 2, pp. 206–10.
Torbet, J 1999, ‘Globalisation and its impact on access to medicines’, ScripMagazine, May, pp. 8–10.
UNCTAD 2005, World Investment Report: Transnational Corporations and the Inter-nationalization of R&D, United Nations Conference on Trade and Development,New York.
———2007, World Investment Report: Transnational Corporations, Extractive Indus-tries and Development, United Nations Conference on Trade and Development,New York.
UNCTC 1993, World Investment Report: Transnational Corporations and IntegratedInternational Production, The United Nations Centre on Transnational Corpora-tions, New York.
312 References
UNDP 2003, Making Global Trade Work for People, Earthscan Publications, London.———2005, Human Development Report, United Nations Development Pro-
gramme, Geneva.United Nations 2005a, India Demographic Profile 2000–2050, United Nations Pop-
ulation Division, Department of Economic and Social Affairs, New York, viewed12 August 2008, http://esa.un.org/unpp/p2k0data.asp.
———2005b, World Population Prospects: The 2004 Revision, Department of Eco-nomic and Social Affairs, Population Division, New York.
Verband der Forschender Arzeneimittelhersteller 2007, Heath Care Reform 2007,German Association of Research-based Pharmaceutical Companies, 27 March,viewed 23 July 2007, http://www.vfa.de/en/articles/art_2007-03_010.html.
Verheugen, G 2005, ‘Commission push on pharma innovation’, viewed1 June 2007, http://www.euractive.com/Article?tcmuri=tcm:29-140360-16&type=News.
Vernon, JA & Manning, RL 2007, ‘Editorial’, Managerial and Decision Economics,vol. 28, no. 4–5, p. 229.
Weissman, R 2007, ‘Big pharma and AIDS: Act II patents and the price of second-line treatment’, Multinational Monitor, vol. 28, no. 2.
WHO 2002a, ‘Promoting rational use of medicines: Core components’,WHO Policy Perspectives on Medicines, no. 5, World Health Organization,Geneva.
———2002b, ‘The selection of essential medicines’, WHO Policy Perspectives onMedicine, no. 4, World Health Organization, Geneva.
———2002c, The World Health Report 2002: Reducing Risks, Promoting Healthy Life,World Health Organization, Geneva.
———2003a, ‘Effective medicines regulation: Ensuring safety, efficacy and qual-ity’, WHO Policy Perspectives on Medicine, no. 7, World Health Organization,Geneva.
———2003b, ‘How to develop and implement a national drug policy’, WHOPolicy Perspectives on Medicine, no. 6, World Health Organization, Geneva.
———2004a, ‘Equitable access to essential medicines: A framework for collectiveaction’, WHO Policy Perspective on Medicines, no. 8, World Health Organization,Geneva.
———2004b, The World Medicines Situation, World Health Organization, Geneva.———2006a, ‘Elements of a global strategy and plan of action, A/PHI/IGWG/
1/4’, Intergovernmental Working Group on Public Health, Innovation andIntellectual Property, World Health Organization, Geneva.
———2006b, The World Health Report 2006: Working Together for Health, WorldHealth Organization, Geneva.
———2007, World Health Report 2007: A Safer Future – Global Public Health Securityin the 21st Century, World Health Organization, Geneva, Switzerland.
WHO/WTO 2001, ‘Report of the workshop on differential pricing and financingof essential drugs’, Hosbjor, Norway, 8–11 April.
Wikipedia 2008, ‘Cipla and the fight against HIV/AIDS in the developing world’,viewed 21 September 2008, http://en.wikipedia.org/wiki/Cipla.
Wilding, I 2002, ‘Injecting innovation into the drug development process’, ScripMagazine, October, pp. 15–6.
World Bank 2002, India: Raising the Sights – Better Health Systems for India’s Poor –Findings, Analysis and Options, World Bank, Washington, DC.
References 313
———2003, The Little Data Book, The World Bank, Washington, DC.———2006, World Development Report: Equity and Development, The World Bank,
Washington, DC.WTO 1994, Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS),
The World Trade Organization, Geneva, 15 April, viewed 12 February 2003,http://www.wto.org/english/docs_e/legal_e/27-trips_01_e.htm.
———2000, Canada: Patent Protection of Pharmaceutical Products, WT/DS114/R,World Trade Organization, Geneva, 17 March, viewed 17 February 2007, http://www.wto.org/english/tratop_e/dispu_e/7428d.pdf.
———2006a, 10 Common Misunderstandings About the WTO, World Trade Organi-zation, Geneva.
———2006b, Compulsory Licensing of Pharmaceuticals and TRIPS, World TradeOrganization, Geneva, viewed 28 May 2007, http://www.wto.org/english/tratop_e/trips_e/public_health_faq_e.htm.
———2010, Understanding the WTO: The Agreements, World Trade Organization,Geneva, viewed 16 March 2010, http://www.wto.org/english/thewto_e/whatis_e/tif_e/agrm1_e.htm.
Wyllie, MG 2005, ‘Evergreening: There’s life in the old drug yet’, British Journal ofUrology, vol. 95, no. 9, 12 May, pp. 1359–60.
Yusuf, A & Moncayo von Hase, A 1992, ‘Intellectual property protection andinternational trade-exhaustion of rights revisited’, World Competition, vol. 16,no. 1, pp. 115–31.
Zutshi, BK 1998, ‘Bring TRIPS into the multilateral trading system’, in J Bhagwati& M Hirsch (eds), The Uruguay Round and Beyond: Essays in Honour of ArthurDunkel, Springer, Berlin, pp. 37–49.
Index
Abbott, F., 19, 95, 97, 187Abegunde, D., 143, 160access to medicines, 1–6, 9, 14, 22, 31,
51–3, 57, 63–7, 76, 81, 85, 97,103–4, 137–8, 141–60, 175–6,180, 184, 190–1, 201–2, 204,211–12, 214, 216, 220–1
Indian population with, 2, 15, 60,117, 125, 132–33, 136, 144
Acharya, A., 134Acquired immune deficiency
syndrome (AIDS), see HIV/AIDSAderibigbe, M., 70Adikibi, O., 70advance purchase commitments
(APC) model, 207adverse drug reactions (ADRs), 44Aggarwal, A., 59, 61Ahuja, R., 134Aiyer, S., 73Alexander, J., 108Alphapharm, 42Alsegård, E., 201alternative models, 201–213Angell, M., 49antiretrovirals (ARVs), 63–5, 81,
203, 205Apotex, 97Arrow Pharmaceuticals, 42Ashton, T., 13, 16AstraZeneca, 50, 59, 66, 71, 75, 97AT Kearney, 69Australia, 25, 71, 87, 92, 131, 183
ageing population, 141generics in, 40–41patient co-payments, 137–9,
149, 154pharmaceutical market, 38, 40private health insurance in, 135trade margins in pharmaceuticals,
120Australian Bureau of Statistics, 141
Australian Institute of Health andWelfare, 161
Austrom, D., 46Ayurvedic, Yoga, Unani, Siddha, and
Homeopathic (AYUSH), 135, 170see also traditional medicines
Babu, G., 78Baker, B., 27Balance, R., 111Balasubramaniam, K., 183Barry, M., 51Barton, J., 202, 204–5, 208–9below poverty line (BPL), 133–5,
141–2, 149, 152, 155Berndt, E., 207Berry, A., 207Bhagat, M., 2, 60–1, 143Bidwai, P., 89Biocon, 75Bisserbe, N., 74Blech, J., 37, 50, 61Blendon, R., 138, 148blockbuster drugs, 34–5, 53, 81,
92, 189Bloomberg, 36Boldrin, M., 177, 179Bower, D., 62, 74, 76Braee, R., 127Bristol-Myers Squibb (BMS), 37, 75,
77, 101Brown, P., 39Bureau of National Affairs, 188
Cai, Q., 111Caplow, T., 92Cefaclor, 80Central Drug Research Institute
(CDRI), 105, 210Chadha, A., 71, 78Chataway, J., 73Chataway, M., 190
314
Index 315
Chaturvedi, K., 105Chaudhuri, S., 1, 59, 62, 95–6,
114, 179Chin, J., 185CIMS, 121, 123Cipla, 59, 64, 92, 97–8,
122Clements, P., 27Clift, C., 101Cole, J., 13–14, 17Collier, R., 47Commission on Intellectual Property
Rights, 192–5Commission on Intellectual Property
Rights Innovation and PublicHealth, 101
Commission on Macroeconomics andHealth, 51
compulsory licensing, 20–4, 84, 86,94–7, 103, 143, 215
Congressional Budget Office (CBO),44–6
contract research and manufacturing(CRAM), 34, 75–9
contract research organizations, 75co-payments, see patient
co-paymentsCornish, W., 24Correa, C., 19, 23–4, 26, 29Council of Scientific and Industrial
Research (CSIR), 108, 110, 219Cruddas, J., 50Cutler, D., 35–6, 39, 43Cygnus, 58, 75
Danzon, P., 36–7, 202Darbourne, A., 203Das, S., 60, 113, 121data exclusivity, see data protectiondata protection, 15, 26–8, 87,
99–103, 109David, P., 12Davis, M., 16–17Deardof, A., 185Deloitte Recap, 36DeNavas-Walt, C., 131, 135Department of Health, 127, 197Department of Health and
Ageing, 129
developing new drugs, 5, 14–16, 32–4,42–4, 50–2, 106
costs of, 46–8process of, 43time to, 44–6
differential patenting model, 203differential pricing model, 202DiMasi, J., 44–5, 47–9disability adjusted life years (DALYs),
204, 207Doha Declaration, 22, 24, 95donating drugs model, 204Dongre, R., 12Drohan, M., 11Douglas Pharmaceuticals, 42Drahos, P., 21, 27, 90, 183, 190Drug Today, 121, 123DRL, see Dr Reddy’sDr Reddy’s, 52, 59, 64, 73, 75drug price controls, 14, 16, 84,
111–17, 131, 136, 219Drug Price Control Order (DPCO),
112, 159of 1970, 112, 114–15of 1979, 70, 112, 115of 1987, 112, 116of 1995, 112–14, 125of 2004, 116–17
Drug Price control models, 126Australia, 127, 129Canada, 128Germany, 128–9New Zealand, 127United Kingdom, 127
Drug prices, 2–4, 14–15, 43, 67, 79, 81,84, 98, 103, 121–6, 143, 146, 188
post-TRIPS changes to, 123–6voluntary reductions to, 121–2
Duckett, S., 129, 141Dukes, G., 33, 47–8Dunkley, G. 10Dutta, A., 182
Economic Research Foundation, 142,168
The Economist, 17, 191Edison, T., 18effective patent life, 45Eli Lilly, 71, 80
316 Index
Elliott, R., 97Ellis, R., 131–3, 137Embassy of the United States, 93Essentialdrugs, 59EurActiv, 28European Commission, 24, 34, 40,
42–3, 89, 92, 110, 192, 198–9European Generic Medicines
Association (EGMA), 16European Federation of
Pharmaceutical Industries andAssociations (EFPIA), 25, 34, 37–8,40, 42, 44, 47
European Parliament, 89ever-greening, 87, 109
see also frivolous claimsexclusive marketing rights (EMRs),
82–4The Expert Committee, 59, 61
Food and Drug Administration (FDA),44, 46, 62, 71, 77, 87, 94, 103
Federal Trade Commission (FTC),195–7
Federation of Indian Chambers ofCommerce and Industry (FICCI),62, 74, 76
Ferreiro, A., 137FierceBiotech, 78Finger, J., 181–2, 184Flink, J., 13Foroohar, R., 207foreign direct investment (FDI), 4–5,
68–72, 217Foreign Exchange Regulation Act
(FERA), 69–70Frank, R., 36frivolous claims, 84, 88–9, 92, 110
Galpalli, N., 58–9Gambardella, A., 43, 47Garg, C., 133, 137Gassmann, O., 34–5, 37, 45, 188Genepharm, 40, 42General Agreement on Tariffs and
Trade (GATT), 5, 9–11, 214General Insurance Corporation of
India, 132Generic Handbook, 39
generics, 3, 15–16, 23–7, 37–42, 57,60, 64, 74–5, 77, 81–3, 85, 92,101–3, 120, 126–30, 180, 188,198, 203–4, 215
GlaxoSmithKline (GSK), 37, 42, 50,71, 75, 91, 115
Glivec, 82, 84Global-Challenges, 64Global Forum for Health Research, 51Global pharmaceutical industry, 2–4,
14, 20, 22, 25, 36–7, 40, 47–50product, 34–5structure, 33–4
Goddard, M., 111, 127Goozner, M., 47–8Government of Australia, 12, 41, 154,
159Government of Canada, 128Government of India, 58–65, 67–9,
71, 76, 78, 81, 83–4, 87, 92, 94,106, 108, 112–13, 116, 120–1,141–3, 147–8, 151–2, 155–8, 161,164–9, 181
Government of the United States,205–6
Grabowski, H., 47–8, 205–6Graf von der Schulenburg, J., 128Gray, A., 111Gupta, A., 60Gupta, I., 132–3
Hansen, R., 47Harten, C., 135, 138Harvey, K., 51, 61, 126Hatch-Waxman Act, 27, 62, 81, 101Hathi Committee Report (HCR), 61,
115, 147Haub, C., 161–3Hawthorne, F., 52, 177–8Hayek, F., 17health expenditure, 38, 52, 130–1, 139
private, 5, 39, 142, 155–9, 166–71,220
public, 142, 156–9, 166, 222health impact fund (HIF) model, 210health insurance, 6, 39, 118, 128,
131–40, 166in India, 131–5; private, 135–7
Heinen, C., 72, 76
Index 317
Henry, D., 146Hertz, A., 11Hesse, C., 12Hexal Australia, 42Hiddleston, S., 87High Court, 83, 89, 93, 97–8, 104HIV/AIDS, 63–5, 81–2, 91, 97–8,
114–25, 188, 203Hoekman, B., 10Hofstede, G., 13Hollis, A., 206, 210Hope, J., 13House of Commons Health
Committee, 87, 89, 197–8Hughes, J., 188Humer, F., 33
Ibrahim, M., 136incremental value based rewards
model, 206IDR, 121, 123IMS Health, 87IndiaHealth model, 144–58
benefits of, 159–60costing of, 161–8funding, 168–70implementing, 147out-of-pocket expenditure under,
155–9structure of, 170
India Patent Act, 13–14, 28, 59, 70,84–7, 89, 92–3, 95–7, 99, 105,109, 115, 178–9, 194, 196
Appellate Board, 90, 99impact of, 81–5, 103provisions to oppose, 90–8uncertainties and ambiguities
under, 99–108Indian pharmaceutical industry,
58–62, 77, 79–80, 159business models, 4, 72–8, 218development of, 57–61exports, 61–2; impact of TRIPS on,
63–7, 72, 216foreign acquisitions by, 77–8imports, 61, 68new drugs, 191product, 58small scale units, 59–61
Indian pharmaceutical market, 58–61India population, 141–5, 148–9,
151–66, 169–71insurance, see health insuranceintellectual property rights (IPRs),
10–14, 20, 69–70, 79, 89, 101,111, 182, 192–3, 200
case for, 13–16case against, 16–19see also patents
Inter-Ministerial ConsultativeCommittee (IMCC), 102–3
International Federation ofPharmaceutical ManufacturersAssociations (IFPMA), 101, 188
International Monetary Fund (IMF),167–9
INHATA, 147Insurance Regulatory and
Development Authority (IRDA),136
IP-Watch, 91
Jack, W., 182Jatania, P., 82Jefferson, T., 17Jeremy, D., 177Jorge, M., 19, 183Jyothi-Datta, P., 91
Kamath, G., 40, 64, 75, 78Kassirer, J., 50Kaul, S., 78Keayla, B., 103Khan, B., 13, 15Khosla, R., 191Klein, N., 23Knowledge@Wharton, 151Koshy, S., 24KPMG, 76Kremer, M., 190, 203–5, 207Kumar, R., 89, 105, 177
Labonte, R., 51Lacetera, N., 33Lalitha, N., 80Lall, S., 112Lanjouw, J., 80–1, 115, 179–80, 182,
203–4
318 Index
Lehman, B., 11, 14–15, 190–1least developed countries (LDCs), 96,
98, 179, 215Levine, D., 177, 179Lewis, G., 37Lichtenberg, F., 187, 189Light, D., 207Lippoldt, D., 69Lleras-Muney, A., 189Lloyd, I., 45Lofgren, H., 41, 207low- and middle income countries
(LMICs), 57, 65, 67, 72, 79
Macdonald, S., 180Machlup, F., 12–13, 18Madanmohan, T., 72Mahal, A., 136, 168Malhotra, P., 9, 26, 65–6, 81, 101, 108Managing Intellectual Property, 91Mansfield, E., 14, 69Mashelkar, R., 286Maskus, K., 9, 69, 209Mathew, J., 77, 98Mathew, T., 38Mathieu, M., 46, 50May, C., 12Mayne, R., 14, 32Mazumdar-Shaw, K. 75, 105McEwan, J., 92McLachlan, A., 61Medecin Sans Frontiere (MSF), 82,
91, 101Medicines Australia, 34Medicines and Healthcare Products
Regulatory Agency (MHRA),62, 77
Medico Friends Circle, 60–1MedIndia, 99Melethil, S., 18Merck, 37, 39, 52, 205minimum patenting model, 211Minwalla, S., 61Misra, R., 143, 190Mokyr, J., 16Morag-Sela, T., 27Moran, M., 191, 208Mueller, J., 90, 95, 99Mukherjee, S., 71
Mukreja, D., 64multinational corporations (MNCs),
4–5, 11, 13, 23, 32–4, 51, 59,62–3, 68, 71–4, 79, 89, 94, 97,101, 105, 107, 114–15, 175, 178,180, 182, 184–5, 187, 203, 210
Murray, C., 51mX, 115
Nagendranath, A., 132Nanda, N., 34, 57, 143Nard, C., 12Narrain, S., 82, 113, 117Narula, R., 83National Academies Board on Science
Technology and Economic Policy,197
National Commission onMacroeconomics and Health(NCMH), 117
National Essential Drugs List, 117National Institute of Pharmaceutical
Education and Research (NIPER),125
National Institute of ScienceTechnology and DevelopmentStudies (NISTADS), 94, 104, 106–7
National Institutes of Health (NIH),16, 43, 49–50
National List of Essential Medicines(NLEM), 114, 117–18, 125
National ManufacturingCompetitiveness Council(NMCC), 117
National Pharmaceutical PricingAuthority (NPPA), 116, 118, 130,146
Nicolas Piramal, 59, 60, 65, 101, 106Nordmann, R., 190North, D., 14Novartis, 71, 82, 89, 110, 195Nunnenkamp, P., 69
OneIndia, 135open access model, 208Organisation for Economic
Co-operation and Development(OECD), 32–3, 35, 37–8, 40, 50,62, 130
Index 319
Organisation of PharmaceuticalProducers of India (OPPI), 57, 59
Orphan Drugs Act as a model, 205Outterson, K., 26Oxfam, 182, 184
Palit, A., 70, 72Pammolli, F., 285parallel imports, 22, 24–5, 30, 143, 215parallel trade, 202, 204Patent Lens, 183patents, 11–21, 23–30, 33–4, 36, 38,
40–2, 52, 59, 63, 65–8, 80–110,118–19, 127–8, 176, 195–7, 203,215, 217–19, 222–4
in developed countries, 176in pharmaceutical products, 177–80see also intellectual property rights
(IPRs)patient co-payments, 137–40, 155–9Patnaik, U., 286Perlitz, U., 61Pettypiece, S., 190Pfizer, 35–7, 45, 48, 59, 71, 91, 97,
108, 115, 175–6, 190Phadke, A., 68Pharmaceutical Benefits Scheme (PBS),
40–2, 129, 131, 138–9, 183Pharmaceutical & Drug
Manufacturers, 58pharmaceutical innovation, 11–17,
29, 33–4, 42–4, 47, 50, 59, 73,80–1, 84, 87, 104–9, 189, 218
pharmaceutical marketing, 17, 25–7,34–5, 43–4, 47, 50–1, 57, 61, 73–5,82–3, 90–4
pharmaceutical markets, 37–42pharmaceutical patents investigated,
192–200see also patents
pharmaceutical research anddevelopment, 16, 32–4, 42–3,45–6, 48–9, 51, 106, 189, 197,202–8
Pharmaceutical Research andManufacturers of America(PhRMA), 14–16, 28, 39–40, 46,49, 175–6, 217
pharmaceutical trade margins, 119–20
Pogge, T., 184Posner, R., 17, 176Pradhan, S., 58, 60Prahalad, C., 74President’s Ordinance, 84, 90price controls, see drug price controlsPublic Citizen, 49public good, 21, 209public health expenditure, see health
expenditurePublic-Private Partnerships (PPPs)
model, 207Pugatch, M., 101
Ram, P., 85, 94–5, 107Ranbaxy, 36, 59, 64, 74–5, 77, 80, 83,
98, 106, 122Rangnekar, D., 80Raymus, P., 142, 168reference pricing, 119, 126–7Reichman, J., 11, 19, 209Reserve Bank of India (RBI), 69,
73, 142Rhein, R., 183Roche, 33, 91, 97–8Rogers, A., 179Roumeliotis, G., 68Roy, N., 61Ruston, G., 12
Sachs, J., 185Sager, A., 38Sakthivel, S., 120, 123–4The Sandhu Committee, 117–20Sanofi-Aventis, 50, 71Santerre, R., 131, 188Sauer, C., 100Saunders, P., 205Scherer, F., 24, 178, 186–87, 189Schiff, E., 178Schneider, F., 70Schreyoegg, J., 129Schweitzer, S., 32Scott, A., 35Scrip, 73Scrip News, 35, 50, 61, 208Sen, A., 185The Sen Committee, 61, 116,
118–20, 129
320 Index
The Seth Committee, 117Seyoum, B., 69–70Shadlen, K., 27, 73Shah, D., 59, 69–70Shiva, V., 19Singh, K., 97Singleton, A., 17Sketris, I., 128Smith, S., 69So, A., 101Solow, R., 13Special 301, 101, 183Srinivasan, S., 104Stiglitz, J., 17, 180, 186Stoate, N., 15–16Swain, N., 58Sweeny, K., 40–41, 120
Tagamet, 34, 92, 189Tamilnadu Pharmaceutical Sciences
Welfare Trust, 94Taxol, 101Taylor, P., 78test data, 198
see also data protectionTherapeutic Goods Administration
(TGA), 62, 77, 129traditional medicines, 135, 148,
159–60, 171see also Ayurvedic, Yoga, Unani,
Siddha, and Homeopathic(AYUSH)
Therapeutic Goods Act, 92Timmermans, K., 101Torbet, J., 191trade margins, see pharmaceutical
trade marginsTrade Related Aspects of Intellectual
Property Rights (TRIPS), 9–10, 15,19, 70, 94–5, 100, 104, 111, 143,176–80, 222–4
appropriateness of, 175–200, 222–24Articles, 20, 25, 28–9, 96Bolar exemption, 15–16, 25–6, 85,
103costs and benefits of, 180; to
developed countries, 183; to
developing countries, 180–3,184–92
flexibilities, 10, 21–2, 25–6, 94–5,98, 215
The Tribune, 120TRIPS-plus, 20, 26, 179, 215tropical diseases, 14, 32, 51–2, 72, 79,
114, 160, 187, 189–91, 204, 206,210, 224
tuberculosis, 51, 64, 71, 108, 190
United Nations, 151, 161–5United Nations Centre on
Transnational Corporations(UNCTC), 70
United Nations Conference on Tradeand Development (UNCTAD), 71
United Nations DevelopmentProgramme (UNDP), 20, 176
Uruguay Round, 9, 181, 183United States-Australia Free Trade
Agreement, 92, 183
Verband der ForschenderArzeneimittelhersteller, 128
Verheugen, G., 15Vernon, J., 48
Watal, J., 24Weissman, R., 64The Wharton School, 63Wikipedia, 64Wilding, I., 44Wockhardt, 59, 65, 77, 91, 106, 122World Bank, 17, 69–70, 143, 181, 202World Health Organization (WHO),
59–60, 62, 114, 117, 127, 142–3,146, 190, 202, 205
World Trade Organization (WTO),9–11, 19, 22–3, 25–7, 68, 70, 82,86, 94, 96–7, 104–5, 179, 181–6,201, 209, 214–15
Wyllie, M., 195
Yusuf, A., 24
Zidovudine, 66, 87, 91Zutshi, B., 10, 30